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Abbrevations 
 
A 
A 
aa 
AFM 
AgNO3 
AM 
AP 
APS 
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Bro 
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C 
C 
Ca 
CF 
CRD 
D 
ddNTP 
DNA 
dNTP 
E 
EDTA 
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Fev1 
FL 
G 
GOLD 
HCl 
H2SO4 
HS 
IgG 
K 
L 
LC 
M 
MALDI-TOF 
MgCl2 
Alanine 
Adenosine 
Amino acid 
Atomic force microscopy 
Silver nitrate 
Alveolar macrophages 
Alveolar Proteinosis 
Ammonium persulfate 
Bronchoalveolar lavage 
Body mass index 
Chronic bronchitis and asthma 
Bovine serum albumin  
Control 
Cytosine 
Calcium 
Cystic fibrosis 
Carbohydrate recognition domain 
Aspartatic acid 
Dideoxynucleotide 
Deoxyribonucleic acid 
Deoxynucleotide 
Glutamic acid 
Ethylenediaminetetraacetic acid 
Enzyme linked immunosorbent assay 
Forced expiratory volume in one second 
Fluorescine 
Guanine 
Global initiative for chronic obstructive lung disease 
Hydrochloric acid 
Sulfuric acid 
Healthy subjects 
Immunoglobulin G 
Lysine 
Leucine 
Light cycler 
Methionine 
Matrix assisted laser desorption/ionisation - time of 
flight 
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min 
N 
Na2CO3 
Na2S2O3 
NaOH 
NCF 
P 
P.aer. 
PAGE 
PCR 
PPR 
Q 
R 
s 
S 
SAP 
SDS 
SFTPA 
SFTPD 
SNP 
SP-A 
SP-D 
T 
T 
Taq 
TBS 
TBS-T 
TEMED 
TLR 
TMB 
UTR 
V 
W 
WHO 
Magnesium chloride 
Minute 
Asparagine 
Sodium Carbonate 
Sodium sulphite 
Sodium hydroxide 
Non-cystic fibrosis 
Proline 
Pseudomonas aeruginosa 
Polyacryl-amide-gelelectrophorese 
Polymerase chain reaction 
Pattern recognition receptor 
Glutamine 
Arginine 
Second 
Serine 
Shrimp alkaline phosphatase 
Sodium dodecyl sulfate 
SP-A gene 
SP-D gene 
Single nucleotide polymorphism 
Surfactant protein A 
Surfactant protein D 
Threonine 
Thymine 
Thermophilus aquaticus 
Tris-buffered saline 
TBS with TWEEN 
N,N,N',N'-tetramethylethylenediamine  
Toll like receptor 
3, 3’, 5, 5’-tetramethylbenzidine 
Untranslated region 
Valine 
Tryptophan 
World health organisation 
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1) Introduction 
 
1.1) The surfactant 
Pulmonary surfactant covers the alveoli and terminal airspaces as a complex film made of lipids (90% 
by mass) and proteins. The vital biophysical functions of surfactant are known for a long time and this 
knowledge has been very successfully translated into novel therapeutic options, e.g. exogenous 
surfactant therapy of neonatal and adult respiratory distress syndrome (1). The anti-microbial and 
immunomodulatory properties of surfactant have also been noticed for a long time (2-5), however the 
precise molecules and their functions involved have only been recently unravelled.  
On average we inhale with every second or third breath one micro-organism into the lungs (6) Thus 
there must be a reliable defence system in the airways and alveoli that can eliminate incoming micro-
organisms, but also prevent a significant inflammatory reaction which would destroy the lungs pivotal 
function of gas exchange.  
Pulmonary surfactant is synthesized by alveolar type II cells and stored as intracellular inclusion 
organelles called ‘lamellar bodies’. Then it is secreted into the airspaces where complex structures like 
tubular myelin and mono- and multilayer films are built (7,8) (Fig. 1). The major surfactant associated 
proteins surfactant protein A (SP-A) and SP–D are hydrophilic. These are known to play a crucial role 
in pulmonary immunity (9-12). The surfactant proteins SP-B and SP–C are very hydrophobic proteins. 
They are closely linked to alveolar surface-tension, phospholipid packaging and organization of 
surfactant structure.    
 
Figure 1.1.1: Surfactant synthesis.  The pulmonary surfactant (phospholipids and proteins) is 
synthesized by the type II alveolar cell and stored as lamellar bodies. After secretion into the alveolar 
space, lamellar bodies develop tubular myelin. Used surfactant is recycled or degraded by the type II 
alveolar cells (90% under normal conditions) and alveolar macrophages. 
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1.2) Surfactant protein A 
1.2.1) SP-A gene structure (SFTPA1/2) 
 
The human SP-A-gene locus consists of two functional genes, SFTPA1 and SFTPA2, and a 
pseudogene (Ψ) and is located on chromosome 10q22-q23. 1. The SFTPA1 and SFTPA2 genes are 
inversely orientated (Fig. 1) and expressed independently (13). Each functional gene stretches across 
4. 6 kb and consists of four coding exons (1-4) and three non-translated exons (A-C) in the 5’ 
untranslated region (UTR) (Fig. 2) (14). The pseudogene contains besides exon 4 of the SFTPA 
genes a large number of highly repetitive sequences and is not translated. From the primary transcript 
arise through different splicing of the exons A-D different mRNAs (15), but these mRNAs lead to 
similar protein sequences. The leading sequence of the mRNA consisting of parts of the untranslated 
exons A-D influences the expression rate or the mRNA stability. The major transcripts are the AD’ type 
for SP-A1 and the ABD and ABD’ types for SP-A2. The D and D’ splice sites differ by three 
nucleotides with D’ being shorter (16). These SP-A transcripts are translated in vitro (17) and in vivo 
(18). 
 
 
 
 
Figure 1.2.1.1: Gene Locus SFTPA and SFTPD. The orientation of the SP-A-genes is shown. The 
arrow (→) marks the direction of transcription (according to (19)). MBL stands for mannose-binding-
protein, Ψ for the pseudogene. 
 
 
 
 
 
Figure 1.2.1.2: Gene structure SP-A. Intron-exon-structure of a SP-A-gene is demonstrated. Coding 
exons 1-4 are highlighted [according to (20)]. 3’-UTR stands for the 3’ untranslated region. 
 
 
1.2.2) SP-A mRNA 
 
A number of studies using human fetal lung explant culture have investigated the response of SP-A 
protein and its mRNA to a variety of stimulatory and inhibitory regimens. Of particular interest was the 
observation of Ballard and co-workers (21) that there was a considerable variability in the amount of 
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both SP-A and its message among different specimens. The observed variability in the level of SP-A 
mRNA among specimens may have been a reflection of differences in SP-A genotypes of the fetal 
lungs used in their experiments. The results of those studies show that, in general, the protein level 
tends to follow the mRNA level (22,23). For example, the response to glucocorticoids of both SP-A 
and its message is biphasic, showing increased expression at low concentrations of glucocorticoids 
and inhibition of expression at high concentrations (24,25). The lung levels of total SP-A mRNA varies 
remarkably among adult individuals (26). The ratio of SP-A1:SP-A2 mRNA among individuals differs 
from the initially assumed (27) ratio of 2:1 (28). The majority of individuals studied by Karinch et al. 
had a SP-A1/SP-A2 ratio greater than one examining their lung tissues (29), indicating an excess of 
SP-A1 mRNA. 
 
1.2.3) SP-A Protein Structure  
 
The gene products of both functional genes are propeptides containing 248 amino acids. After 
separation of the signal sequence, monomers of 228 amino acids evolve (30). The amino acidic 
sequences of SP-A1 and SP-A2 are homologous by 98% (31). The proteins deviate from each other 
by 6-10 residues (32). At the amino acidic positions 9, 19, 66, 73, 81 and 83 they differ constantly and 
at the positions 50, 91, 219 and 223 there are polymorphisms which cause similar or different amino 
acids at these positions. Four domains can be differentiated in the primary structure (33). The N-
terminus is followed by the collagen-like region which is linked to the globular head by the neck region 
(Fig. 3). The intermolecular disulfide bonds at the N-terminal end enable the aggregation of trimers to 
higher oligomers (Fig. 4). In this formation SP-A participates in the regulation of the surfactant 
metabolism and phospholipid aggregation (34,35). The collagen-like domain is recognized by the 
collectin receptor C1q (36). The neck region arranges the trimer association of the globular domain 
and influences the binding to phospholipids and the bacterial lipid A (37). Aggregates are formed with 
lipids in the presence of calcium ions (38). Tubular myelin is a characteristically organized lipid 
aggregate formed in the presence of SP-A, calcium ions, SP-B and phospholipids that accelerates the 
development of the surface active film at the air-water interface in the lungs (39). The globular domain 
contains the recognition site for carbohydrates (CRD). Besides its interaction with microorganisms, 
lectins or other molecules with attached sugar sequences, the CRD is also a ligand for phospholipids 
(40), macrophage membrane proteins (41) and the calcium-dependent binding and endocytosis of SP-
A by type-II pneumocytes (42). 
 
 11 
 
Figure 1.2.3.1: Schematic representation of the primary protein structure of SP-A monomers. 
Free sulfhydryl and hydroxyl groups are involved in forming intermolecular bonds during 
oligomerization (see Fig. 1.2.3.1). 
 
1.2.4) Molecular Structure and Sites of Expression 
 
SP-A belongs to a family of innate host defence proteins termed collectins because of the presence of 
a collagenous and a lectin-like domain (11). In the lungs, SP-A is the most abundant surfactant protein 
by weight. The SP-A monomer consists of 228 amino acids and has a molecular weight of 26-32 kDa. 
The three dimensional structure is shown in Fig. 6. Different post-translational modifications are 
responsible for this molecular range. SP-A is glycosilated at position 187 to enable additional 
interactions with viruses and mycobacteria as well as with other SP-A molecules (43-45). But the lack 
of glycosylation does not affect either the collagen domain stability or conformational changes induced 
by calcium in the globular domain (46). SP-A accumulates in vivo predominantly as octadecamers 
composed of six trimeric subunits forming a flower bouquet-like structure (47,48). SPD is also a 
hydrophilic surfactant protein belonging to the family of collectins. Recent studies showed that in 
contrast to SP-A, SP-D monomers preferentially assembly as dodecamers composed of four trimeric 
subunits forming a cruciform structure (49,50).  
Assuming that mRNA levels in the lungs reflect protein levels, the variable SP-A1:SP-A2 mRNA ratio 
indicates that single gene products may exist. These can form functional homotrimers and/or 
homooligomers. The extra cysteine of SP-A1 at position 85 can be involved in the formation of a SP-A 
intertrimeric or intratrimeric disulfide bond. It may account, in part, for differences in the 
oligomerization pattern between SP-A1 and SP-A2 variants (51). The majority of SP-A2 oligomers 
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exist in the dimer and trimer forms, whereas the majority of SP-A1 were found in larger molecular 
forms (e. g. trimers, hexamers) (52). 
Human SP-A mRNA is expressed in alveolar epithelial type II cells (53), Clara cells (54), in tracheal 
and bronchial submucosal gland cells, in breast (55) and Eustachian tube epithelium (56), peritoneum, 
synovium (57), small and large intestine (58), colon, salivary gland, prostate, pancreas and thymus 
(59). In human tissues other than lung, except for vaginal mucosa, peritoneum, synovium and 
Eustachian tube epithelium, only SP-A mRNA was found and no protein expression could be detected 
(60,61). Recently, Lee et al. found SP-A mRNA and protein expressed in paranasal sinus mucosa 
(62). Functional SP-A is involved in various aspects of surfactant biology, for example constitution of 
tubular myelin and innate immunity (63-67). 
 
 
 
Figure 1.2.3.1: Oligomerization of SP-A. Three polypeptide chains assemble to trimers. For SP-A 
those can be hetero- and homotrimers concerning SP-A1 and -A2. Up to six SP-A trimers form the 
characteristically bouquet-of-flowers. 
 
 
1.2.5) SP-A variants 
 
1.2.5.1) SP-A Polymorphisms and Genotypes 
 
Since the decryption of the SFTPA DNA-sequences many single base substitutions have been 
detected (68,69). For SFTPA1 are 54 and for SFTPA2 are about 80 substitutions listed in the SNP 
database of the University of California. Sequence variability within the coding region of both genes 
results in a number of allelic variants for each gene (70,71). These SP-A alleles have been denoted as 
6A
n
 for the exons of the SP-A1 gene and as 1A
n
 for the SP-A2 gene (72). 
Tables 1.2.5.1.1 and 1.2.5.1.2 show the relevant polymorphisms of SFTPA 1/2 to determine the 
individual alleles separated for each gene (73,74). Populations differ in frequencies of these alleles 
(75). This is demonstrated by the comparison of the American and Finnish population’s haplotype 
frequencies, as illustrated in Tables 1.2.5.1.1-1.2.5.1.3. Five SP-A1 alleles (6A, 6A
2
 
5
) and six SP-A2 
alleles (1A, 1A
0-3
, 1A
6
) occur at a generally moderate frequency in the populations studied, whereas 
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the remaining more than 30 alleles described yet, are found less frequently (74,76). Previously, only a 
small number of single nucleotide polymorphisms (SNP) were used to determine the alleles of the 
genes (74,77).  
 
 
Table 1.2.5.1.1: Alleles of SP-A1 
 
The table shows the alleles of the SP-A1 gene named 6A-6a
5
 and their frequency in different 
populations (Fi: Finnish population; US: American population). The alleles are defined by genotypes 
(bases:a, c, g, t) concerning specific polymorphisms, e.g. N9T which means an amino acidic exchange 
from asparagine to threonine at position 9 of the protein sequence caused by a single base 
polymorphism in the DNA sequence.  
 
 
 
Table 1.2.5.1.2: Alleles of SP-A2 
 
Allele Amino acid exchange 
 N9T V19A V50L P62P P91A T133T S140S Q223K Allele frequency 
1A c c g g c a c c 0.04 (Fi); 0.12 (US) 
1A
0 
a c g g g a c c 0.57 (Fi); 0.57 (US) 
1A
1 
c c g g g a t a 0.16 (Fi); 0.22 (US) 
1A
2 
c c g g g a c c 0.13 (Fi); 0.09 (US) 
1A
3 
a c g g g a t a 0.03 (Fi); 0.08 (US) 
1A
4 
c    g  t a <0.01 (Fi) 
1A
5 
c c g g c a t c 0.07 (Fi) 
1A
6 
c c g g g a t c <0.01 (Fi) 
The table presents the same pattern as table 1a for the SP-A2 gene. The alleles are named 1A-1A
6
 
and the allele frequencies are shown of the same populations as for the SP-A1 gene (Fi: Finnish 
population; US: American population) 
Allele Amino acid exchange 
 N9T V19A H39H V50L P62P P91A T133T S140S Y184Y Q223K Allele 
frequency 
6A a c c c g c g c t c 0.04 (Fi) 
0.09 (US) 
6A
2 
a t c g a c a c t c 0.60 (Fi) 
0.54 (US) 
6A
3 
a t c c a c a c t c 0.28 (Fi) 
0.28 (US) 
6A
4 
a t c c g c a c t c 0.09 (Fi) 
0.09 (US) 
6A
5 
a t t c a c a c  c <0.01 (Fi) 
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Table 1.2.5.1.3: Haplotypes of the SP-A genes 
Frequency  6A/1A 6A
2
/1A
0
 6A
2
/1A
1
 6A
2
/1A
2
 6A
2
/1A
3
 6A
3
/1A
0
 6A
3
/1A
1
 6A
3
/1A
2
 6A
4
/1A
5
 
Fi (74) 0.04 0.56 0 0 0.03 0.02 0.16 0.10 0.07 
US (78) 0 0.33 0.1 0.07 0.02 0.16 0.05 0.04 0.01 
Haplotypes are created by combining different alleles. The table displays some frequencies of such 
haplotypes in different populations. Fi stands for Finnish population (74), US for American (79). 
 
 
A number, but not all of polymorphisms for each SP-A gene are listed in the database of the University 
of California, Santa Cruz (UCSC). Some of those SNPs are not validated by population studies, e.g. 
S140S and P62P (for SP-A2) as you can see in Table A.1 in the appendix. Therefore it remains 
unclear whether one can extrapolate these data based only on a few subjects, to populations. 
 
 
1.2.5.2) Allelic Variants and mRNA 
 
The different alleles and their combinations result in different mRNA splice variants which differ in their 
stability and expression levels. The haplotype 6A
2
/1A
0
 was shown to be associated with low to 
moderate levels of mRNA (80). The 6A
3
 allele-derived mRNA was more prone to the destabilization 
effect of glucocorticoid treatment than 6A
2
 or 1A
0
 derived mRNA in a cell culture model (81). Both 
alleles, 1A
0
 and 1A
1
, are also associated with the splice variant ABD, whereas 1A and 1A
2
 are 
associated with ABD’ (82). Therefore the leader sequences resulting by those splice variants could be 
responsible for the different outcome of the mRNA. The SP-A2 splice variant ABD has a higher 
activity, higher mRNA stability and higher translation efficiency compared to SP-A1 variants (83). Five 
structural elements near the 5'-end of the mRNA determine the translational efficiency (84,85). These 
are 1) the m7G cap, 2) the primary sequence or context surrounding the AUG codon, 3) the presence 
of the AUG codons in the 5'-UTR, 4) the secondary structure of the mRNA, and 5) the 5'-UT leader 
length. It is likely that the composition and/or the length of the leader sequence play an important role 
in the translation efficiency and may account for efficiency differences among hSP-A 5'-UTR splice 
variants. The most frequently observed SP-A2 variants (ABD and ABD') have a longer leader 
sequence (ABD and ABD' are 100 and 97 nt, respectively) than SP-A1 (A'D') variants (62 nt). Other 
less frequently found variants with even longer leader sequences, for example AB'D' (137 nt), exhibit 
translational efficiency equivalent to A'D' or lower (86). These observations support the notion that the 
leader sequence composition is more important than simply the length of this sequence. It is 
speculated that the sequence composition of exon B contributes to an enhanced activity of the ABD 
variant, via binding of positive regulatory factors to exon B recognition sites (87). A previous study has 
implicated possible regulatory AP-1-like binding sequences within intron 1 and between exons A and 
B of human SP-A1 and SP-A2 (88). Whether the AP-1 site in exon B’ plays a role in the regulation of 
SP-A concentrations remains to be determined. 
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1.2.5.3) Alleles and Protein Function 
 
The amino acids 215glu, 222glu, 234asn and 235asp are involved in mannose binding of SP-A with 
the participation of calcium ions (89). In line with this, functions of the CRD, i. e. the binding of SP-A to 
type-II-pneumocytes, the regulation of surfactant metabolism and the ability to lipid aggregation, may 
be prevented by exchanging one of these amino acids to alanine (90). In addition, a number of the 
variant amino acids are located near to the mannose-binding sites. For example, in the SP-A1 allele 
6A4 (arg219trp) is the alkaline arginine replaced by a hydrophobic tryptophan. This may also affect the 
functions of the CRD. The affinity of binding of SP-A to the collectin receptor of phagocytes can be 
influenced by the substitution of the val50leu located in the collagen like domain of the SP-A molecule. 
When in the twenty-first collagen triplet of the allele 1A variant the amino acid proline is encoded 
instead of alanine (ala91pro), an amino acidic sequence is generated in 1A as regularly observed for 
SP-A2 alleles. During processing hydroxylated prolines stabilize the triple-helix by hydrogen bonds 
(91). Proline hydroxylation affects also both the arrangement of disulfide bonding and the extent of 
oligomerization, but not conformational changes in the globular domain (92). Therefore the SP-A1 
protein resulting from the 1A allele is more stable during processing than the other SPA1 variants (93). 
In vitro expressed SP-A1 and SP-A2 allelic variants were recently tested for their ability to enhance 
phagocytosis in rat alveolar macrophages. Generally, the SP-A2 variants were more effective than 
SP-A1 variants (94). Although the 1A
0
 variant exhibited higher activity compared with 1A, the 
coexpressed variant 1A
0
/6A
2
 was less active than the 1A/6A
4
. This can be explained by the activity 
level for these coexpressed variants being modulated by the SP-A1 variant present in the SP-A1/SP-
A2 oligomer (95). In conclusion, genetic SP-A variants result in different SP-A protein concentrations 
and different functional properties of the protein. A major goal is to link those variants to specific 
advantages or disadvantages with respect to disease related issues in humans. For this purpose 
many in vitro studies and mouse models have been generated which will provide new insights into the 
functional differences between SP-A1 and SP-A2. 
 
1.2.6) SP-A in vitro studies 
 
Most of the in vitro studies have been performed with human SP-A isolated from bronchoalveolar 
lavage fluid (BALF) of patients with pulmonary alveolar proteinosis (PAP). Alveolar proteinosis is a 
condition of greatly enhanced accumulation of surfactant components in the alveolar space. A few 
studies examined murine SP-A. Of interest, so far no studies have taken the different gene products, 
SPA1 and SP-A2, or other protein variations, into consideration. 
 
1.2.6.1)  SP-A and Pathogens 
 
SP-A is a member of the mannose-type subfamily of C type, i.e. calcium-dependent, lectins. As such it 
can bind with its CRD in its globular domain (Fig. 1.2.3.1) to mannose and glucose, and shows little 
interaction with galactose (96). Most microbial ligands naturally contain these or adequate saccharides 
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on their surface. SP-A can bind to di-mannose-repeating units present in certain Gram-negative 
capsular polysaccharides of Klebsiella bacteria (97). Moreover, SP-A shows CRD dependent binding 
to the N-linked sugars of specific cell wall glycoproteins, including major glycoprotein allergens of 
Aspergillus fumigatus (98). It also binds in a CRD-dependent manner to gpA, a heavily mannosylated 
glycoprotein associated with the trophozoites and cysts of Pneumocystis carinii (99,100). As an 
exception, some interactions of SP-A with viruses require the binding of viral lectins to the complex 
oligosaccharides on SP-A molecules (101). On the other hand SP-A can interact with lipids through its 
collagen like domain. SP-A binds to dipalmitoylphosphatidylcholine (DPPC), the major surfactant 
phospholipid (102,103), the lipid A domain of gram-negative LPS (104,105) and to several glycolipids 
and neutral glycosphingolipids (106-108). Furthermore SP-A was found to have direct effects on the 
survival of Gram-negative bacteria through mechanisms leading to increased permeability of the 
bacterial cell membrane (109). Exposure of the facultative intracellular fungal pathogen Histoplasma 
capsulatum to SP-A resulted in increased cell permeability and enhanced killing of the pathogen (110). 
These results suggest that SP-A plays a crucial role in the host defence. 
 
1.2.6.2) SP-A and Immune Cells 
 
In vitro data show that SP-A affects a variety of immune cell functions (reviewed in (111-113)). Within 
the alveolar space of the lungs, the abundantly present surfactant lipids have an inhibitory effect on 
immune cell function, whereas SP-A may have both stimulatory (114) and/or inhibitory effects (115). 
SP-A binds pathogen associated molecular patterns as described above by its globular head domain 
(CRD) and at the same time initiates phagocytosis through presentation of its collagen like domain to 
phagocytes. This effect is supposed to be mediated via receptors, e. g. cC1q, and activation of NFκB. 
Alternatively, if there are only a few pathogens present, the globular head domain interacts with the 
phagocytes, leading to an inhibition of NFκB. The latter effect is mediated via SIRPα thereby activating 
the tyrosine phosphatase SHP-1, with downstream blockade of signalling through src-family kinases 
and P38 map kinase, leading to a suppression of proinflammatory mediator production. It is assumed 
that SP-A acts in a dual manner, to enhance or suppress inflammatory mediator production depending 
on binding orientation illustrated in Fig. 5 (116). It appears that in the normal lung a fine-tuned balance 
exists between inhibition and stimulation of immune cells through the maintenance of an appropriate 
ratio of the various surfactant components (117,118). For instance, SP-A has been shown to enhance 
the uptake of a variety of bacteria by both alveolar macrophages and monocytes (reviewed in 
(119,120)). Additionally SP-A can act indirectly as an activation ligand to stimulate the phagocytosis of 
microorganisms (121). In this case, binding of SP-A to the cell but not the pathogen is required. The 
pathogen may be opsonized by another ligand, for instance IgG, or may bind directly to the phagocytic 
cell via a cell surface receptor such as the mannose receptor. SP-A has also been reported to inhibit 
the phagocytosis of some pathogens including Pneumocystis carinii (122) and M. tuberculosis (123). 
However, other studies found that SP-A enhanced the uptake of both organisms (124-126). Among 
other factors, such differences may be related to the different SP-A preparations used in the studies. 
Many other functions and properties of various immune cells have been demonstrated to be 
differentially influenced by SP-A (reviewed in (127)).  For example, SP-A stimulates the directional 
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actin polymerization and the chemotaxis of alveolar macrophages (128), but not the migration of 
monocytes. The production of cytokines in response to the inflammatory bacterial cell wall component 
LPS (129), intact Candida albicans (130), and to both intact bacteria and LPS, is inhibited by SP-A in 
the system of mixed buffy-coat cells (131). In alveolar macrophages, SP-A has been shown to directly 
enhance the production of tumour necrosis factor α and granulocyte-macrophage-colonystimulating 
factor (132,133). Similarly in human peripheral blood mononuclear cells, SP-A increased the 
production of tumour necrosis factor α, interleukin (IL) -1β, IL-6, IL-8 and interferon-γ (134). Moreover 
the production of reactive oxygen and nitrogen species by alveolar macrophages and monocytes can 
be modulated by SP-A (135-137). Neutrophils are responsive to SP-A in vitro as well. Thereby, SP-A 
enhances the phagocytosis of E. coli, Streptococcus pneumoniae, and Staphylococcus aureus by 
neutrophils (138), the killing of Aspergillus fumigatus conidia and also neutrophil migration (139). In 
eosinophils, Cheng and co-workers observed that SP-A suppresses ionomycin-induced production of 
IL-8 (140), suggesting that SP-A modulates the inflammatory activities of these cells in response to 
allergen challenge. Further studies defined a role for SP-A in attenuating lymphocyte responses 
(141,142) and inhibiting dendritic cell maturation (143). Migration and maturation of dendritic cells 
result in their movement to the lymphoid tissue compartment where they can activate T cells and link 
the innate and the adaptive immune response (143). 
In highly enriched populations of peripheral blood lymphocytes, SP-A inhibits plant lectin and anti-CD3 
stimulated T-lymphocyte proliferation (144). Partially, this inhibition is secondary to the inhibition of the 
production of IL-2, a potent mitogen for lymphocytes. To conclude, SP-A acts as a potent modulator of 
immune cell functions and enhances and/or suppresses inflammatory mediator production (145). The 
direction of these modulating influences is determined by the presence or absence of microorganisms 
resulting in opposite physical presentation of the CRD or the collagen like domain of SP-A to immune 
cells. 
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Figure 1.2.6.2.1: Stimulation and inhibition of inflammation by SP-A. SP-A acts in a dual manner, 
to enhance or suppress inflammatory mediator production depending on binding orientation (146). SP-
A binds to SIRPα via their globular head domains to initiate a signalling pathway that blocks pro-
inflammatory mediator production. In contrast, their collagenous tail stimulate pro-inflammatory 
mediator production via binding to calreticulin/CD91. SIRPα stands for signal inhibitory regulatory 
protein α, SHP for a protein tyrosine phosphatase, P38 for a map kinase, NFkB for a nuclear factor 
and CD91 for a heat shock protein receptor. 
 
 
1.2.7) Mouse Models 
 
Under resting conditions, the SP-A knock-out mouse reveals normal surfactant homeostasis and 
respiratory function, although the surfactant aggregates lack tubular myelin figures (147). A modest 
increase in the surfactant pool size was shown in 8-week-old SP-A (-/-) mice compared with their wild-
type counterparts (148). On the other hand, SP-A deficient mice have a significant defect in host 
defence (149). The SP-A (-/-) mice show delayed microbial clearance of intratracheally administered 
group B Streptococcus (GBS) (150), Haemophilus influenza (151), respiratory syncytial virus (RSV) 
(152), and Pseudomonas aeruginosa (153). An increased susceptibility to Pneumocystis carinii is also 
reported (154). The uptake of these microbes by alveolar macrophages in SP-A (-/-) mice is 
significantly reduced. In addition, decreased production of superoxide and hydrogen peroxide by 
alveolar macrophages in GBS and RSV infections are observed in SP-A (-/-) mice (155). Furthermore, 
SPA (-/-) mice had increased alveolar protein levels after four days of hyperoxia, but pressure-volume 
curves and the amount of alveolar protein were similar compared to SP-A (+/+) mice (156). After 
exercise, both groups showed no alterations of the amount of alveolar saturated phosphatidylcholine 
(157). This indicates that no functional deficits develop through SP-A dependent alterations in 
surfactant. The surface tension-lowering properties of surfactant from the SP-A (-/-) postnatal pup are 
compromised when the concentration of surfactant components (e. g. lipids) or other molecules (e. g. 
Ca
2+
) are suboptimal (158). In the full-term or postnatal SP-A (-/-) pup the composition of surfactant 
components is similar to that of the wild-type. Mice with sequential targeted deficiency of SP-A and 
SP-D develop progressive alveolar lipoproteinosis and emphysema (159). These doubly deficient mice 
indicate a functional overlap between SP-A and SP-D in regulating the surfactant homeostasis. SP-A 
overexpressing mice showed no alteration of thedistribution of the surfactant phospholipid between 
the air space and lung tissue, although alveolar levels of SP-A were as much as 7-to 8-fold higher in 
transgenic mice than in controls (160). Furthermore, overexpression of SP-A does not appear to 
disrupt lung function, since the transgenic mice show normal exercise tolerance, lung compliance, and 
ex vivo surfactant function. Additionally surfactant isolated from the transgenic mice is more resistant 
to protein inhibition than that from control littermates in the presence of protein inhibitors (161).  
The results show a predominant role of SP-A for host defence and immunologic processes of the 
lungs. Moreover, SP-A is of importance for the biophysical surfactant functions especially during 
increased pulmonary stress. 
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1.2.8) SP-A receptors 
 
An important task has been the identification of specific receptors for SP-A and SP-D. Both proteins 
bind to a multitude of different ligands. A number of potential receptors have been identified including 
surfactant protein receptor 210 (SP-R210) (162,163), glycoprotein-340 (GP-340) (164,165), signal 
inhibitory regulatory peptide (SIRP-α) (166), Toll-like receptors, receptors for C1q, CD14/sCD14 (167), 
the complex of CD91 and calreticulin (168).  
Future studies are required to define the mechanisms by which receptor expression is regulated and 
to determine whether specific cell types express different receptors under basal conditions. 
 
 
1.2.8.1) CD14 
 
Both SP-A and SP-D can directly bind CD14 (a major LPS receptor) as well as recombinant soluble 
CD14 (rsCD14). The binding of rsCD14, pre-incubated with SP-A, to smooth LPS is significantly 
reduced but the association of rsCD14 with rough LPS is augmented, suggesting different actions of 
SP-A upon distinct serotypes of LPS (169). Thus, a direct interaction of SP-A with CD14 constitutes a 
likely mechanism by which SP-A modulates LPS-elicited cellular responses. SPA binds the peptide 
portion containing the leucine-rich repeats of CD14 whereas SP-D binds the carbohydrate moiety of 
CD14 (170). 
 
 
1.2.8.2) Calreticulin-CD91 complex 
 
SP-A (via its collagen region), has been shown to interact with an approximately 60 kDa, Ca
2+
-binding, 
multifunctional protein, called calreticulin (CRT), originally described by Malhotra et al. (171) as cC1qR 
or collectin receptor. Isolated as a 60 kDa acidic glycoprotein from U937 cells and human tonsil 
lymphocytes (and also shown to be present on leukocytes, platelets and endothelium) that formed 
dimers of 115 kDa when solubilised under non-denaturing conditions, this receptor molecule was 
shown to bind C1q via its collagen region (hence the name cC1qR) and related members of the 
collectin family-MBL, SPA and bovine conglutinin (thus the name collectin receptor) (172). The surface 
expression of cC1qR was also shown to be upregulated by interaction with SP-A (173). CRT, when 
bound to collagen region of C1q, MBL, SP-A and SP-D, uses the endocytic receptor CD91 as an 
adaptor molecule for phagocytosis and signal transduction (174,175). The role of CRT-CD91 in the 
clearance of apoptotic cells has been extended to SP-A when the collectin is engaged as opsonin via 
its lectin domain (176). Recently, the CRT-CD91 pair has also been shown to orchestrate SP-A 
mediated induction of pro-inflammatory cytokines (177). Based on a series of elegant experiments, 
Gardai et al. (178) have demonstrated that SP-A can initiate either proinflammatory or anti-
inflammatory mechanisms, depending on the orientation of the molecule.  
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1.2.8.3) SIRPα 
 
SP-A is a potent modulator of macrophage function and may suppress clearance of apoptotic cells 
through activation of the transmembrane receptor signal inhibitory regulatory protein alpha (SIRPα) 
(179). SP-A has been shown to opsonise apoptotic cells in vitro and to facilitate their phagocytosis by 
resting alveolar macrophages (AM) (180-182). This effect has been confirmed in vivo and is mediated 
through CD91 and calreticulin on the phagocyte surface (183). An opposing effect may be seen when 
SIRPa is activated by SPA. Ligation of this receptor blocks Fcg receptor and complement-mediated 
cellular phagocytosis (184,185). Thus, in the naive lung, binding of SP-A to SIRPα on the AM may 
tonically inhibit apoptotic cell engulfment, resulting in the inefficient uptake observed for these cells. 
During inflammation, this inhibitory effect may be lifted to facilitate apoptotic cell removal. 
 
1.2.8.4) SP-R210 
 
One receptor that has been characterized on the surface of macrophages and type II cells and found 
to bind SP-A even in the presence of a 100-fold excess of mannan (186). Polyclonal antiserum raised 
against this 210-kDa receptor (SP-R210) was also able to prevent SP-A from inhibiting 
phosphatidylcholine secretion by phorbol ester-treated type II cells and to inhibit the SP-A dependent 
uptake of bacillus Calmette-Guerin by macrophages (187). Mediated by this specific receptor SP-A 
inhibited T cell proliferation in vitro (188). The domain responsible is a segment of the collagen-like 
domain, so the CRD is not involved (189). 
 
1.2.8.5) Toll like receptors 
 
Toll like receptors (TLR) are important cell-associated and intracellular pattern recognition receptors 
(PRR). There are currently 12 identified mammalian TLRs, of which TLR2 and TLR4 are among the 
most widely studied and are considered the major transmembrane TLRs (190). TLR2 and TLR4 play 
roles in initiating immune responses against pathogens. TLR2 forms a heterodimer with TLR6 or TLR1 
to recognize diacyl and triacyl lipopeptides, respectively. TLR2 binds to zymosan, a particle composed 
of yeast cell wall components and peptidoglycan, a component of the Gram-positive bacteria cell wall 
(191,192). SP-A has been shown to up-regulate certain PRRs, such as scavenger receptor (193) and 
the mannose receptor (194). SP-A also differentially regulates the expression of TLR2 and TLR4 
during primary human monocyte differentiation into macrophages (195). Despite up-regulation of 
TLR2 expression, SP-A markedly diminishes the macrophage proinflammatory response generated by 
both TLR2 and TLR4 agonists (196). The underlying mechanism is related to altered phosphorylation 
of a central regulator of cellular function, Akt, as well as downstream intermediates in the MAPK 
pathway and the activation of NFκB (197). 
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1.2.9) SP-A and human lung diseases 
 
Primary SP-A deficiency in humans has not been demonstrated yet. Similarly, mutations in SP-A1/2 
which cause monogenic disease states have not been found. However, in various human lung 
diseases altered levels of SP-A have been observed in the lungs, i. e. BAL fluid, and also in serum 
(198). Extensive genetic analyses show correlations between certain SP-A alleles and altered risks for 
lung disease (199-202). Taken together these data suggest that SP-A acts as a modifier gene 
influencing the manifestation, progression or pattern of human lung diseases. Few of these studies 
presented below allow genotype/phenotype correlations. More knowledge is required on the exact 
relations between genetic variants of SP-A, protein levels, the macromolecular organization of SP-A 
and its function. In a wide range of paediatric and adult lung diseases, deviations of the concentrations 
and integrity of SP-A have been found. These include the Acute Respiratory Distress Syndrome 
(ARDS), patients with chronic lung diseases like Cystic fibrosis (CF), various interstitial lung diseases 
and others. 
In the following, the human studies on SP-A are summarised and the most important issues are 
discussed. 
 
1.2.9.1) Neonatal and Adult Respiratory Distress Syndrome 
 
The composition of surfactant components in prematurely born infants that died from Respiratory 
Distress Syndrome (RDS) differs from that in term infants or in prematurely born healthy infants (203). 
Reduced levels of SP-A which slowly recover by and by are known for infants with RDS (204). There 
is an association of low levels of SP-A and a lack of tubular myelin in infants with RDS (205). Recently 
it was shown that the SP-A2 allele 1A
0
 occurs at a significantly higher frequency in white infants older 
than 28 weeks gestation and RDS (206). Reduced levels of surfactant components including SP-A 
and altered surfactant composition in infants with or at risk for RDS have been shown (207-209). In 
agreement with animal experiments, these data support a physiological role of SP-A for the surface 
tension lowering function of surfactant during RDS. Abnormalities in surface tension lowering 
properties or host defence functions due to secondary alterations of SP-A levels have also been 
implicated in the pathophysiology of the Adult Respiratory Distress Syndrome (ARDS) (210-212). 
Specific genetic defects have not been identified. However, certain SP-A polymorphisms, e. g. SNPs 
determining the 6A
2
 allele, were identified as risk factors (213,214). Of note, SP-A levels are reduced 
in (bronchoalveolar lavage) BAL fluid (BALF) from ARDS patients (215). In these patients SP-A 
concentrations in sera are significantly elevated compared to healthy controls after the onset of ARDS 
(216). Leakage out of the alveolar space has been suggested as the responsible mechanism for this. 
Thus, serum levels of SP-A were proposed as disease activity or prognostic marker for ARDS and 
other severe lung injuries (217). In patients with ARDS different genotypic subgroups with respect to 
SP-A may be responsible for the susceptibility to lung injury, and this difference may have an impact 
on the success of various therapeutic modalities. 
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1.2.9.2) Allergic Bronchopulmonary Aspergillosis 
 
Allergic bronchopulmonary aspergillosis (ABPA), an allergic and inflammatory disorder of the airways, 
is caused by the pathogenic fungi Aspergillus fumigatus. A series of investigations by Madan et al. 
established that SP-A has an important role in strengthening the host defence against A. fumigatus 
and its allergic disorders (218,219). A significantly higher frequency of the AGA allele (A1660G) of SP-
A2 was observed in patients with ABPA in comparison with controls. 
 
1.2.9.3) Idiopathic Pulmonary Fibrosis 
 
Derangement in pulmonary surfactant or its components are common observations in IPF. In patients 
with IPF, serum SP-A concentrations reflect the disease activity of IPF (220). The associations 
between IPF and genetic variants of SP-A1 and SP-A2 have been examined in a Mexican population 
(221). One SP-A1 allele (6A
4
) was found in higher frequency in non-smoker and smoker IPF 
subgroups compared to healthy controls. 
 
1.2.9.4) Pulmonary Alveolar Proteinosis 
 
PAP is characterized histologically by intra-alveolar accumulation of large quantities of fine granular 
eosinophilic and periodic acid-Schiff positive material (222). SP-A levels in BALF in patients with PAP 
is increased in comparison with controls, but the ratio of SP-A to total protein in BALF is almost 
similar, while the ratio to phospholipid is higher (223). Therefore, measurement of SP-A levels could 
be used as a biochemical diagnostic tool in the clinical laboratory to detect PAP. But SP-A in PAP 
showed not-reducible intramolecular bonds which are not existent in SP-A from healthy subjects or 
other patient groups (224). 
 
1.2.9.5) Cystic Fibrosis  
 
SP-A is increased in BALF of infants and young children with Cystic fibrosis (CF) in the absence of 
pulmonary inflammation (225), whereas in older children and adults with CF SP-A is consistently 
decreased in BALF (226-228). Furthermore, proteolytic degradation of SP-A was shown in CF, 
supporting the hypothesis that inflammation may play a role in decreasing SP-A function in CF airways 
and that lower levels are not a primary abnormality associated with this disorder (229,230). Chronic 
airway inflammation caused by Pseudomonas (P.) aeruginosa is an important feature of CF. SP-A 
enhances the phagocytosis of P. aeruginosa in some (231), but not in all in vitro studies (232). A direct 
modification of the chance to acquire P. aeruginosa or to eliminate it from the CF lungs has not been 
demonstrated in humans so far. There is also a suggestive linkage of the fibrotic lung phenotype and 
regions on chromosome 10, where the SP-A genes are located (233). A genome-wide linkage scan in 
CF knock-out mice shows an association between intestinal distress and a locus on chromosome 10 
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in male CF mice (234). A recent study showed an association between the haplotype 6A
3
/1A
1
 and 
lower pulmonary function as well as poor pulmonary scores (235). 
 
1.2.9.6) Asthma and chronic bronchitis 
 
The possible involvement of pulmonary surfactant in the pathophysiology of respiratory diseases with 
a predominant disturbance in the conducting airways, such as asthma, has only recently been 
addressed (236). In patients with asthma the SP-A levels were found to be unchanged (237). Van de 
Graaf et al. (238) reported that BALF levels of SP-A were decreased in patients with asthma. 
Accordingly, it has been reported that mite-allergen-induced airway inflammation leads to decreased 
levels of SP-A and SP-D in BALF from sensitized mice (239). In contrast, Cheng and co-workers (240) 
found increased levels of SP-A in bronchial and alveolar lavages in mild, stable asthmatics compared 
with controls. The discrepancy of these findings might be due to different time points and methods of 
sampling of the lavage fluids, and requires further clarification. A very early step in the induction of 
allergic inflammation is allergen uptake by dendritic cells, antigen processing and subsequent antigen 
presentation to T lymphocytes. SP-A has been shown to bind to pollen grains (241). In addition, it has 
been demonstrated that SP-A interacts with mite allergens in a carbohydrate-specific and calcium-
dependent manner (242). Moreover, SP-A was found to inhibit allergen-specific IgE binding to the mite 
allergens. 
 
 
1.3) Surfactant protein D 
 
SP-D belongs as SP-A to the family of C-type lectins called ‘collectins’ (243-245). The primary 
structures of both collectins are very similar and contain four regions, (i) a cysteine-containing N-
terminus, (ii) a triple-helical collagen region composed of repeating Gly-X-Y triplets, (iii) an α-helical 
coiled coil neck region, and (iv) a globular structure at the C-terminus comprising the C-type lectin or 
CRD (246) (Fig. 2). Surfactant protein D is encoded by a single gene on chromosome 10 located near 
SP-A and other members of the collectin family (247). It forms multimers like SP-A, which increase its 
affinity to immune cells and pathogens (248). The SP-D gene (SFTPD) is translated into a protein 
consisting of 345 amino acids (249). These monomers form trimers and four trimers assemble to a 
cruciform structure (Fig. 1.3.1). As SP-D has the largest and most flexible collagen domain among the 
collectins, it forms networks with various bound organisms (250). Surfactant protein D is primarily 
expressed and secreted by type II alveolar cells but is also detected in Clara cells and in the tracheal 
and bronchial glands of the lower airways (251,252). Although SP-D was first identified in the 
respiratory tract, current studies demonstrate the expression of SP-D in almost all mucosal surfaces, 
including epithelial cells in exocrine ducts, the mucosa of the gastrointestinal and genitourinary tract 
and recently in human tear fluid, protecting the eyes against Pseudomonas aeruginosa invasion(253-
255). SP-D knock-out mice exhibit an enhanced pulmonary Th2 response, leading to a predisposition 
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of allergic dysregulation and inflammation (256). These data clearly show that despite many structural 
similarities between the two proteins, their roles in physiology are distinct. Therefore we will discuss all 
structural and functional data separately for each of the proteins to facilitate the understanding of their 
differential roles.  
 
 
 
Figure 1.3.1: Oligomerization of SP-D. Three polypeptide chains assemble to trimers. Up to four SP-
D trimers form the characteristically cruciform structure. 
 
 
1.3.1) SP-D in human lung diseases 
 
Primary deficiency in humans has been demonstrated for SP-D (257). The composition of surfactant 
components in prematurely born infants that died from Respiratory Distress Syndrome (RDS) differs 
from that in term infants or in prematurely born healthy infants (258). Reduced levels of SP-D which 
slowly recover by and by are known for infants with RDS (259). Two studies demonstrated that ARDS 
patients have reduced SP-D levels in BALF compared with control subjects (260,261). Increased SP-
D serum levels are associated with worse clinical outcome and greater risk of death in ARDS. 
The levels are also severely decreased in CF patients, except in infants and young children (262-264). 
The CF-associated protease human leucocyte elastase (265), proteinase 3, cathepsin G (266) and 
Pseudomonas elastase (265) degrade SP-D proteolytically. The proteolytic damage may impair the 
host defence functions in lungs of CF patients (267).  
Chronic interstitial lung diseases (ILD) involve the most peripheral compartment of the lungs and are 
associated with chronic injury to the cells of the alveolar region, i.e. hypertrophy of type-II 
pneumocytes, and damage to the surfactant system (268). Under these conditions alterations of SP-D 
levels have been demonstrated, as well as abnormalities in surface tension-lowering properties or host 
defense functions. SP-D levels are elevated in patients with systemic sclerosis and 
polymyositis/dermatomyositis. 
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1.4) Aim of the study 
 
Surfactant associated protein-A (SP-A) is the most abundant pulmonary surfactant protein and 
belongs to the family of innate host defence proteins termed collectins. Besides pulmonary host 
defence, SP-A is also involved in the formation of pulmonary surfactant, as it is essential for the 
structure of tubular myelin. The human SP-A gene locus includes two functional genes, SFTPA1 and 
SFTPA2 which are expressed independently, and a pseudo gene. SP-A polymorphisms play a role in 
respiratory distress syndrome, allergic bronchopulmonary aspergillosis and idiopathic pulmonary 
fibrosis. The levels of SP-A are decreased in the lungs of patients with CF, respiratory distress 
syndrome and further chronic lung diseases. Future areas for clinical research include disease specific 
SP-A expression pattern and their functional consequences, the differential roles of SP-A1 and SP-A2 
in human lung diseases, and therapeutic approaches to correct altered SP-A levels. 
The aim of the study was to elucidate the role of SP-A in human lung disease. There were numerous 
studies about the structure and function of SP-A in vitro or ex vivo using PAP-SP-A. Although studies 
had proved that SP-A structure arising from in vitro samples does not equal ex vivo samples (269) the 
relation between genetic polymorphisms in SFTPA and SP-A structure was analyzed with in vitro 
samples. PAP-SP-A has been shown to contain additional intramolecular bonds and is existent in 
different isoforms (270). Therefore it is not representative for SP-A of healthy individuals. This study 
was designed to analyze the relation between genetics, structure and function of SP-A in a CF, 
chronic bronchitis and asthma and healthy control population ex vivo. 
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2) Material and Methods 
 
All reagents were purchased from Merck (Darmstadt, Germany) if not otherwise entitled. Aqua 
injectabili was purchased from Delta Select (Munich, Germany). The tips were purchased by Greiner 
BioOne (Frickenhausen, Germany), the tubes from Eppendorf (Hamburg, Germany) and the pipettes 
from Qiagen (Hilden, Germany). 
 
2.1) Study populations 
 
From all patients clinical data was collected and they gave written consent that their material can be 
analyzed for scientific studies.  
 
2.1.1) Cystic Fibrosis study population 
 
The CF patients whose samples were analyzed in this study were 371 patients from the Dr.-von-
Haunersches children’s hospital, Munich, not included in the BEAT study group while 82 were from a 
previous study (BEAT) including CF centres in Berlin (17 patients), Essen (18 patients), Hannover (12 
patients), Cologne (26 patients) and Munich, the Dr.-von-Haunersches children’s hospital (9 patients). 
For the BEAT study BAL and serum of each patient was analyzed. Because BALs are rarely used for 
diagnostic and therapeutic reasons in routine clinical management of CF patients only four additional 
BAL samples were available from the Hauner CF population. The diagnosis of CF had been confirmed 
by repeated sweat test with chloride concentrations exceeding 60 mmol/l. Genetic analysis for the 30 
most prevalent CFTR mutations in Germany was available for 404 of the 453 patients.  
 
2.1.2) Bronchitis study population 
 
All 72 patients included in the bronchitis study population were chronic bronchitis and asthma patients 
from the Dr.-von-Haunersches children’s hospital, Munich. All patients were diagnosed after the 
definition criteria. The chronic bronchitis patients had a daily cough for at least 3 months. In all patients 
primary ciliary dyskinesia, CF, gastro-oesophageal reflux disease, anomalies of the lungs and airways 
and immunodeficiency were excluded. The asthma patients had an increased responsiveness of the 
bronchi to various stimuli, had manifested as narrowing of the airways in exercise or cold air 
provocation tests and were responsive to β-agonists. 
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2.1.3) Control study population 
 
The control study population includes only persons who had no airway diseases or abnormalities. 25 
persons were recruited from the Dr.-von-Haunersches children’s hospital, Munich, and 10 from the 
children’s hospital in Hannover. 
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No. Patients Clinical data SNPs ELISA Gel chromatography Agglutination-assay 
BAL Serum BAL Serum F BAL F Serum W BAL W Serum 
1    10 CF-BEAT   
2    15 CF-BEAT 
     1 CF-Hauner 
    
3      2 CF-BEAT 
     1 CF-Hauner 
   
4  12 CF-BEAT         
5    4 CF-Hauner        
6  10 Bro-Hauner 
   7 C-Hauner 
             
7    1 CF-Hauner  
   4 Bro-Hauner 
   4 C-Hauner 
      
8  11 Bro-Hauner 
   1 C-Hauner 
     
9  10 C Hannover       
10  41 CF-BEAT    
11 202 CF-Hauner 
    1 CF-BEAT 
       
12 154 CF-Hauner 
   1 CF-BEAT 
 47 Bro-Hauner 
 14 C-Hauner 
       
13 102 CF-London      
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Figure 2.1.1: Scheme of the study design. The figure shows the data analyzed and methods used in 
this study and the number of patients included. CF stands for cystic fibrosis patients, Bro for bronchitis 
and asthma patients and C for the control group. BEAT means a special study population including 
patients from CF centres in Berlin (17 patients), Essen (18 patients), Hannover (12 patients), Cologne 
(26 patients) and Munich, the Dr.-von-Haunersches children’s hospital (9 patients). Hauner means that 
those are patients from the Dr.-von-Haunersches children’s hospital not included in the BEAT study 
group. F stands for fractions of gel chromatography, W for whole samples. In the left column the 
identification number of each group is listed. The thick lines enframe the two major study populations, 
the structure and function population (orange: Gel chromatography and Agglutination-assay; exact 
groups see table 2.1.1) and the genetic population (blue: SNPs and ELISA; exact groups see table 
2.1.1). The clinical data were used for both groups. Grey areas indicate variables not assessed in 
these groups of subjects. 
 
 
 
 
Table 2.1.1: Methods and group distribution. 
Clinical 
data 
MALDI-TOF 
and Probes 
ELISA Gel 
chromatography 
Agglutination 
assay F 
Agglutination 
assay W 
No.  1-9 
No. 11-13 
No.  1-8 
No. 10-12 
No.  1-11 
No. 13 
No.  1-9 No.  1-6 
 
No.  1-5 
The table shows the patient groups analyzed by the different methods. The group numbers are the 
identification numbers of figure 2.1.1. In addition within these groups the grey shaded areas of Fig. 
2.1.1. indicate variables not assessed in these subjects. 
 
 
2.2) DNA extraction from whole blood with a QIAmp-Kit 
To extract the DNA from whole blood samples of the patients and controls a kit from QIAmp (Qiagen, 
Hilden, Germany) was used after the provided protocol. In a 50 ml Falcon tube 3 ml whole blood were 
mixed with 500 µl Protease and 5 ml lyzation buffer. The solution was incubated in a water bath for 10 
min (minutes) at 70 °C. Then 5 ml Ethanol were added and everything was mixed by a vortex. The 
solution was transferred to a column (QIAmp) placed in a clean collection 50 ml Falcon tube. After 
closing the cap the column was centrifuged at 3000 rpm for 3 min. The filtrate was discarded and the 
column placed back into the tube. Afterwards 5 ml buffer AW1 were added to the column and the 
column was centrifuged at 5000 rpm for 1 min. 5 ml buffer AW2 were added followed by another 
centrifugation at 5000 rpm for 15 min. The column was placed in a new tube while the collection tube 
and the filtrate were discarded. 1 ml elution buffer was pipetted on the membrane of the column and 
incubated for 5 min. Afterwards the column was centrifuged at 5000 rpm for 2 min. The last step was 
repeated. The DNA solution was transferred in an Eppendorf tube (Eppendorf, Hamburg, Germany). 
The concentration of the solution was measured with SybrGreen and then adjusted to a concentration 
of 20 ng/ml. 
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2.3) Bronchoalveolar lavage (BAL) 
BAL was performed as described (271) with 4 × 1 ml/kg body weight normal saline warmed to body 
temperature. The first aliquot of the recovered BAL fluid was treated separately; all other samples 
were pooled for analysis. The total cell count was measured in a hemocytometer; the differential cell 
count was assessed from cytoprep slides. Aliquots of the cell free BAL supernatant of the pooled BAL 
sample were used for the analysis of total protein, and the surfactant proteins by enzyme linked 
immunosorbent assay (ELISA). 
 
2.4) SP-A structure 
 
2.4.1) Gel Chromatography with Superose 6 column 
 
Table 2.4.1.1: Population. 
Patient group Serum BAL Pairs 
Cystic Fibrosis 34 42 30 
Bronchitis 14 21 10 
Control 11 18 7 
The table shows the number of the samples analyzed by gel chromatography (total n=94) from the 
three patient groups. 
 
 
Buffers 
 
ÄKTA buffer 
  20 mM Tris  
150 mM NaCl  
    1 mM EDTA  
pH 7.4 
 
 
Procedure 
To determine structural differences in BAL and serum between the study populations a gel 
chromatography method with a superpose 6 column (Amersham Pharmacia Biotech, Uppsala, 
Sweden) in an ÄKTA Purifier 900 (Amersham Pharmacia Biotech, Uppsala, Sweden) was chosen. In 
this method SP-A molecules were separated with regard to their oligomerization form. The larger the 
oligomers the earlier they were eluted. The column was calibrated by using bluedextran (2000 kDa), 
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holotransferrin (669 kDa) and bovine serum albumin (66 kDa). The column was equilibrated with 
ÄKTA buffer and then loaded with either 0.5 ml serum or 1 ml BAL. 39 fractions were collected in 
Eppendorf safe lock tubes á 0.8 ml volume (Eppendorf, Hamburg, Germany). Flow rate was 0.4 ml per 
min; the void volume was 6.8 ml. The fractions 6-25 were loaded on a Slot-Blot for further analysis. 
The other fractions were excluded by a prior experiment to analyze whether SP-A or SP-D is 
detectable in the fractions. Because of a constantly negative result the fractions from 1-5 (void 
volume) and from 26 to 39 were not further analyzed. 
 
2.4.2) Dot-Blot 
 
Buffers 
 
Blocking buffer  TBS (Tris-buffered saline) 
2 g TWEEN 
6 g Fish gelatine 
200 ml TBS 
 20 mM Tris-HCl 
150 mM NaCl 
pH 7.5 
 
TBS-T (Tris-buffered saline with Tween) 
20 mM Tris-HCl 
150 mM NaCl 
pH 7.5 
0.05 % Tween20 
 
Procedure 
After gel chromatography the SP-A amount of the eluted fractions had to be determined. For this a 
Slot-Blot method was used. The membrane (BioRad, Munich, Germany) was incubated for 1 min in 
100% methanol and then with 3 BioRad filters (BioRad, Munich, Germany) washed with H2O for 5 min. 
Further everything was equilibrated in TBS/methanol (4:1). Cells were washed with 200 µl TBS. 100 µl 
Standard recombinant human SP-A (gift of Dr. Wolfram Steinhilber, Nycomed, Konstanz, Germany) 
and 200 µl of the fractions were loaded in the cells and washed by 200 µl TBS. Membrane was 
blocked with blocking buffer for 3 h. After washing 3 times with TBS for 10 min the membrane was 
incubated with a polyclonal recombinant rabbit-anti-human SP-A antibody (Nycomed, Constance, 
Germany) and 1 % bovine serum albumin (BSA, Paesel+Lorei, Duisburg, Germany) overnight. Again 
the membrane was washed 3 times for 10 min with TBS-T and then incubated with a second goat-
anti-rabbit antibody (1:10,000, Biozol, Eching, Germany) and 1 % BSA for 2 h. The membrane was 
washed three times with TBS-T for 10 min. For signal detection the membrane was incubated for 1min 
in a mixture of 500 µl of each reagent from Super Signal West Dura (Pierce, Bonn, Germany) and 1 ml 
of each reagent from ECL Western Blot Detection Reagents (GE Healthcare, Munich, Germany). 
Signals were measured with a DIANA III camera (raytest, Straubenhardt, Germany) by 15 min 
duration of exposure and evaluated by AIDA Software (raytest, Straubenhardt, Germany). 
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2.4.3) Reproducibility of gel chromatography and Dot-Blot 
 
The reproducibility of the gel chromatography and the Slot-Blot assay were tested (see fig. 2.4.3.2 and 
2.4.3.3). Four serum and 2 BAL samples of 5 different individuals were analyzed twice by gel 
chromatography and Slot Blot at intervals of four weeks. Two serum samples of one person were each 
twice analyzed at one day and one sample analysis was repeated after 4 days. Also from the same 
person another serum sample was taken after these four days and twice analyzed by gel 
chromatography and Slot-Blot. For testing the reproducibility of the Slot-Blot assay separately the SP-
A standard curve was compared (see fig. 2.4.3.1). The reproducibility of the slot-blot assay was good, 
as determined by the coefficient of variation at the highest (41.6 ng/ml; rel CV 6.1 %) concentration of 
the standard curve. 
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Figure 2.4.3.1: SP-A standard variance. The graph shows on the x-axis the predetermined SP-A 
amount in ng/ml and on the y-axis the measured SP-A amount in ng/ml (n = 10). The variance was 
insignificant. 
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Figure 2.4.3.2: Reproducibility of gel chromatography. The graphs show the fraction number on the 
x-axis and the SP-A amount in ng/ml on the y-axis. All samples were measured twice in an interval of 
4 weeks. The curve form varied only little in comparison to the SP-A amount, but the variances are 
insignificant. 
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Figure 2.4.3.3: Reproducibility of serum gel chromatography. The graph shows the reproducibility 
of serum samples from one person. On the x-axis is the fraction number and on the y-axis is the SP-A 
amount in ng/ml plotted. The curve form varied only little in comparison to the SP-A amount, but the 
variances are insignificant. 
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2.4.4) Calibration of the Superose column 
 
After validation of the reproducibility the column was calibrated with different molecules, Bluedextran, 
Holotransferrin and bovine serum albumin (BSA), of a known molecular weight which had been used 
in published studies (272,273).  
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Figure 2.4.4.1: Calibration of Superose 6 column. The graph plots on the x-axis the number of the 
fractions and on the y-axis the OD 270. The calibration curves of Holotransferrin with a molecular 
weight of 669 kDa, Bluedextran with a molecular weight of 2000 kDa and BSA with a molecular weight 
of 66 kDa are shown. 
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Figure 2.4.4.2: Column calibration and SP-A peaks. The graph illustrates the defined peaks of SP-A 
after gel chromatography and the calibration. On the x-axis the number of the fractions and on the y-
axis the relative SP-A amount in % is plotted. With regard to the molecular weight of the calibration 
proteins the first peak should contain octadecamers or more complex oligomers, the second sixmers 
to twelvemers and the last peak dimers and trimers.  
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2.4.5) SP-A isolation 
 
For testing the SP-A isolation assay, first BAL samples from controls, in particular fraction 10 derived 
from gel chromatography of 12 controls (group no. 9 and controls C Hauner 1 and 4), were pooled and 
used in 2.4.5, 2.4.6 and 2.4.7. Because the complete pooled sample was spent in the first test, for 
2.4.8 12 BAL fractions (F 10) of CF patients (group no.2) were pooled which showed the same high 
relative SP-A amount in the first peak and had also comparable SP-A levels in BAL. Because the self-
agglutination ability of SP-A derived from CF patients was less effective than of SP-A derived from 
controls the test was only done with fraction 10 (first peak) of CF patients which showed nevertheless 
a high self-agglutination ability.    
 
Buffers 
 
TBS 
20 mM Tris-HCl 
150 mM NaCl 
pH 7.5 
 
Procedure 
For investigating the SP-A structure with another method, SP-A was isolated of the fractions from the 
first peak (F10) after gel chromatography by beads. The beads were coupled to an anti-SP-A antibody 
by biotin-streptavidin binding and could therefore pull the SP-A down in the fractions. The fractions 
were taken from 12 BAL control samples. All 10 samples from group no. 9 (C Hannover) and 2 
samples from group no. 6 (C Hauner) were used, see also Fig. 2.1.1. The streptavidin-coated 
Dynabeads M-280 (Invitrogen, Karlsruhe, Germany) were separated from the solution by holding the 
tube near a magnet (magnetic bubbler), and the solution was discarded by pipetting. The beads were 
washed twice with 1ml of water followed by 1ml of TBS. Then the beads were resuspended in 200 µl 
of TBS and add 100 µl biotinylated mouse anti-human SP-A antibody (HYB 238-04, Antibodyshop, 
Gentofte, Denmark). This suspension was mixed for 1h under constant movement. Afterwards the 
beads were washed sequentially with 1 ml TBS, 1 ml TBS with 1% Triton X-100 (SIGMA, Munich, 
Germany) to inhibit unspecific binding, and 3 times with 1ml of TBS. The beads were resuspended in 
450µl of TBS and stored at 4°C till use. Then the beads were incubated with 600 µl of a fraction or 500 
µl of BAL or serum samples under constant movement for 1 h at RT. The beads were washed three 
times with TBS to remove calcium to inhibit self-agglutination and binding to other proteins or 
pathogens. Thereafter the beads were incubated for 30 min with 400 µl 100 mM glycine-HCL buffer 
pH 2.5 at RT to dissolve SP-A. The SP-A solution was separated from the beads and the pH was 
changed to about 5 (isoelectric point of SP-A) with 1 M NaOH. At last the beads were washed for 
reactivation 3 times with glycine-HCL buffer and resuspended in 450 µl TBS and store at 4°C. 
In the supernatant after the pull-down, almost none SP-A was left in solution. Also after dissolving and 
separating the beads from the SP-A solution only a small amount of SP-A was left with the beads and 
detected in the wash solution. 
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Figure 2.4.5.1: Efficiency of the SP-A isolation assay. The graph shows the amount of SP-A in ng 
(y-axis) in the different solutions before (BAL fractions pool), during (supernatant, bead wash) and 
after (end solution) the SP-A isolation measured by Slot-Blot. SP-A was isolated of the fractions from 
the first peak of 12 controls after gel chromatography by beads. The beads were coupled to an anti-
SP-A antibody by biotin-streptavidin binding and could therefore pull the SP-A down in the fractions. 
Almost the complete SP-A amount from the starting pool solution could be isolated. 
 
2.4.6) Protein gel 
 
Buffers 
 
Separation gel  Collecting gel 
 10 ml acryl amide 
   5 ml separation gel buffer 
   5 ml Aqua dest. 
200 µl SDS (20%) 
100 µl APS (20%) 
   8 µl TEMED 
 0.75 ml acryl amide 
     1 ml collecting gel buffer 
  4.1 ml Aqua dest. 
   60 µl SDS (20%) 
   30 µl APS (20%) 
     6 µl TEMED 
 
Sample buffer  Electrophoresis buffer 
   7 ml Tris/SDS pH 7.8 
   3 ml glycerol 
1.2 ml Bromphenolblue 
   1 g   SDS 
  10 ml Aqua dest. 
 30.2 g Tris-base 
 144 g glycine 
   10 g SDS 
     1 l Aqua dest. 
 
 
 
Separation gel buffer  Collecting gel buffer 
1.5 M Tris 
0.4 % SDS 
pH 8.8 
 0.5 M Tris-base 
0.4 % SDS 
pH 6.8 
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Procedure 
For determining the purity of the isolated SP-A sample (derived from step 2.4.5) it was first separated 
by gel chromatography. The denaturizing SDS-polyacryl-amide-gelelectrophoresis (SDS-PAGE) was 
executed after the protocol of Lämmli (275). The polymerization of the gel was started by adding APS 
as a radical starter and catalyzed by TEMED. The polyacryl-amide-gel consisted of a collecting gel 
where the proteins were focused and a separation gel in which the proteins were separated. The SDS 
which contained the sample buffer destroyed non-covalent interactions in native proteins. By SDS 
binding to the protein it influenced the migration behaviour of the complex, so the proteins were 
separated by molecular size only. The protein lysates were dissolved in 6x sample buffer and 
incubated at 70 °C for 10 min. Then the samples were loaded on the collecting gel which was cast on 
a 15 % separation gel. Also a molecular weight standard (Novex Sharp Protein Standard LC5800, 
Invitrogen, Karlsruhe, Germany) was loaded.  
 
2.4.7) Silver staining 
 
Solutions 
Fixing solution  Washing solution 
500 ml ethanol 
100 ml acetic acid 
400 ml Aqua dest. 
 0.5 ml formaldehyde (37%) (Roth,   
            Karlsruhe, Germany) 
 500 ml ethanol 
500 ml Aqua dest. 
 
Sensitizing solution  Dyeing solution 
0.1 g sodium sulphite (Na2S2O3) 
500 ml Aqua dest. 
  0.4 g silver nitrate (AgNO3) 
200 ml Aqua dest. 
150 µl formaldehyde (37%) 
 
Developer solution  Stop solution 
 15 g sodium carbonate (Na2CO3) 
   1 mg sodium sulphite(Na2S2O3) 
250 ml Aqua dest. 
125 µl formaldehyde (37%) 
   60 ml acetic acid 
220 ml ethanol 
220 ml Aqua dest. 
 
Procedure 
To determine the purity of the SP-A sample the gel was stained with silver. To fix the proteins on the 
gel the gel was incubated over night in the fixing solution. Then it was washed 2 times for 25 min with 
the washing solution. For a better silver binding the gel was sensitized for 1 min with the sensitizing 
solution and afterwards washed 3 times for 20 s with Aqua dest.. For staining the gel was incubated 
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20 min with the dyeing solution and washed again 3 times for 20 s. To make the protein bands visible 
the gel was incubated in the developer solution for 3-5 min. Next it was washed one time for 20 s 
before it was laid for 10 min in the stop solution. At last it was washed 3 times for 10 min to remove 
surplus staining and kept in 1 % acetic acid at 4 °C. 
 
                                       
Figure 2.4.7.1: Silver stained protein gel of isolated reduced SP-A. The figure shows the relevant 
part of the silver stained protein gel. In the left lane ran the sample taken from the SP-A isolation and 
in the right lane the protein marker. Next to the marker the molecular weight of the marker bands are 
shown. The SP-A isolation band is between the 30 and 40 kDa. 
 
 
There was only one band for the SP-A isolation sample at about 35 kDa. SP-A monomers have a 
molecular weight of 28-35 kDa. Therefore the purity of the SP-A isolation sample is more than 90 %, 
but there seems to be only glycosylated SP-A monomers. The gel chromatography results of the 
samples can be seen in the appendix D.   
 
2.4.8) Single molecule force spectroscopy   
 
Procedure 
To finally examine the structure of SP-A in a fraction after gel chromatography the method of single 
molecule force spectroscopy based on atomic force microscopy was used. SP-A was isolated of 
pooled fractions from the first peak (F10) after gel chromatography of BAL from 12 CF patients out of 
group no. 2 (see figure 2.1.1) by beads. Only one molecule was attached to a gold layer and then 
pulled of by a cantilever, while the applied force is measured. The protein solution was incubated for 
20 min on a glass substrate with freshly evaporated gold surface at a concentration of 1 mg/ml. After 
washing with PBS, the cantilevers (Olympus, Mannheim, Germany) were calibrated using the 
equipartition theorem, and the automated recording of force extension traces was started with a 
pulling speed of 1 mm/s. In classical statistical mechanics, the equipartition theorem is a general 
formula that relates the temperature of a system with its average energies and makes quantitative 
predictions. The original idea of equipartition was that, in thermal equilibrium, energy is shared equally 
among its various forms; for example, the average kinetic energy in the translational motion of a 
molecule should equal the average kinetic energy in its rotational motion. For measuring an atomic 
force microscope (custom-built, Biophysics, Ludwig-Maximilians-University, Munich) was used.  
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2.5) SP-A function 
2.5.1) SP-A self-agglutination-assay for demonstration of supra-
quaternary organisational structure of SP-A 
 
Table 2.5.1.1: Sample size. 
Patient group  BAL and serum 
pairs, fractions 
BAL, 
fractions 
Serum 
fractions 
BAL and 
serum pairs 
 BAL Serum 
Cystic Fibrosis 10 8 20 27 15 4 
Bronchitis 10      
Control 7      
The table shows the number of the samples analyzed by the SP-A self-agglutination-assay from the 
three patient groups after gel chromatography (fractions) and from whole BAL or serum samples.  
 
Procedure 
Because it is known that there are structural differences of SP-A between individuals, it was necessary 
to elucidate if there are functional differences between different oligomeric states or between different 
oligomeric compositions. For this a new agglutination assay with carboxylate-modified, streptavidin-
labeled latex beads (SIGMA Aldrich, Munich, Germany) was established. 50 µl Streptavidin-beads 
(1.82x10
10 
beads/ml) were incubated with 200 µl biotinylated rabbit anti-goat antibody (1.3 mg/ml, 
Dianova, Hamburg, Germany) for 18 h at 23°C in 0.2 ml Eppendorf tubes (Eppendorf, Hamburg, 
Germany). The mixture was washed 2 times with Hank solution (8 g/l NaCl, 1 g/l glucose, 0.4 g/l KCl, 
0.35 g/l NaHCO3, 0.14 g/l CaCl2, 0.1 g/l MgCl2·6H2O, 0.06 g/l Na2HPO4·2H2O, 0.06 g/l KH2PO4 and 
0.06 g/l MgSO4·7H2O, pH 7.4; Apotheke Innenstadt, University Munich, Germany) and resuspended in 
600 µl Hank solution. Then 5 µl of the samples (end concentration: 100 ng/ml SP-A from peak 
fractions) were incubated with 2 µl bead suspension (6.5 mM Ca
2+
), 3 µl Aqua injectabili and 0.01 µg 
goat anti-human-SP-A antibody (N19, Santa Cruz, Heidelberg, Germany) for 3 h at 4°C on a 
microscope slide (Menzel, Braunschweig, Germany) under a cover slip (Menzel, Braunschweig, 
Germany). To avoid non-specific agglutination of the SP-A, all assays were done in the presence of 
0.1 % (v/v) Triton X-100.  Under the light-optical microscope (Axioskop, Zeiss, Aalen, Germany) the 
biggest, pure bead-agglutinate was searched and photographed. The picture was viewed by the 
software Adobe Photoshop (Adobe, Munich, Germany) at a size of 764x573 pixel and the size of the 
determined agglutinate was measured in pixel by drawing a square around it.  
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Figure 2.5.1.1: Scheme of the SP-A self-agglutination-Assay. The streptavidin beads were coupled 
to biotinylated rabbit anti-goat antibodies which bound goat anti-human SP-A antibodies. These anti-
SP-A antibodies bound SP-A at its N-terminal end, so SP-A could self-agglutinate by its CRD. 
 
2.5.2) SP-A self-agglutination-assay establishment 
 
Because of the structural differences of SP-A between individuals, it was necessary to analyze 
whether there are functional differences between different oligomeric states. For this analysis the new 
agglutination assay with streptavidin beads was used. First the assay-construction was tested. The 
conditions of the assay were varied with respect to the reagent addition as listed in table 2.5.2.1 to 
prove that the assay functions because of the binding chain bead-anti-goat antibody-anti-human SP-A 
antibody-SP-A and not because of other influences. The results state that the beads only agglutinate 
when also the anti-goat antibody, the goat-anti-human SP-A antibody and SP-A is present. Secondly 
to prove that the assay was calcium and carbohydrate dependent the assay conditions were changed 
as shown in table 2.5.2.2. Without calcium and/or with mannose no agglutination could be observed. 
The tests were repeated three times.  
  
Table 2.5.2.1: SP-A self-agglutination-assay conditions. 
Condition Reagent Agglutination 
 SP-A SP-D Goat-anti-
human-SP-A 
antibody 
Anti-goat 
antibody 
 
1 + - + + + 
2 - + + + - 
3 + - - + - 
4 + - + - - 
5 - - + + - 
The table shows five different conditions of the bead-assay. The beads were incubated alternatively 
with anti-goat antibody, goat-anti-human antibody, SP-A or SP-D in a buffer containing calcium ions. 
The “+” means that the reagent was used. After incubation the mixture was analyzed by light 
microscopy and agglutination was only detected under condition 1 when SP-A was added. The 
experiments were repeated three times.   
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Table 2.5.2.2: Tests for SP-A self-agglutination-assay dependency. 
Beads Goat-anti-
human-SP-A 
antibody 
Anti-goat 
antibody 
Serum Ca
2+ 
Agglutination 
+ + + + - - 
+ + + + + + 
+ + + - + - 
+ + + - - - 
+ - + + + - 
+ - - + + - 
- + + + + - 
+ + + SP-D - - 
+ + + SP-D + - 
+ + + - + with Mannose - 
+ + + + + with Mannose - 
+ + + +/without SP-D + + 
+ + + +/+Triton X  + - 
The table shows twelve conditions of the bead assay with varying reagents: beads, anti-goat antibody, 
goat-anti-human antibody, human serum and calcium ions (Ca
2+
). The “+” means that the reagent was 
used for incubation. Without SP-A in serum, serum and calcium ions and also with Mannose no 
agglutination was detected. The experiments were repeated three times. For the last condition a 
concentration of 0.1 % (v/v) Triton X-100 was used. 
 
 
                                               
Figure 2.5.2.1: SP-A self-agglutination-assay with serum lacking SP-D. The microscope picture 
with a magnification of 10 times was taken under a light microscope. It illustrates that SP-A and not 
SP-D was causing the agglutination. 
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Figure 2.5.2.2: Agglutinated and spread beads. The microscope pictures with a magnification of 10 
times were taken under a light microscope. Picture a shows an agglutinate while picture b illustrates 
beads without agglutination. These pictures were representative for condition testing and dependency 
testing. 
 
 
After proving that the assay was SP-A dependent the SP-A self-agglutination-assay was further 
analyzed by incubation with an increasing serum amount. As illustrated in figure 3.2.2.2 the more SP-
A containing serum is added the bigger the bead agglutinates are. The test was repeated three times 
with two different sera. This supports the SP-A dependency of the SP-A self-agglutination-assay.   
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Figure 2.5.2.3: SP-A dependent agglutination. The graph illustrates the SP-A dependency of the 
bead agglutination. The agglutinate size is plotted against the amount of serum containing SP-A which 
was incubated with the beads, anti-goat antibody and goat-anti-human antibody in a buffer with 
calcium ions. Two different sera were used (▲and ■) in the experiments which were repeated three 
times. 
 
 
Afterwards it was tested what part of the SP-A protein is responsible for agglutination. The goat-anti-
human SP-A antibody binds at the N-terminal end of SP-A, so binding at this end is unlikely. Therefore 
the hypothesis was that the agglutination is caused by self-agglutination of the CRD. Therefore the 
calcium and carbohydrate dependency was tested specifically. Figures 2.5.2.3 and 2.5.2.4 show that 
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with increasing Mannose concentration or addition of EDTA (removing calcium) significantly smaller 
agglutinates are formed. Both tests were repeated five times for three or four serum samples 
respectively.  
 
 
Figure 2.5.2.4: Carbohydrate-dependency of the bead-assay. The pictures were taken under a light 
microscope by a 10 time magnification. The beads were incubated with anti-goat antibody, goat anti-
human SP-A antibody, 5 µl serum and an increasing amount of Mannose (a: 0 mM Mannose; b: 10 
mM Mannose; c: 20 mM Mannose; d: 30 mM Mannose; e: 40 mM Mannose; f: 50 mM Mannose). The 
agglutinate size decreased corresponding to an increasing Mannose concentration.  
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Figure 2.5.2.5: Mannose inhibition of SP-A agglutination. The figure shows a graph of the 
agglutinate size arisen from beads incubated with anti-goat antibody, goat-anti-human antibody and 
human serum from three different test persons under varying mannose concentration in a buffer 
containing calcium ions. The higher the mannose concentration the smaller the bead agglutinates. The 
experiments were repeated five times. 
 
 
a   b  
Figure 2.5.2.6: Calcium-dependency of the bead-assay. The pictures show the Calcium-
dependency of the agglutination-assay. The beads were incubated with anti-goat antibody, goat-anti-
human antibody and human serum from three different test persons and either 5 mM Calcium (a) or 0 
mM Calcium (b). 
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Figure 2.5.2.7: Calcium-dependency of the bead-assay. The graph displays the dependency on 
calcium ions of the bead agglutination caused by SP-A. Four different serum samples were incubated 
with beads, anti-goat antibody, goat-anti-human antibody in a buffer containing calcium ions first 
without EDTA (■) and then with 50 mM EDTA (▲). After repeating the experiments five times it 
became obvious that addition of EDTA leads to smaller bead agglutinates.  
 
 
 
2.6) SP-A genetics, clinical and biochemical data 
 
2.6.1) Body Mass Index (BMI) 
 
The BMI of the patients and controls was determined according to the formula:  
BMI = weight (kg)/(length (m))
2  
and classified at enrolment according to the World Health Organisation (WHO). The enrolment criteria 
are listed in the tables below separated by age. 
 
Table 2.6.1.1: BMI classification for women older than 19. 
Age [years] Underweight Normal weight Overweight 
19-24 <19 19-24 >24 
25-34 <20 20-25 >25 
35-44 <21 21-26 >26 
45-54 <22 22-27 >27 
55-64 <23 23-28 >28 
>64 <24 24-29 >29 
The table shows the cut-off values used to define weight status groups (underweight, normal, 
overweight) from the global database on body mass index (http://www.who.int/bmi/index.html). 
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Table 2.6.1.1: BMI classification for men older than 19. 
Age [years] Underweight Normal weight Overweight 
19-24 <20 20-25 >25 
25-34 <21 21-26 >26 
35-44 <22 22-27 >27 
45-54 <23 23-28 >28 
55-64 <24 24-28 >28 
>64 <24 24-29 >29 
The table shows the cut-off values used to define weight status groups (underweight, normal, 
overweight) from the global database on body mass index (http://www.who.int/bmi/index.html). 
 
 
 
 
 
Table 2.6.1.2: BMI classification for Girls between 7-18 years of age. 
Age [years] Severe 
underweight 
Underweight Normal weight Overweight Severe 
Overweight 
7 < 12 12-13 13.1-18 18.1-23 >23 
8 < 12 12-13 13.1-19 19.1-22 >22 
9 < 13 13-15 15,1-19.9 20-23 >23 
10 < 13 13-14 14.1-20 20.1-23 >23 
11 < 14 14-15 15.1-20 20.1-23 >23 
12 < 15 15 16-21 21.1-23 >23 
13 < 15 15.1-16 16.1-22 22.1-24 >24 
14 < 16 16-17 17.1-23 23.1-26 >26 
15 < 17 17-18 18.1-23 23.1-27 >27 
16 < 17 17-18 18.1-23 23.1-24 >24 
17 < 17 17-18 18.1-23 23.1-25 >25 
18 < 17 17-18 18.1-23 23.1-25 >25 
The table shows the cut-off values used to define weight status groups (underweight, normal, 
overweight) from the global database on body mass index (http://www.who.int/bmi/index.html). 
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Table 2.6.1.3: BMI classification for Boys between 7 to 18 years of age. 
Age [years] Severe 
underweight 
Underweight Normal weight Overweight Severe 
Overweight 
7 < 13 13-14 14.1-19 19.1-21 >21 
8 < 13 13-14 14.1-19 19.1-22 >22 
9 < 13 13-14 14,1-19 19.1-22 >22 
10 < 14 14-15 15.1-21 21.1-25 >25 
11 < 14 14 15-21 21.1-23 >23 
12 < 15 15 16-22 22.1-25 >25 
13 < 16 16 17-22 22.1-24 >24 
14 < 16 16-17 17.1-23 23.1-26 >26 
15 < 17 17-18 18.1-23 23.1-26 >26 
16 < 18 18-19 19.1-24 24.1-26 >26 
17 < 18 18-19 19.1-24 24.1-26 >26 
18 < 18 18-19 19.1-24 24.1-26 >26 
The table shows the cut-off values used to define weight status groups (underweight, normal, 
overweight) from the global database on body mass index (http://www.who.int/bmi/index.html). 
 
 
2.6.2) Pseudomonas aeruginosa infection 
 
 
The status of Pseudomonas aeruginosa infection for CF patients was determined after the criteria 
shown in the following table. 
 
Table 2.6.2.1: Classification criteria for Pseudomonas aeruginosa infection. 
 Criteria 
Chronic 7 out of 8 samples of the last 2 years must be positive 
Negative No positive result in the last 2 years 
Real-negative Never a positive result 
Intermittent Minimum one positive result, maximum 6 in the last 2 years 
First initial infection First positive result 
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2.6.3) Lung Function Analysis 
 
2.6.3.1) Lung disease status of bronchitis patients  
 
 
The lung disease status of the bronchitis study population was determined according to the 
classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD). The enrolment 
criteria are listed in the table below and are used for classification in adults. 
 
 
Table 2.6.3.1.1: Classification of lung disease status in Bronchitis patients. 
Stadium Fev1 [%pred.] 
mild ≥ 80 
moderate 50 ≤ Fev1 [%pred.] > 80 
severe < 50 
The table shows the cut-off values used to define severe, moderate and mild groups. 
 
2.6.3.2) Lung disease status of cystic fibrosis patients  
 
As there is a strong dependency on age and sex it is difficult to normalize lung function values. 
Several approaches are available and were used. These are listed in table 2.6.3.2.1. 
 
Table 2.6.3.2.1: The different methods for lung function classification in CF. 
Method 
Pattern analysis – see paragraph 2.6.3.3 
Fev1 (% pred.)age 20 – see paragraph  2.6.3.4 
Mean ΔFev1 (% pred.) – see paragraph 2.6.3.5 
Last Fev1 (% pred.) value available – here not used 
 
 
2.6.3.3) Pattern analysis (“extremes”) of CF lung disease according to 
Schluchter 
 
One specific type of case-control genetic association study design compares patients at the extremes 
of phenotype (i.e., those with severe versus mild disease) because it provides additional power to 
detect gene modifiers. In such studies, it is particularly important to be able to accurately identify 
patients at the extremes of phenotype. 
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First the data from the last 3 years were examined, in particular the mean lung function value per year 
for three years. These data were taken to determine the lung disease status with respect to the 
enrolment from Schluchter et al. {Schluchter, 2006 3711 /id} (see table 2.6.3.4.1). Categorization by 
severity group was based on age-specific cut-off values for Fev1 (% pred.). These values derived 
approximately from quartiles of lung function for patients <34 years of age in the U.S. Cystic Fibrosis 
Foundation Patient Registry.  
The mean value of each year was calculated and all three values had to fit in the enrolment criteria for 
one group (mild young: age 15-24 years; mild old: age ≥ 25 years; severe: age 8-25 years) to 
determine a status. If a patient did not match these criteria he had to be excluded. All patients ≥ 34 
years of age were considered “mild” regardless of their Fev1, on the basis of survival.  
Longitudinal Fev1 data were analyzed using a mixed model, assuming that the mean Fev1 (% pred.) 
follows a linear regression versus time for each patient with random patient-specific slope and 
intercept, with a separate population regression line for each of the three severity groups. This means 
that first for each patient a linear regression was calculated and then a mixed model of the patients’ 
data grouped by their lung disease status to check the classification ability of the method (see figure 
3.3.2.1.1). 305 CF patients from 453 could be classified. {Schluchter, 2006 3711 /id} 
 
2.6.3.4) Mixed-Regression-model Fev1 (% pred.) estimated for age 20 
 
The results from Schluchter et al. developed in their first study (method 2.6.3.3) indicated a good 
separation of lung disease severity groups mild and severe from the extrapolated Fev1 (% pred.) at 
age 20 (Fev1 (% pred.)age20). The graph of our results showed also a very good data ability to 
distinguish the disease status groups at age 20 (see figure 3.3.2.1.1). Therefore as a second 
approach and to strengthen data resulting from further analysis respecting the lung disease status we 
also estimated with respect to the linear regressions a value for Fev1 (% pred.)age20 for each patient 
(see above). For the regression calculation this time the complete lung function data of each patient as 
mean values per year was used. This estimated value is used again to classify the patients (Fev1 (% 
pred.)age20 ≥ 84 is mild and ≤54 is severe). All classification results derived by this method (paragraph 
2.6.3.4) matched the ones analyzed by the method in paragraph 2.6.3.3. This method helped to 
classify 82 of those patients not definable by the initial approach (paragraph 2.6.3.3.). Now 387 out of 
453 CF patients were classified. Children younger than 8 years (n = 35), patients with less than one 
Fev1 (% pred.) value per year over the last 3 years (n = 10) and patients who didn’t match the criteria 
(n = 21) could not be classified. 
 
In addition Fev1 (% pred.) estimated for age 20 was also used directly as stand alone variable to 
describe overall pulmonary disease course of a particular CF patient (e.g. Fig. 3.1.3.3).  
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Table 2.6.3.4.1:Classification of the lung disease status in CF patients. 
Age Mean Fev1 (% pred.) per year 
 mild severe 
8  ≤ 80 
9  ≤ 79 
10  ≤ 78 
11  ≤ 77 
12  ≤ 75 
13  ≤ 72 
14  ≤ 69 
15 
≥ 97 
≤ 67 
16 ≥ 92 ≤ 63 
17 ≥ 90 ≤ 60 
18 ≥ 87 ≤ 59 
19 ≥ 86 ≤ 57 
20 ≥ 84 ≤ 54 
21 ≥ 82 ≤ 50 
22 ≥ 77 ≤ 45 
23 ≥ 70 ≤ 39 
24 ≥ 68 ≤ 36 
25 ≥ 67 ≤ 34    
26 ≥ 62  
27 ≥ 58  
28 ≥ 54  
29 ≥ 52  
30 ≥ 50  
31 ≥ 45  
32 ≥ 32  
33 ≥ 32  
≥ 34 x  
The table shows the cut-off values used to define severe and mild groups, based on the mean Fev1 % 
predicted per year. The x means that patients of 34 years of age or older are grouped into the mild 
lung disease group no matter of their Fev1 % pred. value.  
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Figure 2.6.3.3.1: Examples for lung disease classification. All graphs show the mean lung function 
data per year of CF patients at different ages (10 years: a, 20 years: b and c, 30 years: d). The patient 
described in graph a could not be classified according to the first method of pattern analysis because 
he was too young. Using linear regression a Fev1 (% pred.)age20 of > 84 % could be extrapolated. 
Therefore this patient could be classified as having a mild lung disease. The patient described in 
graph b could be classified with both methods as having a severe lung disease because the last three 
Fev1 (% pred.) values were like the Fev1 (% pred.)age20 below 54 %. Graphs c and d show CF patients 
with mild lung diseases because the Fev1 (% pred.)age20 was > 84 % and the last three Fev1 (% pred.) 
values were higher than the limiting values shown in table 2.6.3.3.1. 
 
 
2.6.3.5) Comparing Mean Δ Fev1 (% pred.)  
 
A third approach to analyze the lung function data was to calculate the mean Δ Fev1 (% pred.) per 
year of each patient over all data available. For example there were Fev1 (% pred.) data available for 
one patient over 4 years. Then the Δ Fev1 (% pred.) for each year was calculated. Then the annual Δ 
Fev1 (% pred.) were averaged and a mean Δ Fev1 (% pred.) value per year was calculated using the 
four Δ Fev1 (% pred.) calculated before. As many as possible Δ Fev1 (% pred.) values of a patient 
were used. The average available lung function data spanned over 7 years. 
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2.6.4) Classification of IgG and IgE levels 
 
Because the IgG and IgE levels are age-dependent the measured level values had to be converted 
into a comparable characteristic. Therefore the ratio of the level compared to the upper standard value 
for the correspondent age was calculated. The upper standard values are shown in table 2.6.4.1. 
 
Table 2.6.4.1: Upper standard values of IgG and IgE. 
Age (years) IgG (mg/dl) IgE (lU/ml) 
1-5 1200 60 
5-9 1507 90 
9-14 1507 200 
> 14 1800 200 
   The table shows the upper standard values of the IgG and IgE levels depending on age. 
 
2.6.5) Selection of single nucleotide polymorphisms (SNP) for analysis 
 
First the gene structure and sequence of SFTPA1, SFTPA2 and SFTPD were taken from the 
databank of the UCSC Genome Browsers, University of California, U.S.A.. In the database the known 
SNPs of the genes are also marked. For each SNP the kind of SNP (deletion, insertion and 
exchange), the validation status and the mean rate of heterozygosis is stated. SNPs were chosen for 
each gene if the SNP was likely to be found in Caucasians (validation status) and appeared frequently 
(mean heterozygosis > 0.1), so that over the length of the gene the analyzed SNPs were evenly 
distributed. The oligonucleotides necessary for polymerase chain reaction (PCR) were designed with 
“Primer Express” (Applied Biosystems, Darmstadt, Germany). 
 
2.6.6) Polymerase chain reaction (PCR) 
 
The PCR is a method to amplify in vitro specific DNA fragments. The fragment that should be 
amplified is defined by two synthetic oligonucleotides called primer. These primers are complementary 
to sequences which flank the relevant fragment and serve as the starting point for the DNA-
polymerase.  
The PCR comes off in three themselves repeating steps. In the first step, the denaturation, the 
reaction mixture is heated up to 95 °C to separate the DNA strands. The temperature of the second 
step, the annealing or hybridization, is variable and depends on the length and the base composition 
of the primers. It should usually be about 5 °C lower than the melting temperature of the primers to 
prevent unspecific hybridization. After primer annealing the primers are extended by the DNA-
polymerase (elongation) at 72 °C. Because of the high temperature at the denaturation step heat-
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stable enzymes are needed. Such polymerases are found in thermophilic bacteria which live in hot 
springs. The Taq-polymerase out of the bacterium Thermophilus Aquaticus is the most common used. 
 
 
 
Figure 2.6.6.1: Scheme of a PCR. The figure shows the three steps of a PCR from denaturation (A) 
over primer annealing (B) to elongation (C) to amplify a certain DNA-fragment.  
 
2.6.7) Probes 
 
Table 2.6.7.1: Probe sequences. 
Gene SNP Probe sequences 
SFTPA1 V19A LC RED640-TGAAGGACGTTTGTGTTGGAAGCCCT-P 
5-CCTCTGGTGCTGCGTGCGA-FL 
 L50V LC RED705-GCCCTCCAGGTACTGTGCTGCAGA-P 
5-GATGGTGTCAAAGGTGACCT-FL 
 R219W LC RED640-CTCCCCTCGGTACCAGTTGGTGTAG-P 
5-CTCTTTTCTCCAACCTGCGG-FL 
SFTPA2 N9T LC RED640-CTTGATGGCAGCCTCTGGTGC-P 
5-CTCTGGCCCTCACCCTCA-FL 
 A91P LC RED705-CTTCTCTCCACGCTCTCCAGGGACAC-P 
5-CCTCTCTGGCCAGGCTCCC-FL 
 Q223K LC RED705-CACAGATGGGCAGTGGAATGACAG P 
5-GGAAAAGAG CAGTGTGTGGAG AT-FL 
SFTPD M31T LC RED640-TGCTTGCACCCTGGTCATGTGTAGC P 
5-CTCCCACAGAACAACGCCCA-FL 
 A180T LC RED705-GTGAGCAGTGGAAAGAGCTGGGCT P 
5-CTGG+AAAC+ACAGGGGCAGCA 
 S290T LC RED640-CTCTGCCGCTGAGAATGCCGC P 
5-GACAGT+TGGCC+ACTCCAC-FL 
The table shows the sequences of the probes used to genotype SNPs in SFTPA1, SFTPA2 and 
SFTPD by melting analysis. 
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Table 2.6.7.2: Primer sequences for probe assay. 
Gene SNP Primer sequences and Annealing temperature 
SFTPA1 V19A GCTCACGGCCATCCCTCCT 
CTAGGGGCCTGGACAGATGG 
 
58°C 
 L50V GCTCACGGCCATCCCTCCT 
CTAGGGGCCTGGACAGATGG 
 
58°C 
 R219W GAGACTTCCGCTACTCAGAC 
GCCGAAGGCCAGAGAGCG 
 
60°C 
SFTPA2 N9T CCCGCCCTGCCTCTCGCT 
TGAAAAGGGGTCTGTGTCCC 
 
59°C 
 A91P TGGGTCCGCCTGGAGAAACA 
ATTGCCCTTGGGGTACCTGC 
 
59°C 
 Q223K ACTTCCGCTACTCAGATGGGA 
ACAGACCAAGTGGATCCTGG 
 
58°C 
SFTPD M31T TCTTCCTCCTCTCTGCACTG  
GACCAGGCAGGCCACTC 
 
61°C 
 A180T GCCTCGCAGGCCCTAA  
TGTAGGCATTGACAGCTCCAA 
 
58°C 
 S290T GTGCACACAGGCTGATGG  
CCCTCTGTCTTGGAATCAGTCAT 
 
59°C 
The table lists the sequences and annealing temperatures of the primers used to amplify DNA parts 
surrounding the SNPs which were chosen to be genotyped by melting analysis with probes. 
 
Procedure Probes 
For determining the genotypes of the study populations some SNPs (see table 2.6.6.2) which cause 
an amino acidic exchange were analyzed by melting curves with hybridized probes in a Light Cycler 
(Roche, Mannheim, Germany). First the relevant DNA fragment was amplified. Then the fluorescent 
and fluorescein marked probes given by Heiko Witt (Charité Berlin, Germany) and purchased from 
Metabion (Planegg-Martinsried, Germany) were hybridized with the DNA fragment. A signal could only 
be detected if both markers were located near each other so that the laser energy could be transferred 
from the Fluorescein to the fluorescent marker. During the melting progress the probes detached from 
the DNA fragment and the energy transfer was interrupted. By determining the temperature when the 
detachment took place the base of the relevant SNP locus could be detected. The probe could be 
designed either be complementary to the wildtype allele or the mutated allele. The melting 
temperature was higher if the complementary allele was existent in the DNA fragment. After extraction 
of the DNA from whole blood with Qiagen Maxi Kit (Qiagen, Hilden, Germany) the solutions of 202 CF 
patients were adjusted to a concentration of 20 ng/µl. The DNA samples were amplified in a 25 µl 
reaction mixture containing 50 ng of template DNA, 2.5 µl of 10 x PCR buffer without MgCl2, 2 µl 
MgCl2 (25 mM), 1.25 µl dNTPs (10 mM), 1 µl of each primer (10 µM) and 0.1 µl HotstarTaq® (Qiagen, 
Hilden Germany). The cycling conditions were as follows: initial denaturation at 95 °C for 10 min, 
followed by 48 cycles at 95 °C for 20 s (seconds), 40 s at annealing temperature (see table) and 72 °C 
for 90 s and a final extension at 72 °C for 120 s in an Eppendorf cycler (Eppendorf, Hamburg, 
Germany). 1 nmol lyophilized probe was resupended in 200 µl H2O. Then 13 µl FL-probe 1 
(Fluoresceine-probe) and 16 µl LC-probe (Light Cycler probe, LC 750) were mixed with 13 µl FL-probe 
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2 and 16 µl LC-probe (LC 640). 1.5 µl of the probe mixture and 4 µl PCR-product were pipetted in LC-
glass capillaries (Roche, Mannheim, Germany). Afterwards melting curves were run in a LightCycler 
with 95 °C for 60 s, 40 °C for 40 s and an increase to 80 °C with a ramp of 0.1 °C/s.  
 
 
 
 
Figure 2.6.7.1: Scheme of the probe procedure. First the relevant DNA fragment was amplified. 
Then the fluorescent and Fluorescein marked probes were hybridized (B) with the DNA fragment after 
the DNA fragment was denaturized (A). A signal could only be detected if both markers were located 
near each other that the laser energy could be transferred from the Fluorescein to the fluorescent 
marker. During the melting progress the probes detached from the DNA fragment and the energy 
transfer was interrupted (C). By determining the temperature when the detachment took place the 
base of the relevant SNP locus could be detected. The probe could be designed either be 
complementary to the wildtype allele or the mutated allele. The melting temperature was higher if the 
complementary allele was existent in the DNA fragment. 
 
2.6.8) Matrix Assisted Laser Desorption/Ionisation-Time-Of-Flight 
(MALDI-TOF) 
 
Table 2.6.8.1: Population. 
Patient group Number analyzed 
Cystic Fibrosis 482 
Bronchitis 46 
Controls 25 
The table shows the number of the DNA samples analyzed by MALDI-TOF. 
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Procedure 
For a bigger throughput of genotyping the method of Matrix Assisted Laser Desorption/Ionisation-
Time-Of-Flight (MALDI-TOF) was used. The DNA samples were adjusted to a concentration of 1 
ng/ml. The isolated DNA was removed from the 96-well 1.2 ml Storage Plates (ABgene®, Darmstadt, 
Germany), and the fragment of interest was PCR amplified in a heat sealed Thermo-Fast® 384 PCR 
Plate (ABgene®, Darmstadt, Germany). The reaction mixture contained 3.82 µl H2O, 0.625 µl PCR 
buffer (Qiagen, Hilden, Germany), 0.325 µl MgCl2 (Qiagen, Hilden, Germany), 0.1 µl dNTP mix 
(Qiagen, Hilden, Germany) and 0.1 µl Hotstar Taq® (Qiagen, Hilden, Germany) in a total volume of 5 
µl. The cycling conditions were as follows: denaturation for 15 min at 94 °C, 45 cycles of 20 s 
denaturation at 94 °C, 30 s primer annealing at 56 °C and 60 s elongation at 72 °C, an additional 
elongation phase of 3 min at 72 °C and a holding temperature of 20 °C. The amplicons were 
processed with a SAP enzyme mix (Promega, Mannheim, Germany) containing 1.53 µl H2O, 0.17 µl 
SAP buffer (10x, Promega, Mannheim, Germany) and 0.3 µl SAP enzyme solution. The enzyme was 
activated for 40 min at 37 °C and then inactivated at 85 °C for 5 min. Furthermore a primer extension 
reaction was run. The reaction mixture contained 0.755 µl H2O, 0.2 µl iPlex Buffer plus (10x, 
Sequenom, Hamburg, Germany), 0.1 µl i-Plex termination mix (10x, Sequenom, Hamburg, Germany), 
0.1 µl Primer (Metabion, Planegg-Martinsried, Germany) and 0.0205 µl iPlex enzyme (10x, 
Sequenom, Hamburg, Germany) in a total volume of 2 µl. The cycling conditions were as follows: 
denaturation for 30 s at 94 °C, 40 cycles of 5 s denaturation at 94 °C, 5 s primer annealing at 52 °C 
and 5 s elongation at 80 °C, 5 cycles of 5 s at 52°C and 5 s at 80°C, an additional elongation phase of 
3 min at 72 °C and a holding temperature of 20 °C. In this reaction an oligonucleotide was designed to 
bind directly to the 5’end of the identified SNP. Dideoxy nucleotides (ddNTPs) were substituted for one 
of the 4 deoxy nucleotides (dNTPs) in the reaction mix. Therefore, if a SNP was present the 
complementary ddNTP will be incorporated and different allele specific fragments are created. The 
extension products could be spotted on microchips and analysed in the MALDI-TOF Mass 
Spectrometer (Sequenom, Hamburg, Germany). A laser fired on the spotted products on the 
microchip and the DNA was accelerated in a vacuum to a detector. Smaller molecules (e.g. a 24-mer) 
were faster than larger molecules (e.g. a 26-mer) and were detected earlier. The mass of every 
extended product was determined and could be "translated" into one allele of the SNP. 
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Table 2.6.8.1: SNPs analyzed by MALDI-TOF. 
SFTPA1 SFTPA2 SFTPD Other genes 
rs1059047 rs1059046 rs911887 CD14_CMIN159T 
rs4253527 rs17886395 rs721917 TLR1 TMIN2192C 
rs10351 rs17880428 rs2243639 TLR1 A742G 
rs4253518 rs17881665R rs3088308 TLR2 AMIN15607G 
Cys85Arg rs1975006 rs12784549 TLR2 T596C 
rs1059057 rs17886376R rs17885228 TLR2 TMIN16934A 
rs4253526 rs1965708 rs7078012 TLR3 C6300T 
rs4253511 rs17882297 rs726014 TLR4 GMIN2570A_2 
rs4253524 rs17886221 rs726289 TLR4 AMIN2570G 
rs1059056 rs17880349 rs911887 TLR4 C8851T 
rs1136451 rs17885057 rs17880779 TLR4 TMIN1607C 
  rs17881639 TLR6 TMIN2079A 
  rs17885295 TLR9 TMIN2871C 
  rs17886333 TLR10 A2322G 
  rs3088308 TLR10 G1031T 
The table shows all SNPs that were genotyped in the SFTPA1, SFTPA2 and SFTPD genes as well as 
in other genes which proteins are important factors in immunity. 
 
 
2.6.9) SP-A and SP-D ELISA 
 
Buffer 
 
TBS  Carbonate buffer 
20 mM Tris-HCl 
150 mM NaCl 
pH 7.5 
 15 mM Na2CO3 
35 mM NaHCO3 
pH 9.6 
 
Blocking buffer: 1% BSA in TBS  
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Procedure 
To measure the SP-A and SP-D level in human serum and BAL the microplates (Nunc Maxisorp C 96, 
Nunc, Langenselbold, Germany) were coated overnight at 4 °C with either anti-human SP-A (HYB 
238-04, AntibodyShop, Gentofte, Denmark) or anti-human SP-D (HYB 246-08, AntibodyShop, 
Gentofte, Denmark) dissolved in carbonate buffer to a concentration of 1 µg/ml. Then the wells were 
blocked with 200 µl blocking buffer for 2 h at 37 °C. The plates were washed three times with TBS. 
100 µl of the samples were dissolved in 350 µl of 1 mM EDTA, 1 % BSA and 10 mM Tris (pH 7.4). 
Afterwards the samples were put in the ultrasonic bath (Sonorex RK100, Bandelin, Mörfelden-
Walldorf, Germany) for 1 min and 50 µl Triton X-100 (SIGMA, Munich, Germany) was added. They 
were mixed and 10 min at 10,000 g centrifuged (Haeraeus, Hanau, Germany). 50 µl of the standard 
were dissolved in 200 µl of 1 mM EDTA and 10 mM Tris (pH 7.4) and put in the ultrasonic bath for 1 
min. Then 25 µl Triton X-100 was added and the standard was centrifuged for 10 min at 10,000 g. At 
last the standard was filled up to 1,000 µl with blocking buffer. 100 µl of the samples and the standard 
were loaded on the plate. Thereafter 100 µl of the anti-human SP-A (Rabbit anti-human SPA, 
Dianova, Hamburg, Germany) or SP-D (HYB 246-08, AntibodyShop, Gentofte, Denmark) dissolved 
1:100 in blocking buffer were pipetted into each well and incubated for 1 h at 37 °C. The plates were 
washed three times with TBS and then each well was incubated with 100 µl goat anti-rabbit antibody 
(Biozol, Eching, Germany) dissolved 1:5000 in blocking buffer for 1 h at 37 °C. Again the plates were 
washed three times with TBS. 100 µl TMB solution were added to each well and after 10-15 min 100 
µl of 1 N H2SO4. After another 10-15 min the plates were read in the photometer (anthos ht III, anthos, 
Krefeld, Germany) at 405 nm. 
 
2.7) Absence of SP-D in BAL 
2.7.1) Sequencing 
 
If there are more than one SNP in a short DNA-segment or if unknown SNPs are searched for DNA 
fragments are sequenced. The fragment which should be analyzed is first amplified in a 6 times PCR 
to synthesize a sufficient product amount. Then the reactions mixture is purified to remove surplus 
primers and nucleotides. Through sequencing after Sanger the concerning nucleotide-order can be 
determined. In this method fluorescent dideoxynucleotides are used which lead to a chain extension 
stop. The reaction mixture is purified by alcohol precipitation. The fragment length and the ending 
nucleotide are detected by a laser-photo-unit during a sequencing-gel electrophoresis through the 
specific fluorescent dyes of the dideoxynucleotides. With a computer program like CEQ
TM
 8000 
Genetic Analysis system (Beckman Coulter, Krefeld, Germany) the sequences can be illustrated.   
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2.7.2) Procedure SP-D- sequencing 
 
After we identified subjects with no SP-D in their BAL common polymorphisms known to be associated 
with low serum SP-D levels were assessed in those subjects from whom informed consent could be 
obtained and DNA was available.  
The M31T polymorphism in exon 1, A180T in exon 4 and S290T in exon 7 were analyzed. DNA was 
available from 10 of the 12 children who had no SP-D detectable in their BAL by ELISA (Hain 
Lifescience, Nehren, Germany) (n = 6) and Western blotting (n = 4). For comparison 8 children were 
selected with the same clinical characteristics, but detectable SP-D levels in serum.  
To identify these polymorphisms exon 1, exon 4, and exon 7 were amplified in a 25 µl reaction mixture 
containing 50 ng of template DNA, 2.5 µl of 10x PCR buffer without MgCl2, 2 µl MgCl2 (25 mM), 1.25 
µl dNTPs (10 mM), 1 µl of each primer (10 µM) and 0.1 µl HotstarTaq® (Qiagen, Hilden, Germany). 
The cycling conditions were as follows: initial denaturation at 95 °C for 10 min, followed by 48 cycles 
at 95 °C for 20 s, 58 °C for 40 s and 72 °C for 90 s and a final extension at 72 °C for 120 s. The 
reaction mixtures were purified with a DNA purification kit (Qiagen, Hilden, Germany). Then 
sequencing was performed after Sanger using a kit from Applied Biosystems (Darmstadt, Germany).  
Additionally, part of the promotor was sequenced after Sanger (-600 till +79) in 10 patients with the 
forward primer: ttacaagaacagtgcacaagac and reward primer: gctgtaggtcattgtgcaac. The amplification 
with these primers was performed as described above. 
 
2.8) Statistics 
 
For parametric testing one-way ANOVA and Tukey-test and for non-parametric testing the Kruska-
Wallis test and Dunns-test were chosen to compare different groups with each other. For comparing 
only two groups t-test was used. All these tests were analyzed by Graph Pad Prism software (San 
Diego, CA, U.S.A.). 
The SNP data resulting from the genotyping by MALDI-TOF and probes were correlated with the 
clinical data and ELISA level measurements by χ
2
-test on the webpage 
http://home.ubalt.edu/ntsbarsh/Business-stat/otherapplets/Catego.htm and the results were corrected 
according to Bonferroni. Additionally some SNP genotypes were analyzed in Graph Pad Prism by one-
way ANOVA and Tukey-test or t-test respectively.  
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3) Results 
 
For these studies samples from 453 patients with CF, 72 chronic bronchitis and asthma patients and 
35 controls subjects were used, as detailed in fig 2.1.1 in the methods section. As not from all subjects 
all variables were assessed in each instance, in addition the exact number of subjects included or 
materials available is given in the figure and table legends. 
 
3.1)  SP-A structure and function 
3.1.1) Clinical data of the structure and function population 
 
The BAL and serum samples of 46 CF patients, 19 chronic bronchitis and asthma patients and 13 
controls that were genotyped by MALDI-TOF as well as BAL and serum samples from additional 9 
chronic bronchitis patients and 9 controls were analyzed by gel chromatography with a Superose 6 
column. The clinical data for these study populations were also completed.   
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Figure 3.1.1.1: Age and Gender distribution. The graphs illustrate the age (a) and gender (b) 
distribution of all 46 CF, 28 bronchitis patients and 22 controls analyzed by gel chromatography. 
Analyzed by One way ANOVA there were no significant differences between the patient groups. 
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Figure 3.1.1.2: SP-A level in BAL and serum. The graphs show the distributions of the BAL (a) and 
serum (b) levels of the patients analyzed by ELISA. Analyzed by One way ANOVA there were no 
significant differences between the patient groups. The serum SP-A levels of 34 CF, 14 bronchitis 
patients and 8 controls and the BAL SP-A levels of 37 CF, 7 bronchitis and 15 controls were 
measured. 
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Figure 3.1.1.3: Lung function data and lung disease. The graphs plot the distribution of the Fev1 (% 
pred.)age20 (a) and the lung disease status (b) of the patients analyzed by gel chromatography. 
Analyzed by One way ANOVA there were no significant differences between the patient groups 
regarding the Fev1 (% pred.)age20 data at the sampling point. The controls and most of the bronchitis 
patients had a mild lung disease while 28% of the CF patients had a severe lung disease. The Fev1 
(% pred.) data at sampling point was available for 46 CF, 8 bronchitis patients and one control. 
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Figure 3.1.1.4: The weight distribution. The graph illustrates the weight distribution classified by the 
BMI of all patients analyzed by gel chromatography. 34 % of the CF patients had underweight and 16 
% overweight. 17 % of the bronchitis patients had also overweight while the remaining patients and all 
controls had normal weight. The BMI data was available for all 42 CF, 10 bronchitis patients and 19 
controls. 
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Figure 3.1.1.5: IgG and IgE levels in serum. The graphs show the distribution of the ratio of the IgG 
(a) and IgE (b) levels in serum of the patients in comparison to the upper standard values. There was 
no significant difference analyzed by t-test. IgG levels were available for 20 CF and 10 bronchitis 
patients and IgE levels for 11 CF and 7 Bronchitis patients. 
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Table 3.1.1.1:Clinical characteristics of the CF patients included in the structure and function 
population. 
Characteristic  n 
Lung disease (% mild/% severe) 72/28 33/13 
Lung disease not determined (%) 12 7 
Fev1 (% pred.)age20 94 ± 26 46 
∆Fev1 (% pred.) - 3.34 ± 9.8 42 
P. aer. infection at sample point (%) 20 46 
ABPA (%) 7 46 
Neutrophils in BAL (%) 28 ± 19 39 
In the table the clinical characteristics of the CF patients are listed as mean values with standard 
deviation or the percentage.  
 
The CF patients included in this population had mild lung disease as indicated by a normal mean 
FEV1 and the majority had a normal weight expressed as BMI, a low rate of P. aeruginosa positive 
culture status and normal level of serum IgG, a marker of the systemic inflammatory response. In 
contrast to the controls and the subjects with chronic bronchitis, the CF patients had a moderately 
increased neutrophilic airway inflammation. The total levels of SP-A in serum or BAL were not different 
between the patients with CF and those with bronchitis and the controls (Fig. 3.1.1.1-3.1.1.5 and table 
3.1.1.1). 
 
3.1.2) SP-A structure analysis by gel chromatography 
 
To determine structural differences in BAL and serum between the study populations a gel 
chromatography method with a superpose 6 column was chosen. In this method SP-A molecules were 
separated with regard to their oligomerization form. 1 ml BAL and 500 µl serum were loaded. The 
larger the oligomers the earlier they were eluted. After gel chromatography the SP-A amount of the 
eluted fractions (800 µl) was determined by Slot-Blot. The void volume of the column was about 6.8 ml 
(between fraction 8 and 9). The peaks were defined as a relative SP-A amount of more than 20 % of 
the total SP-A eluate from the column and a distance of 5 fractions (each 0.8 ml) between each peak 
(mainly in fraction 10, 15 and 20).  The peak areas ranged from fraction 9-12, 13-17 and 18-22. For 
calculation also the first peak from fraction 9-12 and the last peak from fraction 18-22 were defined.  
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Figure 3.1.2.1: Peak definition. The graph illustrates a scheme of the defined, possible peaks of SP-A 
after gel chromatography and the calibration with proteins of a known molecular weight. On the x-axis 
the number of the fractions and on the y-axis the relative SP-A amount in % is plotted. With regard to 
the molecular weight of the calibration proteins the first peak should contain octadecamers or more 
complex oligomers, the second sixmers to twelvemers and the last peak dimers and trimers. 
 
 
 
 
3.1.3) Different peak distribution in study populations 
 
After analysis of the 59 serum (34 CF, 14 Bro and 11 C) and 81 BAL samples (42 CF, 21 Bro and 18 
C) by gel chromatography a wide variability of oligomeric SP-A forms could be observed. For an 
easier handling the peak distribution was coded as 1 if there was a peak at the first, second or third 
peak position and 0 if there was none (all individual results are shown in appendix D). This coding 
system is illustrated in Table 3.1.3.1. 
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Table 3.1.3.1: Peak distribution patterns and translation. 
Graphs of SP-A peak distribution Coded as 
 
001 
 
011 
 
010 
 
101 
 
110 
 
111 
 
100 
The table illustrates the different peak distribution patterns of SP-A resulting by analysis of BAL and 
serum samples with gel chromatography and the translation. 
 
 
In BAL most commonly forms that contained the first peak were observed and there was no obvious 
difference of distributions between the study populations, but the bronchitis and control populations 
had more SP-A in the last peak (see figures 3.1.3.1).  
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In serum all control samples showed the second peak and partly the last peak, but none contained the 
first peak. In sera of patients with CF or chronic bronchitis and asthma there was more variability, but 
only the CF samples contained mainly the first peak (see figure 3.1.3.2).  
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Figure 3.1.3.1: Oligomeric distribution of SP-A in BAL. The graphs illustrate the distribution 
frequency (y-axis) in correlation with the oligomeric form distribution (x-axis). The BAL samples of 42 
CF patients, 21 chronic bronchitis and asthma patients (bronchitis) and 18 controls were separated by 
gel chromatography and then the fractions were analyzed with regard to their SP-A content by Slot-
Blot. The most common forms contained the first peak and there was no obvious difference of 
distributions between the study populations. Analyzed by Fisher’s exact test there were no significant 
differences between the patient groups with respect to the frequency comparing each form separately, 
but comparing the complete distribution frequency there is a highly significant difference (p < 0.0001). 
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Figure 3.1.3.2: Oligomeric distribution of SP-A in serum. The graphs illustrate the distribution 
frequency (y-axis) in correlation with the oligomeric form distribution (x-axis). The serum samples of 34 
cystic fibrosis (CF) patients, 14 chronic bronchitis and asthma patients (Bro) and 11 controls (C) were 
separated by gel chromatography and then the fractions were analyzed with regard to their SP-A 
content by Slot-Blot. In controls all samples showed the second peak and partly the last peak, but 
none contained the first peak. In sera of CF, chronic bronchitis and asthma patients there were more 
variability, but only the CF samples contained mainly the first peak. Analyzed by Fisher’s exact test 
there was a significant difference between the patient and control groups regarding the frequency of 
the SP-A form 010 (p = 0.0008), 001 (p = 0.006), 110 (p = 0.0027) and 101 (p = 0.036). Comparing 
the complete distribution of all forms between the patient and control groups there is also a significant 
difference (p < 0.0001). 
 
Next the corresponding pairs of 47 BAL and serum samples from 30 CF, 10 bronchitis patients and 7 
controls were examined (see table 3.1.3.2). The most frequent pairs contained the first peak in BAL 
and serum. There were some sample pairs with the same form in BAL and serum, but also pairs with 
the opposite forms. No correlation between the SP-A distributions in BAL and serum could be found. 
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Table 3.1.3.2: BAL and serum pair distribution.  
CF Bronchitis Control 
Serum BAL Serum BAL Serum BAL 
111 111 111 101 111 011 
111 110 111 001 011 111 
111 110 110 100 011 111 
111 010 110 100 011 100 
111 010 110 010 011 001 
110 111 101 101 010 101 
110 111 101 010 010 001 
110 111 011 101     
110 111 011 100     
110 110 001 001     
110 110         
110 110         
110 110         
110 101         
110 101         
110 101         
110 101         
110 101         
110 100         
110 100         
110 100         
110 100         
100 110         
011 111         
011 101         
011 100         
010 111         
010 111         
010 110         
010 110         
The table shows the distribution of BAL and serum forms for each disease group and controls. The 
yellow cells mark same SP-A structure distributions in BAL and serum levels and the red cells 
opposite distributions. Generally the concordance between BAL and serum was very low. In the CF 
group there were 5 matches and 1 opposite distributions in 47 patients, in the bronchitis group were 2 
matches and 2 opposite distributions in 10 patients and in the control group there were no matches 
and 2 opposite distributions in 7 controls. 
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Because different oligomeric distributions between individuals and study populations were observed in 
the following the correlations between the lung function and the oligomeric SP-A distribution form in 
BAL and serum were analyzed.  
A slight increase regarding Fev1 (% pred.)age20 can be observed the more SP-A is existent in the first 
peak in BAL (111 to 100, see figure 3.1.3.3). In BAL samples where all three peaks could be observed 
(111) SP-A is present in dimers/trimers, smaller oligomeric forms like hexamers and only partly in 
complex oligomeric forms like octadecamers. In samples where only the first peak is present (100) 
SP-A is mainly existent in complex forms. The slightly better lung function of the 101 form in 
comparison to the 110 form could be explained in BAL by comparing the peaks in each form. In the 
101 form the first peaks were bigger in contrast to the first peaks in the 110 forms (mean percentage 
of first peak in 101 = 45 % and 110 = 39%). 
In serum the distributions show the same correlation except for the 101 form (see figure 3.1.3.4). 
There were no correlations between the Δ Fev1 (% pred.)/year or the lung disease (mild/severe) and 
forms in serum or BAL. 
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Figure 3.1.3.3: Oligomeric SP-A distribution in BAL and lung function in CF. The graph plots the 
correlation between the lung function (y-axis) and the oligomeric SP-A distribution in BAL. An increase 
in Fev1 (% pred.)age20 can be observed the more SP-A is existent in the first peak (111 to 100). In BAL 
samples where all three peaks could be observed (111) SP-A is present in dimers/trimers, smaller 
oligomeric forms like hexamers and only partly in complex oligomeric forms like octadecamers. In 
samples where only the first peak is present (100) SP-A is mainly existent in complex forms. 43 BAL 
samples of CF patients were analyzed. For analysis One way ANOVA with Tukey as post-test was 
used. * means a p-value < 0.05.  
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Figure 3.1.3.4: Oligomeric SP-A distribution in serum and lung function in CF. The graph plots 
the correlation between the lung function (y-axis) and the oligomeric SP-A distribution in serum. As in 
BAL samples a slight, but not significant increase in Fev1 (% pred.)age20 can be observed the more SP-
A is existent in the first peak (111 to 100). In the samples where all three peaks could be observed 
(111) SP-A is present in dimmers/trimers, smaller oligomeric forms like hexamers and only partly in 
complex oligomeric forms like octadecamers. In samples where only the first peak is present (100) 
SP-A is mainly existent in complex forms. 34 serum samples from CF patients were analyzed by One 
way ANOVA with Tukey as post-test. * means a p-value < 0.05. 
 
In conclusion there were no correlations between serum and BAL SP-A distribution forms. The forms 
showed only a significantly different distribution comparing serum samples from bronchitis patients 
and controls. In serum and BAL of CF patients the forms containing the first peak were correlated with 
a better lung function (Fev1 (% pred.)age20). 
 
3.1.4) Influence of SP-A structure on self-agglutination 
  
Finally the self-agglutination abilities of BAL and serum were analyzed and compared to the oligomeric 
distribution forms of SP-A derived from gel chromatography using 100 ng SP-A from the 43 BAL and 
34 serum samples of CF patients. While in serum the different forms indicated a marginal association 
with the self-agglutination ability, in BAL the differences were more distinctive.  
In serum only the 010 and 110 forms showed a significant difference regarding the self-agglutination 
ability (see figure 3.1.4.1).  
In BAL the 100 form agglutinated significantly better than the 111 and 110 form and the 101 form 
significantly better than the 111 form (see figure 3.1.4.1). Altogether the results imply that the 100 form 
agglutinates best with the rest showing a declining ability in the following rank order: 
100>101>110>111>010. 
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Figure: 3.1.4.1: Self-agglutination ability of different structure compositions. The graphs illustrate 
the self-agglutination ability differences between different oligomeric structure compositions (forms) in 
BAL (a) and serum (b) analyzed by gel chromatography. 42 BAL samples and 31 serum samples of 
CF patients were analyzed. The SP-A amount in the BAL or serum sample was adjusted to 100 ng for 
the self-agglutination analysis. While in serum the different forms indicated an approximate 
association with the self-agglutination ability, in BAL the differences were more distinctive. In serum 
only the 010 and 100 forms showed a significant difference regarding the self-agglutination ability. In 
BAL the 100 form agglutinated significantly better than the 111 and 110 form and the 101 form 
significantly better than the 111 form. Altogether imply the results that the 100 form agglutinates best 
with the rest showing a declining ability in the following order: 100>101>110>111>010. * stands for a 
p-value < 0.05 and ** for a p-value < 0.01 analyzed by One way ANOVA. 
 
 
Next it was important to analyze if these correlations were caused by the structure composition of the 
whole samples, or if the individual fraction was responsible for the activity and if the fractions differed 
in activity. Therefore individual fractions (e.g. F10, F15 or F20) were isolated from various patients’ 
samples with different forms, brought to the same final concentration and compared for their ability to 
self-agglutinate.  
Whereas the individual fractions F10, F15, and F20 were very different in their activity, it did not matter 
what the source of these fractions was, as the activity within a certain fraction was the same. From 
these data we can conclude that the relative composition of the whole sample with respect to 
representation of the different oligomeric forms is responsible for its activity and not potential 
differences among the oligomeric forms within a particular fraction. 
In BAL the self-agglutination ability in all fractions showed a wide variability without any correlation to 
the corresponding distribution form, while in serum the self-agglutination ability was on a same level in 
all forms for each fraction (see figure 3.1.4.2). 
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Figure 3.1.4.2: Self-agglutination ability of fractions regarding the SP-A structure distribution in 
CF. The graphs plot the SP-A structure distribution on the x-axis (form) against the self-agglutination 
ability on the y-axis (agglutinate size) for fraction 10, 15 and 20 derived from gel chromatography of 
BAL and serum samples of all study populations. In BAL and serum the increasing order correlated to 
the increasing lung function (Fev1 (% pred.)age20) could not be supported. In BAL and serum there was 
no correlation analyzed by One way ANOVA (p > 0.05). The SP-A amount in the BAL or serum 
sample was adjusted to 100 ng for each test. 
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These data suggest that the correlation of Fev1 (% pred.)age20 with the different oligomeric forms is 
related to the degree of the presence of active oligomeric forms within a sample. Therefore the relative 
contribution of higher oligomers within a sample was calculated, i.e. the percentage of SP-A present in 
the first peak. 
 
3.1.5) Oligomerization in CF patients is influenced by lung disease, 
genetics and SP-A level  
 
3.1.5.1) SP-A oligomerization and lung disease 
 
Another approach to evaluate the distribution of SP-A oligomers, was to calculate the relative amount 
of SP-A in the first and the last peak. This was done by integrating the area under the peak, when the 
fraction number was plotted against the amount of SP-A in ng/ml; then the proportional amount of SP-
A per peak was calculated. Only the first and the last peak were chosen for correlation analysis 
because the extremes of phenotype provide additional power to detect genetic modifiers or clinical 
influences.  
There was a significant association of the lung disease status in CF patients and the percentage of 
SP-A that is existent as octadecamers or more complex structures (first peak) in BAL (p = 0.02, see 
figure 3.1.5.1.1), while in serum an association was slightly detectable but not significant. 
Then the correlation between the course of lung disease (∆Fev1 (% pred.)) and the percentage of SP-
A that was present in the first peak was analyzed and there was also a significant association in BAL 
and serum (p = 0.0008 and 0.0038, see figures 3.1.5.1.2 and 3.1.5.1.3). The more SP-A is existent in 
octadecamers or more complex structures the better is the lung function and the course of lung 
disease in CF patients. 
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Figure 3.1.5.1.1: BAL SP-A structure and lung disease in CF. 42 BAL samples of CF patients were 
separated by gel chromatography. For the analysis of the 38 CF patients which could be classified 
regarding to their lung function the t-test was used. The graphs plot the lung disease status on the x-
axis against the amount of SP-A existent in the first (a) or the last peak (b) respectively. There was a 
significant association of the lung disease status in CF patients and the percentage of SP-A that is 
existent as octadecamers or more complex structures (first peak) in BAL analyzed by t-test (p = 0.02, 
*).  
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Figure 3.1.5.1.2: BAL SP-A structure and course of lung disease in CF. 42 BAL samples of CF 
patients were separated by gel chromatography. 38 CF patients with lung function data could be 
included for analysis. The graphs plot the course of lung disease on the y-axis against the amount of 
SP-A existent in the first (left) or the last peak (right) respectively. The correlation between the course 
of lung disease (∆Fev1 (% pred.)/year) and the percentage of SP-A that was present in the first peak 
was analyzed by linear regression and there was a significant association (p = 0.009, r
2 
= 0.8) also by 
excluding too extreme values above or under a ∆Fev1 (% pred.)/year of 10 or -10 respectively.  
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Figure 3.1.5.1.3: Serum SP-A structure and course of lung disease in CF. 34 serum samples of CF 
patients were separated by gel chromatography. For 30 patients lung function data was available. The 
graphs plot the course of lung disease on the y-axis against the amount of SP-A existent in the first 
(left) or the last peak (right) respectively. The correlation between the course of lung disease (∆Fev1 
(% pred.)) and the percentage of SP-A that was present in the first peak was analyzed by linear 
regression and there was a significant association (p = 0.004, r
2 
= 0.5) also by excluding too extreme 
values above or under a ∆Fev1 (% pred.)/year of 10 or -10 respectively (p = 0.008, r
2 
= 0.6). 
 
 
 
There was no correlation between the Fev1 (% pred.)age20 and the SP-A structure distribution in BAL or 
serum (see figure 3.1.5.1.4). 
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Figure 3.1.5.1.4: BAL and serum SP-A structure and Fev1 (% pred.)age20. The graphs show the 
relative SP-A amount in the first peaks (a, c) and the last peaks (b, d) of BAL (a, b) and serum (c, d) in 
relation to the Fev1 (% pred.)age20. There was no significant correlation analyzing the 38 (BAL) and 30 
(serum) CF patients by linear regression. 
 
In conclusion a higher relative SP-A amount in the first peak is associated with a milder lung disease 
and a better course of lung disease. 
 
3.1.5.2) SP-A oligomerization and self-agglutination 
 
Also the self-agglutination abilities of BAL and serum were analyzed and compared to the relative 
amount of oligomerization of SP-A derived from gel chromatography using 100 ng SP-A from the 43 
BAL and 34 serum samples of CF patients. Like the oligomeric distribution forms also the relative SP-
A amounts in the first and last peak in BAL showed a correlation with the self-agglutination ability (see 
fig.3.1.5.2.1). In serum there was no such correlation (see fig.3.1.5.2.1).  
There was no correlation between the self-agglutination of the SP-A fractions 10, 15 and 20 and the 
relative SP-A amount in the first and last peak. 
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Figure 3.1.5.2.1: BAL and serum SP-A structure and self-agglutination. The graphs illustrate the 
relative amount of SP-A in the first (black) and last (grey) peak after column separation in BAL (a) and 
in serum (b) with regard to the self-agglutination ability. The SP-A amount in the BAL or serum sample 
was adjusted to 100 ng for the self-agglutination analysis. On the x-axis the size of the SP-A 
agglutinate is shown, while the y-axis plots the relative SP-A amount. There was a significant 
correlation between the relative SP-A amount in the first and last peak in BAL and the self-
agglutination ability (first peak: r
2
=01971; p=0.0174; last peak: r
2
=01591; p=0.0355). For serum, only 
trends, but no significant correlations were observed. This was analyzed by linear regression of 28 
(BAL) and accordingly 15 (serum) data of CF patients. 
 
The more SP-A was present as higher oligomers (in the first peak) and the less in smaller oligomers 
(last peak) the bigger was the agglutinate.  
SP-A self-agglutination is dependent on the amount of particular SP-A oligomers present in a sample, 
i.e. the relative strength of SP-A molecular forms in a sample. This supports the finding that also the 
correlation of the oligomeric distribution patterns with the Fev1 (% pred.)age20 is caused by the 
composition of the different oligomeric forms and not by differences of the oligomeric forms in the 
fractions because the self-agglutination ability is supposed to be adequate to the functional ability of 
SP-A.        
      
3.1.5.3) Influence of SP-A self-agglutination ability on Fev1 (% pred.)age20 and 
ΔFev1 (% pred.)/year 
 
Because of the correlation between SP-A structure and lung function and between the SP-A structure 
and the self-agglutination ability it was also searched for a correlation between the self-agglutination 
ability and lung disease severity. For Fev1 (% pred.)age20 there was in BAL (p = 0.0137) and serum (p 
= 0.0338) a significant correlation (shown in fig. 3.1.5.3.1 a and b). Additionally, for ΔFev1 (% 
pred.)/year there was also a significant correlation in BAL (p = 0.0213) and weakly in serum (p = 
0.0.497) which is shown in fig. 3.1.5.3.2 a and b. These results indicate the better the self-
agglutination ability of SP-A the better is the lung function. There was no correlation between the lung 
disease status (mild/severe) and the agglutination size. 
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a    b  
Figure 3.1.5.3.1: Correlation of Agglutinate size and Fev1 (% pred.)age20. The graphs show on the 
x-axis the SP-A agglutination size in BAL (a) and serum (b) in Pixel and in the y-axis the Fev1 (% 
pred.)age20. 28 BAL samples and 12 serum samples of CF patients were used. The p-values analyzed 
by linear regression were 0.0137 (r
2 
= 0.2119) for BAL and 0.0338 (r
2
 = 0.3480) for serum. 
 
a  b  
Figure 3.1.5.3.2: The Agglutinate size and ΔFev1 (% pred.)/year. The graphs plot on the x-axis the 
agglutinate size in BAL (a) or serum (b) and on the y-axis the ΔFev1 (% pred.)/year. 26 BAL samples 
and 14 serum samples of CF patients could be included. The p-values analyzed by linear regression 
were 0.0213 (r
2 
= 0.2017) for BAL and 0.0497 (r
2
 = 0.2841) for serum. 
 
These results indicate the better the self-agglutination ability of SP-A the better is the lung function. 
 
3.1.5.4) SP-A oligomerization and genetics 
 
Because of the different oligomeric SP-A distribution patterns it was searched for a genetic 
background in the CF structure group (no.:1-5, 7; n=46). Therefore the SFTPA1 and SFTPA2 
genotypes from MALDI-TOF were correlated with the percentage of SP-A (>20% yes/no) which was 
present in the first peak in relation to the percentage of SP-A which was present in the last peak. Only 
the extremes (first and last peak) were examined to have a better capability of to find significant 
correlations.  
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In BAL, but not in serum, two SNPs, rs1136451 (SFTPA1, see figure 3.1.5.4.1 a) and rs17881665 
(SFTPA2, see figure 3.1.5.4.1 b), were significantly associated with the formation of octadecamers or 
more complex structures presented by the first peak (p = 0.0108 and 0.0122). The wildtype alleles of 
both SNPs were associated with octadecamers or more complex structures. An analysis of a 
correlation between both SNPs indicated a linkage disequilibrium (p = 0.00001). The SFTPA1 SNP is 
a polymorphism in the coding region of the gene (P62P), but it doesn’t lead to an amino acidic 
exchange. The SFTPA2 SNP is located in the 5’-UTR of the gene where also splicing and other 
regulative sequences influencing the SP-A expression exist.  
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Figure 3.1.5.4.1: a) SNP rs1136451 and BAL SP-A structure. and b) SNP rs17881665 and BAL SP-A 
structure. 11 SFTPA1 and 11 SFTPA2 SNPs were genotyped by MALDI-TOF and correlated with the 
SP-A structure in BAL (ratio of the relative amount of SP-A existent in octadecamers to the relative 
amount of SP-A existent in dimers/trimers). The genotype (wildtype, heterozygous, mutated allele; x-
axis) was plotted against the ratio of the relative amount of SP-A in the first peak compared to the 
relative SP-A amount in the last peak on the y-axis. The wildtype allele of the SNP rs1136451 in the 
coding region of SFTPA1 was significantly associated with the formation of octadecamers or more 
complex structures (p = 0.0108) analyzed by One-way ANOVA with Tukey as post-hoc test. The 
wildtype allele of the SNP rs17881665 in the 5’-UTR of SFTPA2 was also significantly associated with 
the formation of octadecamers or more complex structures (p = 0.0122) analyzed by One-way ANOVA 
with Tukey as post-hoc test.  
 
 
No other correlation between these SNPs and other parameters (e.g. lung function) could be found. 
This supports again the results that the composition of the oligomers and not the nominal amount of a 
particular oligomeric type (e.g. monomers, trimers, etc.) is important for the functional ability of SP-A. 
There were also no other significant correlations between any other SNPs and parameters in this 
group. 
Because both SNPs don’t lead to an amino acid exchange, the only possible influence on the protein 
could be on the expression level. Therefore the next step was the analysis of the correlation between 
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the SP-A level and the SP-A structure. There was a significant association (p = 0.0006, see figure 
3.1.5.4.3) indicating that the higher the SP-A level was in BAL the bigger was the percentage of SP-A 
which was existent in octadecamers or more complex structures. 
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Figure 3.1.5.4.3: Correlation of BAL SP-A level and structure in CF. The graphs illustrate the 
correlation of the SP-A level in BAL (a, b) or serum (c, d) (x-axis) and the SP-A structure (y-axis) as 
the relative amount of SP-A in the first (a, c) or the last peak (b, d) after gel chromatography.  
There was a significant association (p = 0.0006, r
2
 = 0.5) analyzed by linear regression indicating that 
the higher the SP-A level was in BAL the bigger was the percentage of SP-A which was existent in 
octadecamers or more complex structures (in the first peak) in BAL.  
In serum there was no correlation (p = 0.46, r
2
 = 0.02). 38 BAL samples and 24 serum samples were 
analyzed. 
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3.1.6) Single molecule forced microscopy 
 
 
To finally examine the structure of SP-A in a fraction after gel chromatography the method of single 
molecule force spectroscopy based on atomic force microscopy was used. Only one molecule was 
attached to a gold layer and then pulled of by a cantilever, while the applied force is measured. 
 
 
 
Figure 3.1.6.1: Force spectrum of SP-A. The graph illustrates the superimposed curves of unfolding 
force spectrums of SP-A fragments. SP-A was isolated of pooled fractions from the first peak (F10) 
after gel chromatography of BAL from 12 CF patients by beads at pH 2.5. Only one molecule was 
attached to a gold layer and then pulled of by a cantilever, while the applied force is measured. 
 
 
 
About 2,000 measurements were completed. There were curves about 100 nm long which would 
correspond to about 270 aa. These curves could depict SP-A monomers. There were also curves 
corresponding to about 66 aa which could display the collagen-like domain. Because there were no 
longer curves it must be concluded that there were no multimers in the solution. There were also a lot 
of smaller curves which had to be fitted and put in order. After all a force spectrum of a SP-A monomer 
could be developed by superimposition of the curves.    
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3.2) SP-A self-agglutination  
For a better understanding of the SP-A self agglutination assay used to correlate the SP-A function 
with different parameters and to analyze possible differences of SP-A function between patient groups 
(CF, chronic bronchitis and controls) further experiments were executed. 
3.2.1) Samples analyzed by SP-A self-agglutination-assay 
 
Because it is known that there are structural differences of SP-A between individuals, it was necessary 
to elucidate if there are functional differences between different oligomeric states. Therefore the BAL 
and serum sample fractions arisen from gel chromatography of 10 CF patients, 10 chronic bronchitis 
and 7 control patients were further analyzed with a SP-A self-agglutination-assay (100 ng SP-A per 
sample was analyzed). These patients correspond to group no. 1-6 in scheme 2.1.1.in the methods. 
The DNA from all patients was genotyped by MALDI-TOF, the samples were analyzed by gel 
chromatography and the clinical data were collected. 
 
Table 3.2.1.1: Sample distribution of the BAL and serum analysis. 
Sample N 
BAL and serum pairs 8 
BAL 20 
Serum 7 
The table shows the number of samples available for the SP-A self-agglutination analysis of the BAL 
and serum samples.  
 
3.2.2) Relation between SP-A self-agglutination and structure 
 
The self-agglutination assay was used to determine the functional capability of SP-A regarding its 
CRD. Because different oligomeric structures of SP-A were found in BAL and serum of all study 
groups the fractions number 10, 15 and 20 of the gel chromatography representing the three peaks 
were analyzed by the self-agglutination assay. In all three study populations, CF, asthma and chronic 
bronchitis patients and controls, there was a significant difference regarding the self-agglutination 
ability between the fractions in BAL and serum (see figure 3.2.2.1). There was a significant decrease 
regarding the self-agglutination ability from SP-A octadecamers or more complex structures present in 
fraction 10 over the hexamers present in fraction 15 to the dimers and trimers present in fraction 20. 
Comparing the fractions between BAL and serum in the patient groups there was also a significant 
difference (see figure 3.2.2.2). The serum SP-A structures had significantly better self-agglutination 
ability than the corresponding structures in BAL. While in CF patients this difference was highly 
significant for all structures in the bronchitis study population the significance decreased from fraction 
10 over fraction 15 to fraction 20. In controls all fractions and therefore all SP-A structures in serum 
and the corresponding structures in BAL showed the same self-agglutination ability. At last the 
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fractions in BAL and serum were compared between the study populations (see figure 3.2.2.3 and 
3.2.2.4). For all BAL fractions the SP-A oligomers derived from controls agglutinated significantly 
better than the SP-A oligomers derived from patients. Also all BAL structures from the bronchitis study 
population agglutinated better than the structures derived from CF patients, but the difference was 
only significant in fraction 15. In contrast to these findings in serum there were no differences 
regarding the self-agglutination ability between the study populations. 
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Figure 3.2.2.1.: SP-A self-agglutination and fractions. The graphs show the self-agglutination ability 
(y-axis) of different SP-A structures derived from BAL and serum (x-axis) of the study populations. The 
streptavidin beads were coupled to biotinylated rabbit anti-goat antibodies which bound goat anti-
human SP-A antibodies. These anti-SP-A antibodies bound SP-A at its N-terminal end, so SP-A could 
self-agglutinate by its CRD. The SP-A amount was adjusted to 100 ng. In all study populations (10 CF, 
10 Bro, 7 C) there was a significant difference (*** means p < 0.0001 and * means p < 0.05) between 
the self-agglutination ability of the different structures (F10, F15 and F20) analyzed by One way 
ANOVA. The octadecamers or more complex structures showed the best self-agglutination ability 
followed by the hexameric structures and then the dimers/trimers. 
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Figure 3.2.2.2: Self-agglutination ability of SP-A out of BAL vs. serum. The graphs illustrate the 
self-agglutination ability (y-axis) of different SP-A structures derived from BAL and serum (x-axis) of 
the study populations. The streptavidin beads were coupled to biotinylated rabbit anti-goat antibodies 
which bound goat anti-human SP-A antibodies. These anti-SP-A antibodies bound SP-A at its N-
terminal end, so SP-A could self-agglutinate by its CRD. The SP-A amount was adjusted to 100 ng. 
Only in the patient populations (10 CF, 10 Bro, 7 C) all SP-A structures derived from serum fractions 
agglutinated significantly better than the corresponding structures derived from BAL (* stands for p < 
0.05, ** for p < 0.01 and *** for p < 0.001) analyzed by One way ANOVA. While in CF patients this 
difference was highly significant for all structures in the bronchitis study population the significance 
decreased from fraction 10 over fraction 15 to fraction 20. In controls all fractions and therefore all SP-
A structures in serum and the corresponding structures in BAL showed the same self-agglutination 
ability. 
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Figure 3.2.2.3: Self-agglutination ability of BAL SP-A structures. The graphs show the self-
agglutination ability (y-axis) of different SP-A structures derived from BAL comparing the study 
populations. The streptavidin beads were coupled to biotinylated rabbit anti-goat antibodies which 
bound goat anti-human SP-A antibodies. These anti-SP-A antibodies bound SP-A at its N-terminal 
end, so SP-A could self-agglutinate by its CRD. The SP-A amount was adjusted to 100 ng. For all BAL 
fractions the SP-A oligomers derived from controls agglutinated significantly better than the SP-A 
oligomers derived from patients except fraction 20 bronchitis samples showed the same self-
agglutination ability as controls. Also all BAL structures from the bronchitis study population 
agglutinated better than the structures derived from CF patients, but the difference was only significant 
in fraction 15 and 20 (* stands for p < 0.05, ** for p < 0.01 and *** for p < 0.001). All experiments were 
analyzed by One way ANOVA. 
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Figure 3.2.2.4: Self-agglutination ability of serum SP-A structures. The graphs show the self-
agglutination ability (y-axis) of different SP-A structures derived from serum comparing the study 
populations. The streptavidin beads were coupled to biotinylated rabbit anti-goat antibodies which 
bound goat anti-human SP-A antibodies. These anti-SP-A antibodies bound SP-A at its N-terminal 
end, so SP-A could self-agglutinate by its CRD. The SP-A amount was adjusted to 100 ng.  In contrast 
to BAL in serum there was no difference between the study populations regarding the self-
agglutination ability of the different fractions analyzed by One way ANOVA (p > 0.05). 
  
 
In summary the more complex the SP-A structure the better was the self-agglutination ability. All SP-A 
structures self-agglutinate in serum better than in BAL in samples of the patients groups while in 
control samples BAL and serum SP-A showed the same abilities. There was also a difference 
between the self-agglutination ability of BAL samples from CF, Bro and control derived SP-A, but none 
in serum. SP-A from control BAL agglutinated better than from bronchitis BAL and this better than 
from CF BAL. This indicates that the analysis of the SP-A structure composition was important 
because the structure had strong effects on the SP-A self-agglutination ability.  
 
3.3) SP-A-genetics, clinical and biochemical data  
For these studies samples from 453 patients with CF, 72 chronic bronchitis and asthma patients and 
25 controls subjects were used, as detailed in fig 2.1.1 in the methods section. As not from all subjects 
all variables were assessed in each instance, in addition the exact number of subjects included or 
materials available is given in the figure and table legends. 
3.3.1) Clinical data of the genetic population 
 
In this study the CF population consisted of two cohorts. The first cohort included 371 patients from 
the Dr.-von-Haunersche children’s hospital, Munich. The second cohort included 82 patients from a 
previous study (BEAT) including CF patients from Berlin (17 patients), Essen (18 patients), Hannover 
(12 patients), Cologne (26 patients) and Munich, the Dr.-von-Haunersche children’s hospital (9 
patients) not included in the first cohort. From the BEAT study group BAL, serum and DNA of each 
patient, for the other CF patients only serum and DNA as available were analyzed. There were also 72 
bronchitis and asthma patients and 25 controls without any lung disease genotyped and BAL and 
serum as available analyzed.  
 84 
 
Table 3.3.1.1: Clinical data of study populations. 
Clinical characteristic CF N Bronchitis N Control N 
Number 453  72  25  
Female (%) 49 230 51 35 56 14 
Age at sampling point (years) 15 ± 9 453 6 ± 6 72 26 ± 17 25 
BAL SP-A level (ng/ml) 3747 ± 2959 86 4639 ± 4867 20 4774 ± 4232 8 
Serum SP-A level (ng/ml) 34 ± 40 292 30 ± 20 5 17 ± 4 5 
Fev1 (% pred.)age20 85 ± 42 387 92 ± 23  32 118 1 
Lung disease status 
(mild/moderate/severe) 
278/0/109 387 23/9/0 42   
Mean ∆Fev1 (% pred.)/year -3 ± 15 376     
BMI 
(underweight/normal/overweight) 
154/225/47 426 6/35/11 52 0/22/0 22 
IgG level in serum (mg/ml) 292 ± 773 384 116 ± 247 51 29 2 
x-times upper IgG standard value 0.6 ± 0.3 384 0.5 ± 0.3 51 0.7 ± 0.1 2 
IgE level in serum (lU/ml) 1027 ± 502 372 653 ± 415 51 423,9 2 
x-times upper IgE standard value 1.6 ± 4 372 0.9 ± 1.7 51 0.42 ± 0.1 2 
ABPA ( % yes) 35 (n = 153) 432 0 72 0 25 
The table shows the clinical data as means ± standard deviation for all three study groups. Included 
were all patients genotyped by MALDI-TOF and probes. N means the actual number of the available 
data. 
 
3.3.2) Lung disease 
3.3.2.1) Classification of the lung disease status in the CF population 
 
The lung disease status of the CF patients was calculated according to Schluchter (1,2). First the Fev1 
(% pred.) values over the last 3 years were examined and taken to determine the lung disease status. 
Enrolment by severity group was based on age-specific cut-off values for Fev1 (% pred.), derived from 
quartiles of lung function for patients <34 years of age in the U.S. Cystic Fibrosis Foundation Patient 
Registry (2). The mean values of each year was calculated and all three values had to fit in the 
enrolment criteria for one group (mild young: age 15-24 years; mild old: age ≥ 25 years; severe: age 8-
25 years) to determine a status. If a patient didn’t match these criteria he had to be excluded. There 
were 35 children who were too young for classification and 31 patients with less than 3 Fev1 % pred. 
values or who didn’t match the criteria. All patients ≥ 34 years of age were considered “mild” 
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regardless of their Fev1 % pred., on the basis of survival. The classification distribution of the CF 
study population is shown in table 3.3.2.1.1. 
 
Table 3.3.2.1.1: Classification distribution of the CF study population. 
Disease Group Number of patients 
Mild young 213 
Severe 109 
Mild old 65 
Total classified (from n = 453) 387 
The table shows how many CF patients could be classified as having a mild or severe lung disease 
status. Children younger than 8 years (n = 35), patients with less than one Fev1 (% pred.) value per 
year over the last 3 years (n = 10) and patients who didn’t match the criteria (n = 21) could not be 
classified. 
 
The data from the patients of the three lung disease groups (mild young, mild old and severe young) 
show a definite distribution (see Fig. 3.3.2.1.1). Therefore the classification into these groups after 
Schluchter is also capable to accurately identify patients at the extremes of phenotypes in our study 
group. (2) 
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Figure 3.3.2.1.1: Lung function distribution. The graph shows on the x-axis the age in years of the 
CF patients and in the y-axis the lung function as Fev1 (% pred.). The CF patients were grouped after 
classification of their lung disease with regard to the calculations of Schluchter et al. (Zitat) and the 
mean Fev1 % pred. for each age was plotted. The bar at age 20 indicates the significant difference of 
lung function curves between the mild old and severe group. Therefore the classification into these 
groups after Schluchter is also capable to accurately identify patients at the extremes of phenotypes in 
our study group and a good separation of lung disease severity groups (mild/severe) from the 
extrapolated Fev1 (% pred.) at age 20 is possible. 
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3.3.2.2) Classification of the lung disease status in the bronchitis population 
 
The lung disease status of the bronchitis study population was determined after the enrolments of the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Only 32 patients could be classified 
because most patients were too young for a lung function test. Therefore no lung function data was 
available to classify the lung disease status.  
 
Table 3.3.2.2.1: Classification distribution of the bronchitis study population. 
Disease Group Number of patients 
Mild 23 
Moderate 9 
Severe 0 
Total classified 32 
The table shows how many chronic bronchitis and asthma patients could be classified as having a 
mild, moderate or severe lung disease status. 
 
3.3.3) Genetic influence on BMI and genotype differences between 
patient groups 
 
For determining the genotypes of the study populations some SNPs which cause an amino acidic 
exchange were analyzed by melting curves with hybridized probes in a Light Cycler. Also for a bigger 
throughput of genotyping the method of Matrix Assisted Laser Desorption/Ionisation-Time-Of-Flight 
(MALDI-TOF) was used.  
The SNP data resulting from the genotyping by MALDI-TOF and probes were correlated with the 
clinical data and ELISA level measurements by χ
2
-test on the webpage 
http://home.ubalt.edu/ntsbarsh/Business-stat/otherapplets/Catego.htm and the results were corrected 
according to Bonferroni. 
No correlation between any genotyped SNPs and BMI with respect to the patient groups (CF, chronic 
bronchitis and controls) could be found. 
The frequency of the alleles was significantly different between the study groups CF, bronchitis and 
controls, for SP-D M31T (p = 0.03), SP-A2 rs1965708 (p = 0.0001) and SP-A2 rs1975006 (p = 
0.0001). The SP-A SNPs were linked. For the SP-D SNP the CF population showed a significantly 
higher amount of the mutated allele, while for the SP-A SNPs the CF population had a significantly 
smaller amount of the mutated allele. 
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3.3.4) SP-A and SP-D level measurements 
 
For a correlation analysis between the clinical and genetic data and the SP-A and SP-D levels the 
levels were measured by ELISA (see figure 3.3.4.1). The mean SP-A levels in BAL were 3747 ng/ml 
for the CF patients, 4639 ng/ml for the bronchitis patients and 4774 ng/ml for the controls. The mean 
SP-A levels in serum were 34 ng/ml for the CF patients, 30 ng/ml for the bronchitis patients and 17 
ng/ml for the controls. The mean SP-D levels in BAL were 699 ng/ml for the CF patients, 34 ng/ml for 
the bronchitis patients and 505 ng/ml for the controls. The mean SP-D levels in serum were 261 ng/ml 
for the CF patients, 382 ng/ml for the bronchitis patients and 388 ng/ml for the controls.    
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Figure 3.3.4.1: The SP-A and SP-D BAL and serum levels. The graphs illustrate the BAL (a, b) and 
the serum (c, d) levels of SP-A (a, c) and SP-D (b, d) of the study populations. The SP-D levels in BAL 
differed significantly (pCF-Bro = 0.0003, pBro-C = 0.02) between the patient groups analyzed by One way 
ANOVA. No other correlation was found. BAL samples of 86 CF, 20 Bro patients and 8 controls were 
analyzed as well as serum samples from 292 CF, 4 Bro patients and 8 controls. 
 
In a former study by Bielecki (“Surfactantproteine A und D im Serum und in Bronchoalveolärer Lavage 
bei Patienten mit Cystischer Fibrose“, MD, 2007) the consistency of the SP-A serum levels in CF 
patients over time was shown. This consistency allows us to compare results arising from sera taken 
at different points of time from CF patients with clinical stability. 
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Figure 3.3.4.2: Time developing of SP-A level in serum of CF patients. The graph shows on the y-
axis the SP-A level in serum (ng/ml) and on the x-axis three different points in time which stand for the 
beginning of the measurements (T1), about a year later (T7) and about two years from the beginning 
(T13). Each line shows the development of the SP-A level in serum of one CF patient with respect to 
time. These results of 11 BEAT-CF patients also included in this study show that the level are 
consistent over time (Doktorarbeit Eva Bielecki, 2007). 
 
 
Analyzing the SP-D BAL and serum levels of all available patients and controls regarding age there 
was a significant correlation between the serum levels and the age (p = 0.001, see figure 3.3.4.3. For 
further analysis of the SP-D level with respect to the age in CF patients see 3.3.5.6.2.    
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Figure 3.3.4.3: SP-D level and age. The graphs show the correlations between SP-D levels in BAL (a) 
and serum (b) on the y-axis and the age on the x-axis. There was a significant association between 
the serum levels and the age (p < 0.0001, r
2
 = 0.08), but no association in BAL (p = 0.9) analyzed by 
linear regression. BAL samples of 86 CF, 20 Bro patients and 8 controls were analyzed as well as 
serum samples from 292 CF, 4 Bro patients and 8 controls. 
 
 
 
The results in section 3.3.5 are only related to the group of the CF patients, as not sufficient clinical 
and biochemical data of the chronic bronchitis patients and controls were available for meaningful 
statistical analysis.  
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3.3.5) Genetics in CF 
3.3.5.1) SP-A SNPs and clinical data 
 
There was a significant association between the mean ∆ Fev1 (%pred.) / year and V50L a SNP in the 
SFTPA1 gene (p = 0.0038, see figure 3.3.5.1.1) while the mutated allele was associated with a worse 
course of lung disease. There was also a significant associations of SP-A2 N9T (p = 0.004) with ABPA 
illness regarding whether the CF patients had an ABPA illness or not analyzed by χ
2
-test. For SP-A2 
N9T the wildtype allele was significantly associated with the group that had never ABPA. 
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Figures 3.3.5.1.1: Significant SNP association with the mean ∆ Fev1 (%pred.) / year in CF. The 
graph plots the genotypes (0101 for the wildtype, 0102 for heterozygous and 0202 for the 
homozygous mutation) on the x-axis and the mean ∆ Fev1 (%pred.) / year on the y-axis. The graph 
shows a significant correlation of the SNP SP-A1 V50L (p = 0.038). * stands for a p-value < 0.05 
analyzed by One way ANOVA. 376 CF patients were analyzed. 
 
The other characteristics, age at the first P. aer. infection, age at the first P. aer. mucoid infection, 
chronic or non-chronic P. aer. infection, age at the first chronic P. aer. infection, BMI and Fev1 (% 
pred.) estimated for age 20, had no significant correlations with any SNPs after Bonferroni correction.  
 
3.3.5.2) SP-A level and genetics in CF 
 
For SP-A there were significant associations with the BAL and serum level. The SP-A BAL level was 
significantly associated with the SP-A1 SNP rs1136451 (p = 0.04) and the SP-A2 SNP rs17881665r (p 
= 0.03) (see fig. 3.3.5.2.1). Here the mutated allele was associated with lower SP-A levels like it was 
shown before with the CF part analyzed by gel chromatography. This significant correlation existed 
only by analyzing the SNP data with the χ
2
-test and grouping after BAL levels (group 1: 0-1,000 ng/ml; 
group 2: 1,000-10,000; group 3: >10,000) to compare the extremes. The correlation of the BAL level 
data by grouping regarding the genotype was not significant. The SP-A serum level was significantly 
associated with SP-A1 N9T (p = 0.028) (see fig. 3.3.5.2.2).  
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Figure 3.3.5.2.1: SNP associations with the SP-A level in BAL. Both graphs plot the association of 
the SNP genotypes (0101 for the wildtype, 0102 for the heterozygous and 0202 for the homozygous 
mutation, x-axis) and the SP-A level in BAL (y-axis). Graph a illustrates the association for SP-A1 
rs1136451 and graph b for SP-A2 rs17881665r. 86 BAL samples of CF patients were analyzed. 
Although the analysis by χ
2
-test showed a significant association, these grouping after genotype 
showed none analyzed by One way ANOVA. 
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Figure 3.3.5.2.2: SNP association with the SP-A level in serum. The graph shows the association 
of the SP-A2 N9T genotype (0101 for the wildtype, 0102 for the heterozygous and 0202 for the 
homozygous mutation, x-axis) with the SP-A level in serum (y-axis) with a p-value of 0.028 analyzed 
by One way ANOVA. 292 serum samples of CF patients were analyzed.  
 
3.3.5.3) Fev1 (% pred.) estimated for age 20 correlates with SP-A level 
 
The SP-A levels in BAL and serum were measured by ELISA and correlated to the clinical data of the 
patients. In the CF study population there was a significant association between the SP-A level in BAL 
and the Fev1 (% pred.)age 20 (p = 0.009, see figure 3.3.5.6.1). The higher the SP-A levels were in BAL 
the bigger were the values of the Fev1 (% pred.)age 20. In serum there was no correlation with this 
characteristic (p = 0.33). The SP-A serum level was associated with the lung disease (p = 0.05, see 
figure 3.3.5.6.2) while patients with severe lung disease had a higher serum level. 
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Figure 3.3.5.3.1: SP-A level and Fev1 (% pred.)age 20. Both graphs plot the SP-A level in BAL (a) and 
serum (b) of the CF study population against the Fev1 (% pred.)age 20. There was a significant 
association between the SP-A level in BAL and the Fev1 (% pred.)age 20 (p = 0.007, r
2
 = 0.1) analyzed 
by linear regression. In serum there was no correlation with this characteristic (p = 0.07). 292 serum 
samples and 85 BAL samples of CF patients were analyzed. 
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Figure 3.3.5.3.2: Lung disease and SP-A level. The graphs illustrate the SP-A level in BAL (a) and 
serum (b) of CF patients grouped according to the lung disease (mild/severe). 292 serum samples and 
12 BAL samples of CF patients were analyzed. In serum there was a significant correlation (t-test, p = 
0.05). In BAL was no correlation. 
 
There were no correlations between the ΔFev1 (% pred.)/year, ABPA (yes/no), BMI, age, gender, IgG 
or IgE in serum and the SP-A BAL or serum level. 
 
3.3.5.4) SP-D genetics in CF 
 
Because the Fev1 (% pred.)age 20 had been shown to be an equivalent classification criteria for lung 
disease of CF patients (2) and the lung disease groups were significantly associated with SP-D M31T 
(p = 0.0005, see figure 3.3.5.4.1) the correlations were again analyzed after grouping the patients 
regarding to their genotype. Both showed the same correlation that the mutated allele leads to a worse 
lung disease outcome (p = 0.0091). Analyzing the mean ΔFev1 (% pred.)/year regarding to the 
genotype of SFTPD M31T there was also a significant correlation (p = 0.019, see figure 3.3.5.4.1).  
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Figure: 3.3.5.4.1: Significant SNP associations with lung disease. The graphs plot the genotype 
(0101 for the wildtype, 0102 for the heterozygous and 0202 for the homozygous mutation) of the M31T 
SNP on the x-axis and the Fev1 (%pred.)age 20 (a) or the mean ΔFev1 (% pred.)/year on the y-axis. The 
graphs show a significant association analyzed by One way ANOVA (p = 0.0091 and p = 0.019). 376 
CF patients were analyzed. 
 
 
3.3.5.5) SP-D SNPs influencing the protein level in CF 
 
There was no significant association between the SP-D BAL level and any of the SP-D SNPs 
genotyped by MALDI-TOF and probes. 
The SP-D serum level was significantly associated with the SNPs SP-D M31T (p = 0.04) and SP-D 
A180T (p = 0.013). In BAL the same correlation could be observed, but the difference was not 
significant (see fig. 3.3.5.5.1). For both SNPs the mutated allele is associated with lower SP-D levels. 
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Figure 3.3.5.5.1: SNP associations with the SP-D level in serum. All four graphs plot the 
association of the SNP genotypes (0101 for the wildtype, 0102 for the heterozygous and 0202 for the 
homozygous mutation, x-axis) and the SP-D level in serum (b, d) and in BAL (a, c) (y-axis). Analyzed 
were 86 BAL and 292 serum samples of CF patients. Graphs a and b illustrate the association for SP-
D M31T with a p-value of 0.04 in serum and graph c and d for SP-D A180T with a p-value of 0.013 in 
serum analyzed by One way ANOVA. There was no significant correlation with the SP-D level in BAL. 
 
 
3.3.5.6) Influence of lung disease, age and BMI on SP-D levels 
 
After analysis of associations between the SNP data and the SP-D levels in BAL and serum measured 
by ELISA, also the correlation between the levels and clinical data was investigated. 
The SP-D level in serum of the CF study population was significantly associated with the lung disease 
(mild/severe, p = 0.005, see figure 3.3.5.6.2) and the Fev1 (% pred.)age20 (p = 0.0027, see figure 
3.3.5.6.1). The higher the SP-D level was in serum the smaller was the value of the Fev1 (% 
pred.)age20. In BAL there was no correlation (p = 0.9). In line with this also the ΔFev1 (% pred.)/year 
was significantly associated with the serum level (p = 0.01, see figure 3.3.5.6.3) indicating that the 
lower the SP-D level in serum was the better was the course of lung disease.  
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Figure 3.3.5.6.1: SP-D level and Fev1 (% pred.) estimated for age 20. Both graphs plot the SP-D 
level in BAL (a) and serum (b) of the CF study population against the Fev1 (% pred.)age 20. There was a 
significant association between the SP-A level in serum and the Fev1 (% pred.)age 20 also after 
excluding too extreme values above 200 % (p = 0.003, r
2
 = 0.3) analyzed by linear regression. In BAL 
there was no correlation with this characteristic (p = 0.9) analyzed by linear regression. 86 BAL and 
292 serum samples of CF patients were analyzed. 
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Figure 3.3.5.6.2: SP-D level and lung disease. The graphs show the SP-D level in BAL (a) and 
serum (b) and the lung disease (mild/severe). Analyzed by t-test there was a significant correlation 
between the serum level and the lung disease (p = 0.005). 86 BAL and 292 serum samples of CF 
patients were analyzed. 
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Figure 3.3.5.6.3: SP-D level and ΔFev1(% pred.)/year. Both graphs show the SP-D level in BAL (a) 
and serum (b) in relation to the ΔFev1(% pred.)/year. Analyzed by linear regression only in serum was 
a significant correlation (p = 0.01). 86 BAL and 292 serum samples of CF patients were analyzed. 
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Analyzing the SP-D levels in BAL and serum with respect to the age of the individuals there was a 
significant association between increasing SP-D serum level and increasing age (p = 0.001), but no 
correlation between the SP-D BAL level and age. The same result was found analyzing only the CF 
patients regarding to SP-D level in serum (p = 0.00003) and BAL (p = 0.19) and the age (see figure 
3.3.5.6.4). Only in CF patients the correlation between the BAL SP-D level and the age seems to be 
oppositional to the correlation between the serum SP-D level and age, leading to the assumption that 
with increasing age the SP-D level in BAL decreases in CF patients. Additionally by analyzing the BMI 
groups underweight, normal weight and overweight and the SP-D levels there was a significant 
difference between the serum levels of the underweight and the overweight group as well as between 
the normal weight group and the overweight group (both p < 0.01), but no significance regarding the 
BAL levels (see figure 3.3.5.6.5). While the underweight and normal weight groups had a similar SP-D 
level distribution in serum, the overweight group had significantly lower serum SP-D levels. 
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Figure 3.3.5.6.4: SP-D level and age in CF patients. The graph b illustrates the significant correlation 
(p = 0.00003, r
2
 = 0.1) between the SP-D level in serum and the age of CF patients, whereas graph a 
indicates an oppositional, not significant (p = 0.19) correlation between the SP-D level in BAL and the 
age of CF patients analyzed by linear regression.  
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Figure 3.3.5.6.5: SP-D level and BMI. The graphs plot the SP-D levels in BAL (a) and serum (b) on 
the y-axis against the BMI classified in underweight, normal weight and overweight on the x-axis. 
There was a significant difference between the serum levels of the underweight and the overweight 
group as well as between the normal weight group and the overweight group (both p < 0.01), but no 
significance regarding the BAL levels analyzed by One way ANOVA. BAL samples of 86 CF, 20 Bro 
patients and 8 controls were analyzed as well as serum samples from 292 CF, 4 Bro patients and 8 
controls.  
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3.4) Absence of SP-D in BAL 
For this study samples from 10 chronic bronchitis and asthma patients (out of group no.12 in scheme 
2.1.1, methods) were used. After we identified subjects with no SP-D in their BAL common 
polymorphisms known to be associated with low serum SP-D levels were assessed in those subjects 
from whom informed consent could be obtained and DNA was available.  
The M31T polymorphism in exon 1, A180T in exon 4 and S290T in exon 7 were analyzed. DNA was 
available from 10 of the 12 children who had no SP-D detectable in their BAL by ELISA (n = 6) and 
Western blotting (n = 4). For comparison 8 children were selected with the same clinical 
characteristics, but detectable SP-D levels in serum. 
No significant genetic association could be found between the common polymorphisms known to be 
associated with low serum SP-D levels and the lack of SP-D in BAL or serum respectively.  
 
 
3.5) TLR SNPs 
 
The SNP TLR4 A-2570G was significantly associated with the lung disease (mild/severe) in CF 
patients analyzed by χ
2
-test (p = 0.0003). No other correlation between any clinical characteristics 
could be found. 
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4) Discussion 
 
Surfactant associated protein A (SP-A) is the most abundant pulmonary surfactant protein and 
belongs to the family of innate host defence proteins termed collectins. Besides pulmonary host 
defence, SP-A is also involved in the formation of pulmonary surfactant, as it is essential for the 
structure of tubular myelin. The human SP-A gene locus includes two functional genes, SFTPA1 and 
SFTPA2 which are expressed independently, and a pseudo gene. The largest amount of SP-A1 
proteins assemble to larger molecular complexes, whereas SP-A2 forms mainly dimers and trimers. 
SPA polymorphisms play a role in respiratory distress syndrome, allergic bronchopulmonary 
aspergillosis and idiopathic pulmonary fibrosis. The levels of SP-A are decreased in the lungs of 
patients with cystic fibrosis, respiratory distress syndrome and further chronic lung diseases. Future 
areas for clinical research include disease specific SP-A expression pattern and their functional 
consequences, the differential roles of SP A1 and SP-A2 in human lung diseases, and therapeutic 
approaches to correct altered SP-A levels. 
The aim of the study was to elucidate the role of SP-A in human lung disease. The study was 
designed to analyze the relation between genetics, structure and function of SP-A in a cystic fibrosis 
(CF), chronic bronchitis and asthma and healthy control population ex vivo. Therefore the DNA was 
genotyped by MALDI-TOF and probes, the SP-A serum and BAL levels were measured by ELISA, 
BAL and serum SP-A was separated by gel chromatography and analyzed by Slot-Blot, the functional 
capability of SP-A was measured by an agglutination-assay with respect to the CRD and clinical data 
was collected. 
 
4.1) Study populations 
The BAL and serum samples of 42 CF patients, 19 chronic bronchitis and asthma patients and 8 
controls that were genotyped by MALDI-TOF as well as BAL and serum samples from additional 9 
chronic bronchitis patients and 10 controls were analyzed by gel chromatography with a Superose 6 
column. Because it is known that there are structural differences of SP-A between individuals, it was 
necessary to elucidate if there are functional differences between different oligomeric states. 
Therefore the BAL and serum samples fractions of 10 CF patients, 10 chronic bronchitis and 7 control 
patients and the whole BAL and serum samples of all patients analyzed by gel chromatography were 
further analyzed with a SP-A self-agglutination-assay. The DNA from 454 CF patients, 72 chronic 
bronchitis and asthma patients and 25 controls was isolated and genotyped by MALDI-TOF. 
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4.2) SP-A structure and function 
4.2.1) Clinical data of the structure and function population 
 
The BAL and serum samples of 42 CF patients, 19 chronic bronchitis and asthma patients and 8 
controls that were genotyped by MALDI-TOF as well as BAL and serum samples from additional 9 
chronic bronchitis patients and 10 controls were analyzed by gel chromatography. Because it is known 
that the SP-A ratio of SP-A1:SP-A2 decreases with respect to the age (3) and that there are 
differences between the oligomerization characteristics of SP-A1 and SP-A2 (4) the patients and 
controls were selected with respect to the mean age of the study populations. The female percentage 
was almost even. The mean SP-A level in BAL of CF patients was lower as in the other populations as 
expected, but not in serum which could be caused be the high variability of the values. The lung 
function was equal between the bronchitis and CF populations. A problem here was that either 
because of the young age of controls or no available data there was only one measurement of lung 
function for controls. The BMI was available for all study populations and underweight could only be 
detected in the CF population as expected (5). The lung disease status shows that there are only in 
the CF population severe disease status. The bronchitis patients had in spite of a few exceptions a 
mild lung disease status. Therefore the bronchitis patients are more comparable to controls with 
respect to lung disease. Leucocytes, neutrophils and eosinophils could be more frequently detected in 
CF patients while the bronchitis patients and controls were on the same low level. This supports the 
idea that the bronchitis group has less inflammation activity in lung than CF patients.  
 
4.2.2) SP-A structure analysis by gel chromatography 
 
To determine structural differences in BAL and serum between the study populations a gel 
chromatography method with a superpose 6 column was chosen. In this method SP-A molecules were 
separated with regard to their oligomerization form. The larger the oligomers the earlier they were 
eluted. After gel chromatography the SP-A amount of the eluted fractions was determined by Slot-Blot. 
The peaks were defined as a relative SP-A amount of more than 20 % and a distance of 5 fractions 
between each peak (mainly in fraction 10, 15 and 20).  The peak areas ranged from fraction 9-12, 13-
17 and 18-22. For calculation also the first peak from fraction 9-12 and the last peak from fraction 18-
22 were defined. The peak area and position definition was evaluated after the main appearance of 
the SP-A peaks. Because the minimum value of 20 % was arbitrary it was considered by determining 
the distribution form resulting in more than one possible form for some patients.  
 
4.2.2.1) Reproducibility of structure analysis 
 
The reproducibility of the gel chromatography and the Slot-Blot assay was tested to exclude 
distribution variations caused by inhomogeneous testing. Regarding the distribution forms the 
reproducibility was very good, only the SP-A amount in the fractions seemed to vary. Therefore the 
relative SP-A amount per fraction was taken for correlation analysis to diminish the varying level. 
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Because the form could be also reproduced after some weeks with freezing and thawing and was 
consistent for different samples of the same individual the samples were comparable for all study 
populations.  
 
4.2.2.2) Calibration of the Superose 6 column 
 
The calibration of the column after Griese et al. and Hickling et al. (6,7) identified the SP-A forms in 
the first peak as octadecamers and more complex structures, in the second peak as hexamers to 
dodecamers and in the last peak as dimers and trimers regarding the molecular weight. This 
calibration is reliable because Hickling et al. determined the Stokes radii and sucrose density gradient 
of the molecular weight markers and based on this calculated the molecular weight of the structures in 
the peaks.  
 
4.2.3) Different peak distribution in study populations 
 
In BAL the most common forms contained the first peak and there was no obvious difference of 
distributions between the study populations, but the bronchitis and control populations had more SP-A 
in the last peak. In the BAL of CF patients elastase and oxidants lead to proteolysis of SP-A (8). 
Smaller oligomers had been shown to be more susceptible to oxidation (9) therefore the dimers and 
trimers in the CF BAL samples could have been destroyed by elastase and oxidants. Hickling et al. 
found a higher percentage of complex oligomers like octadecamers in BAL from healthy persons 
compared to BAL from birch pollen allergic persons (7). The higher variability found in BAL structures 
in this study could be a consequence of analyzing more samples, Hickling et al. analyzed only 11 
allergic persons and 4 healthy persons compared to 21 bronchitis patients and 18 controls in this 
study. The results of the control subjects arising from the study of Griese et al. (6) match with the 
results of this study. They showed in the publication only the mean distribution of 6 from 17 measured 
control BALs. Altogether the distributions showed the same variability. These two studies were the 
only ones analyzing the degree of oligomerization of SP-A ex vivo by gel chromatography.  
In serum all control samples showed the second peak and partly the last peak, but none contained the 
first peak. In sera of CF, chronic bronchitis and asthma patients there was more variability, but the CF 
samples contained mainly the first peak. The distal airspaces of the lung are lined with a continuous 
epithelium comprising two major types of alveolar epithelial cells (type I and type II pneumocytes) 
joined by tight junctions (zonulae occludentes). The normal air-blood barrier of human lungs appears 
to differentially restrict the passage of large proteins as evident by the finding that concentrations of 
macromolecules like IgM in BAL were extremely low compared with the smaller proteins like BSA (10). 
During inflammation the barrier can be disrupted for example by cationic aa and peptides which arise 
from protein degradation which was shown in acute respiratory syndrome (11). This mechanism could 
cause the appearance of octadecamers and more complex structures in serum of CF patients. 
The differences in the degree of SP-A oligomerization between individuals is also caused by the 
composition of SP-A1 and SP-A2.  Recombinant, human SP-A1 forms lower supratrimeric structures 
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as SP-A2, but the proteolysis-resistance is higher for rhSP-A1. Co-expressed SP-A1/A2 forms more 
complex oligomers and leads to a higher degree of self-agglutination compared to SP-A1 and -A2 
alone (4). A gradual decrease (P < 0.05) in SP-A1/SP-A ratio was observed in healthy subjects (HS) 
with increased age, although no significant change was observed in total SP-A content among age 
groups in a study from Tagaram et al. The CF ratio was significantly higher compared with AP, HS and 
non-cystic fibrosis (NCF), even though SP-A1 and total SP-A were decreased in CF compared with 
most of the other groups, but there were only 16 CF patients analyzed compared to 42 in this study. A 
higher ratio would indicate that SP-A in CF BAL is mainly existent in smaller oligomers which would be 
contradictory to the results of the analysis by gel chromatography, but this was not further analyzed in 
the study by Tagaram et al. (3). The statements regarding the structure of SP-A and the ratio of SP-
A1/SP-A2 were exclusively made based on recombinant SP-A assays and native SP-A had shown 
different oligomerization patterns than a mixture of recombinant SP-A1/SP-A2 (4). Therefore the 
conclusions regarding the ratio and the structure are not reliable and this is an important field which 
has to be investigated in the future.  
Next the 47 BAL and serum pairs were examined. The most frequent pairs contained the first peak in 
BAL and serum. There were some sample pairs with the same form in BAL and serum, but also pairs 
with the opposite forms. In controls the complex oligomers were only in BAL not in the corresponding 
serum as was stated before. In CF and bronchitis patients appeared a more variable distribution of 
forms in BAL and serum indicating a higher exchange rate. 
Because different oligomeric distributions between individuals and study populations were observed 
also the correlation between the lung function and the oligomeric SP-A distribution form in BAL and 
serum were analyzed. In BAL a slight increase in Fev1 (% pred.) can be observed the more SP-A is 
existent in the first peak (111 to 100). In BAL samples where all three peaks could be observed (111) 
SP-A is present in dimers/trimers, smaller oligomeric forms like hexamers and only partly in complex 
oligomeric forms like octadecamers. In samples where only the first peak is present (100) SP-A is 
mainly existent in complex forms. The slightly better lung function of the 101 form in comparison to the 
110 form could be explained in BAL by comparing the peaks in each form. In the 101 form the first 
peaks were bigger in contrast to the first peaks in the 110 forms (mean percentage of first peak in 101 
= 45 % and 110 = 39%).  
In conclusion there were no correlations between serum and BAL SP-A distribution forms. The forms 
showed only a significantly different distribution comparing serum samples from bronchitis patients 
and controls. In serum and BAL of CF patients the forms containing the first peak were correlated with 
a better lung function (Fev1 (% pred.)age20). These findings suggest that the more SP-A is existent in 
octadecamers or more complex structures in BAL the better is the lung function. In serum the 
distributions show the same correlation. The better lung function of the 101 form in comparison to the 
110 form is most likely a result of the small sample size for the 101 form. 
4.2.4) Influence of SP-A structure on self-agglutination 
 
The capacity of SP-A from serum and BAL to induce agglutination was linked to the organizational 
structure of naturally occurring macromolecular forms. While in serum the different forms indicated an 
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approximate association with the self-agglutination ability, in BAL the differences were more 
distinctive. In serum only the 010 and 110 forms showed a significant difference regarding the self-
agglutination ability. In BAL the 100 form agglutinated significantly better than the 111 and 110 form 
and the 101 form significantly better than the 111 form. Altogether, the results imply that the 100 form 
agglutinates best with the rest showing a declining ability in the following order: 
100>101>110>111>010. The weaker self-agglutination ability of distributions containing smaller 
oligomeric structures (111 in comparison to 100) and the complex oligomeric structures in the first 
peak could be the result of the actual amount of SP-A which is existent in these forms. While in the 
100 distribution almost the entire SP-A in the sample is existent in complex forms like octadecamers in 
111 a smaller part of the SP-A is existent in complex forms. This decreases the self-agglutination 
ability.   
Focussed on the fractions in BAL and serum the increasing order correlated to the increasing lung 
function could not be supported. In BAL the self-agglutination ability in all fractions showed a wide 
variability without any correlation while in serum the self-agglutination ability was on a same level in all 
forms for each fraction. Only in BAL there seemed to be a correlation between the appearance of 
hexamers in SP-A distribution forms containing octadecamers and more complex forms and weaker 
agglutination ability.  
These data suggest that the correlation of Fev1 (% pred.)age20 with the different oligomeric forms is 
related to the degree of the presence of active oligomeric forms within a sample. 
 
4.2.5) Oligomerization in CF patients is influenced by lung disease, 
genetics and SP-A level 
 
Another approach for the SP-A oligomer distribution evaluation was to calculate the relative SP-A 
amount in the first and the last peak by integrating the area beneath the peak, when the fraction 
number is plotted against the amount of SP-A in ng/ml, and then calculating the proportional amount 
of SP-A per peak. Only the first and the last peak were chosen for correlation analysis because the 
extremes (first and last peak) provide additional power to detect genetic modifiers or clinical 
influences. 
4.2.5.1) SP-A oligomerization and lung disease 
 
There was a significant association of the lung disease status in CF patients and the percentage of 
SP-A that is existent as octadecamers or more complex structures (first peak after separation on 
column) in BAL (p = 0.02), while in serum an association was slightly detectable but not significant. 
Then the correlation between the course of lung disease (∆Fev1 (% pred.)) and the percentage of SP-
A that was present in the first peak was analyzed and there was also a significant association in BAL 
and serum (p = 0.0008 and 0.0038).  
In conclusion a higher relative SP-A amount in the first peak is associated with a milder lung disease 
and a better course of lung disease. This supports the findings correlating the distribution forms in BAL 
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that the more SP-A is existent in octadecamers or more complex structures in BAL the better is the 
lung function. 
4.2.5.2) SP-A oligomerization and self-agglutination 
 
Also the self-agglutination abilities of BAL and serum were analyzed and compared to the relative 
amount of oligomerization of SP-A derived from gel chromatography using 100 ng SP-A from the 43 
BAL and 34 serum samples of CF patients. Like the oligomeric distribution forms also the relative SP-
A amounts in the first and last peak in BAL showed a correlation with the self-agglutination ability (see 
fig.3.1.5.2.1). In serum there was no such correlation (see fig.3.1.5.2.1).  
There was no correlation between the self-agglutination of the SP-A fractions 10, 15 and 20 and the 
relative SP-A amount in the first and last peak. 
These findings support the theses that SP-A self-agglutination is dependent on the amount of 
particular SP-A oligomers present in a sample, i.e. the relative strength of SP-A molecular forms in a 
sample.  
 
4.2.5.3) Influence of SP-A self-agglutination ability on Fev1 (% pred.)age20 and 
ΔFev1 (% pred.)/year 
 
Because of the correlation between SP-A structure and lung Fev1 (% pred.)age20 and between the SP-
A structure and the self-agglutination ability it was also searched for a correlation between the self-
agglutination ability and lung disease severity. For Fev1 (% pred.)age20 there was in BAL (p = 0.0137) 
and serum (p = 0.0338) a significant correlation (shown in fig. 3.1.5.3.1 a and b). Additionally, for 
ΔFev1 (% pred.)/year there was also a significant correlation in BAL (p = 0.0213) and weakly in serum 
(p = 0.0.497) which is shown in fig. 3.1.5.3.2 a and b. These results indicate the better the self-
agglutination ability of SP-A the better is the lung function. There was no correlation between the lung 
disease status (mild/severe) and the agglutination size. 
These results indicate the better the self-agglutination ability of SP-A the better is the lung function. 
 
4.2.5.4) SP-A oligomerization and genetics 
 
Afterwards it was searched for a genetic background of the oligomeric formation of SP-A. Therefore 
the SFTPA1 and SFTPA2 genotypes from MALDI-TOF were correlated with the percentage of SP-A 
which was present in the first peak in relation to the percentage of SP-A which was present in the last 
peak. Two SNPs, rs1136451 (SFTPA1) and rs17881665 (SFTPA2), were significantly associated with 
the formation of octadecamers or more complex structures (p = 0.0015 and 0.004). The wildtype 
alleles of both SNPs were associated with octadecamers or more complex structures. An analysis of a 
correlation between both SNPs indicated a linkage disequilibrium (p = 0.00001). The SFTPA1 SNP is 
a polymorphism in the coding region of the gene (P62P), but it doesn’t lead to an aa exchange. In a 
previous study by Floros et al. (12) it was shown that P62P is associated with the expression level of 
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SP-A. The SFTPA2 SNP is located in the 5’-UTR of the gene where also splicing and other regulative 
sequences influencing the SP-A expression exist. Therefore the SFTPA2 SNP either influence the SP-
A structure or was just associated because of the linkage disequilibrium. 
The next step was the analysis of the correlation between the SP-A level and the SP-A structure. 
There was a significant association (p = 0.0006) indicating that the higher the SP-A level was in BAL 
the bigger was the percentage of SP-A which was existent in octadecamers or more complex 
structures. This indicates that the SNPs are associated with the SP-A structure because they are 
associated with the SP-A level in BAL which influences the structure. Because the SFTPA1 SNP is 
localized in the coding region a direct influence on the expression level is not likely. There could exist 
another coupling with an SFTPA1 SNP in a regulative sequence of the gene responsible for the 
association. 
The results show that the SP-A oligomerization is associated with one SFTPA1 and one SFTPA2 SNP 
which are coupled. 
 
4.2.6) SP-A isolation 
 
For investigating the SP-A structure with another method, SP-A was isolated of the fractions from the 
first peak after gel chromatography by beads. The beads were coupled to an anti-SP-A antibody by 
biotin-streptavidin binding and could therefore pull the SP-A down in the fractions. A pool of 12 
fractions (F10) from control BAL samples was used. In the supernatant after the pull-down, almost 
none SP-A was left in solution. Also after dissolving and separating the beads from the SP-A solution 
only a small amount of SP-A was left with the beads and detected in the wash solution. It was 
important for the following AFM-based force spectroscopy to have a preferably pure sample of SP-A. 
Therefore the isolation had to be done without calcium to prevent the binding of other proteins to SP-
A. Several washing steps were chosen to remove the unbound proteins like one with the addition of 
Triton X-100 to inhibit unspecific binding. The constant movement during incubation assured an 
optimal binding of the antibody or SP-A. The pH had to be adjusted to the iso-electric point of SP-A to 
keep it stable.  
Most of the SP-A amount could be isolated out of the fractions and thus the SP-A isolation assay was 
proved to be effective. 
 
4.2.6.1) Protein gel and silver staining 
 
For determining the purity of the isolated SP-A sample it was first separated by gel chromatography on 
an SDS PAGE and then the gel was stained with silver. 
There was only one band for the SP-A isolation sample at about 35 kDa. SP-A monomers have a 
molecular weight of 28-35 kDa. Therefore the purity of the SP-A isolation sample is more than 90 %. 
This indicates that the SP-A isolation assay shows not only an efficient binding capability, but also 
enables an isolation with high purity. Normally there is more than one band on a reducing gel because 
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of different posttranslational modifications of SP-A which led to different molecular weights from 28 to 
35 kDa, but there seems to be only one form that was isolated. 
 
4.2.6.2) Single molecule forced microscopy  
 
To finally examine the structure of SP-A in a fraction after gel chromatography the method of single 
molecule force spectroscopy based on atomic force microscopy was used. Only one molecule was 
attached to a gold layer and then pulled of by a cantilever, while the applied force is measured. 
About 2,000 measurements were completed. There were curves about 100 nm long which would 
correspond to about 270 aa. These curves could depict SP-A monomers. There were also curves 
corresponding to about 66 aa which could display the collagen-like domain. Because there were no 
longer curves it must be concluded that there were no multimers in the solution. There were also a lot 
of smaller curves which had to be fitted and put in order. After all a force spectrum of a SP-A monomer 
could be developed by superimposition of the curves. This implicates that the oligomers were 
hydrolyzed before because at least dimers or trimers should have been found. This happened most 
probably during the isolation because the samples showed a good reproducibility by gel 
chromatography. The last step of the isolation with an acid glycine buffer could cause the 
hydrolyzation of the bisulfide bonds which link the SP-A monomers to form oligomers. 
After all the single force microscopy would be only useful for analysis of the monomeric SP-A 
domains, but not of the oligomeric structure.     
 
 
4.3) SP-A self-agglutination 
4.3.1) SP-A self-agglutination-assay 
 
Because of the structural differences of SP-A between individuals, it was necessary to analyze 
whether there are functional differences between different oligomeric states. For this a new 
agglutination assay with streptavidin beads was established. The streptavidin beads were coupled to 
biotinylated rabbit anti-goat antibodies which bound goat anti-human SP-A antibodies. These anti-SP-
A antibodies bound SP-A at its N-terminal end, so SP-A could self-agglutinate by its CRD. 
4.3.2) SP-A self-agglutination-assay establishment 
 
The agglutination-assay construction was tested. The conditions of the assay were varied with respect 
to the reagent addition to prove that the assay functions because of the binding chain bead-anti-goat 
antibody-anti-human SP-A antibody-SP-A and not because of other influences. The results state that 
the beads only agglutinate when also the anti-goat antibody, the goat-anti-human SP-A antibody and 
SP-A is present. Also an increasing agglutinate size could be measured with respect to an increasing 
SP-A level. In this way the assay construction was proved to function. Secondly the calcium and 
carbohydrate dependency of the assay was analyzed by changing the assay conditions with regard to 
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the calcium and carbohydrate amount. Without calcium and/or with mannose no agglutination could be 
observed. The pH and the ion concentration were at physical conditions. This was important because 
intact SP-A self-agglutinates at low pH (≤ 4) and/or high ion concentrations (0.1-0.4 M Cl
-
) (13,14).  
Thus the agglutination-assay was specific for measuring the self-agglutination of SP-A caused by its 
CRD. 
4.3.3) Relation between SP-A self-agglutination and structure 
 
In line with the results of the assay establishment the agglutination assay was used to determine the 
functional capability of SP-A regarding its CRD. Because different oligomeric structures of SP-A were 
found in BAL and serum of all study populations the fractions number 10, 15 and 20 of the gel 
chromatography representing the three peaks were analyzed by the agglutination assay. In all three 
study populations, CF, asthma and chronic bronchitis patients and controls, there was a significant 
difference regarding the agglutination ability between the fractions in BAL and serum. There was a 
significant decrease regarding the agglutination ability from SP-A octadecamers or more complex 
structures present in fraction 10 over the hexamers present in fraction 15 to the dimers and trimers 
present in fraction 20. Sanchez-Barbero et al. (9) found out that the complex oligomerization is 
essential for collagen triple helix stability at physiological temperatures, protection against proteases, 
and SP-A-induced ligand aggregation. On the other hand it is not essential for the binding of SP-A to 
ligands and anti-inflammatory effects of SP-A. This corresponds to the results of this study because 
the SP-A out of fraction 10 showed the better agglutination abilities, but also the other fractions could 
cause agglutination. 
Comparing the fractions between BAL and serum in the patient groups there was also a significant 
difference. The serum SP-A structures had significantly better agglutination ability than the 
corresponding structures in BAL from patients. While in CF patients this difference was highly 
significant for all structures in the bronchitis study population the significance decreased from fraction 
10 over fraction 15 to fraction 20. In controls all fractions and therefore all SP-A structures in serum 
and the corresponding structures in BAL showed the same agglutination ability. The reason for this 
could be another way for SP-A to move from lung into serum except for the already discussed way of 
passive diffusion. Restricted passive diffusion of large proteins via the paracellular route plays an 
insignificant role in the net absorption or secretion of these proteins across normal alveolar epithelium 
(15). Receptor-mediated transport through transcytosis could also play a role as for BSA (16). 
Therefore the more effective the SP-A is able to bind to a receptor also represented by its 
agglutination ability the more is transported. In endothelial cells numerous vesicles and membrane 
invaginations (including caveolae and clathrin-coated pits) that are expected to play an important role 
in internalization of proteins and transcellular movement of cargo proteins (17). SP-A binds to high-
affinity binding sites (receptors) at the type II pneumocyte cell membrane (18,19) and has been 
demonstrated in association with coated pits and coated vesicles, suggesting receptor-mediated 
endocytosis via the coated-pit pathway (20,21). Thus receptor-mediated transport could explain the 
difference between the agglutination ability of SP-A derived from BAL compared to SP-A derived from 
serum in one patient.  
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At last the fractions in BAL and serum were compared between the study populations. For all BAL 
fractions the SP-A oligomers derived from controls agglutinated significantly better than the SP-A 
oligomers derived from patients. Also all BAL structures from the bronchitis study population 
agglutinated better than the structures derived from CF patients, but the difference was only significant 
in fraction 15. In contrast to these findings in serum there were no differences regarding the 
agglutination ability between the study populations. A gradual decrease (P < 0.05) in SP-A1/SP-A ratio 
in BAL was observed in healthy subjects (HS) with increased age, although no significant change was 
observed in total SP-A content among age groups in the study from Tagaram et al. (3). The CF ratio 
was significantly higher compared with AP, HS and non-cystic fibrosis (NCF), even though SP-A1 and 
total SP-A were decreased in CF compared with most of the other groups. The ratio was higher in 
culture-positive vs. culture-negative samples from CF and NCF (P = 0.031). This indicates that here 
the more complex forms are associated with culture-negative cells. As SP-A is involved in the 
immunity of the lung and the more complex structures have better agglutination abilities the ratio 
which influences the degree of oligomerization could influence the immunological function of SP-A. 
These findings are consistent with the agglutination results of this study. The lack of difference in 
serum supports the theory of the receptor-mediated transport because the transporting criteria would 
be the same for all study populations and therefore the SP-A which could be transported, shows the 
same agglutination abilities. 
In summary the more complex the SP-A structure the better was the self-agglutination ability. All SP-A 
structures self-agglutinate in serum better than in BAL in samples of the patients groups while in 
control samples BAL and serum SP-A showed the same abilities. There was also a difference 
between the self-agglutination ability of BAL samples from CF, Bro and control derived SP-A, but none 
in serum. SP-A from control BAL agglutinated better than from bronchitis BAL and this better than 
from CF BAL. This indicates that the analysis of the SP-A structure composition is important because 
the structure has strong effects on the SP-A self-agglutination ability.  
 
4.4) SP-A-genetics, clinical and biochemical data 
4.4.1) Clinical data of the genetic populations 
 
The CF population was with 454 patients the largest, while in the bronchitis population 72 and in the 
control population only 25 individuals were included. The problem here was to collect all the samples. 
The controls or bronchitis patients were mostly only once in the hospital and then not enough blood 
samples were taken to be also available for scientific research. Because of this also the mean ages at 
sampling point of the study populations differ. The percentage of female patients and controls was 
almost even. The mean BAL level of the CF population was as expected lower than the BAL levels of 
the other populations, but the serum level was higher. The difference was only marginal between the 
CF and bronchitis population, but significant between the CF and control population. This is most 
probably caused by the small number of controls. Normally as previous studies had shown the serum 
level of CF patients is lowered (22-24).   
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4.4.2) Lung disease 
 
Determining the lung disease status for the chronic bronchitis and asthma patients was could be done 
without any exclusion as long as there was lung function data available. In CF patients there had to be 
at least 3 values to determine the disease status. One problem for all populations was the age of the 
patients. Children younger than 5 weren’t tested for lung function and if they were, the value is only 
partly useful. Sometimes the children don’t do their best while measurement because they have to 
learn the procedure. To get most reliable data the measurements of children under 5 were excluded. 
The next problem aroused by determining the status either by the last three lung function data or by 
estimating the value at age 20 which was chosen because the patients are fully grown and it allows a 
good prediction for the future. Also the lung disease groups differed significantly regarding their Fev1 
at this age. Patients had to be excluded by determining the lung disease status because they didn’t fit 
into the cut-off-values and would have dampened the statement of a correlation analysis. To include 
these CF patients an additional approach was chosen. The mean change of the lung function per year 
were calculated and also used for correlation analysis.  
 
4.4.3) Genetic influence on BMI and genotype differences between 
patient groups 
 
For determining the genotypes of the study populations some SNPs which cause an aa exchange 
were analyzed by melting curves with hybridized probes in a Light Cycler. Also for a bigger throughput 
of genotyping the method of Matrix Assisted Laser Desorption/Ionisation-Time-Of-Flight (MALDI-TOF) 
was used. The SNP data resulting from the genotyping by MALDI-TOF and probes were correlated 
with the clinical data and ELISA level measurements by χ
2
-test and the results were corrected 
according to Bonferroni. 
There were significant p values after comparison of the study populations, CF, bronchitis and controls, 
for SP-D M31T (p = 0.03), SP-A2 rs1965708 (p = 0.0001) and SP-A2 rs1975006 (p = 0.0001). For SP-
D M31T the allelic variant in the N-terminal region at position 11 (methionine exchange for threonine; 
Met11Thr) was associated with susceptibility to Tbc in a Mexican population (25), whereas methionine 
at position 11 was associated with severe RSV bronchiolitis in infants (26). Recently, Leth- Larson et 
al. demonstrated that individuals with the Thr/Thr 11 genotype had significantly lower SP-D serum 
levels compared with Met/Met 11 genotype carriers (27). While the blood of individuals with the 
Met/Met 11 alleles contains the multimeric SP-D forms, the Thr/Thr 11 genotypes lack these forms. 
Multimerization of SP-D is suggested to play a crucial role for the interaction with immune cells and 
pathogens (28). In this study the CF population was associated with the threonine allele. Therefore the 
lack of multimeric forms and the lower SP-D levels could influence the disease. 
SP-A knock-out mice demonstrated a crucial role of SP-A in the regulation of innate immunity and 
adaptive immunity (29). In mice with CF, linkage scans showed an association of the degree of fibrosis 
and a locus on chromosome 10 in mice. A recent study showed an association between the haplotype 
6A
3
/1A
1 
and lower pulmonary function as well as poor pulmonary scores (30,31) and SP-A2 
rs1965708 is one SNP used to describe the 1A
x
 haplotypes. It causes an aa exchange at position 223 
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from glutamine to lysine and the lysine allele from the haplotype 1A
1
 was associated with CF. No other 
SNPs of the haplotype were associated with the disease, but the haplotypes are based on the allele 
distributions in an American population. Differences could occur because of the different genetic 
background and therefore association analyses should first be done according to each analyzed SNP 
and then haplotypes can be tried according the associated SNPs. The SP-A2 rs1975006 is located in 
an intron of the gene and has not been analyzed before. It could be linked to another relevant SNP, 
but in this study no linkage was found.  
According to this, the SP-A2 SNPs rs1965708 and rs1975006 could influence CF by causing a worse 
lung disease outcome.  
 
4.4.4) SP-A and SP-D level measurements 
 
In a former study by Bielecki (“Surfactantproteine A und D im Serum und in Bronchoalveolärer Lavage 
bei Patienten mit Cystischer Fibrose“, MD, 2007) the consistency of the SP-A serum levels in CF 
patients over time was shown. This consistency allows us to compare results arising from sera taken 
at different points of time from CF patients with clinical stability. The SP-D levels in BAL differed 
significantly (pCF-Bro = 0.0003, pBro-C = 0.02) between the patient groups. The bronchitis patients had 
significantly lower SP-D levels in BAL than the CF patients or controls. SP-D is known to be degraded 
by elastase in BAL of CF patients (32), but the elastase levels at sampling point were low. This could 
explain the higher levels of CF in the range of controls. The bronchitis patients included some patients 
with a lack of SP-D in BAL which was further analyzed and discussed in 4.5.  
 
4.4.5) Genetics in CF 
4.4.5.1) SP-A SNPs and clinical data 
 
There was a significant association between the mean ∆ Fev1 (%pred.) / year and V50L a SNP in the 
SFTPA1 gene (p = 0.0038) while the mutated allele was associated with a worse course of lung 
disease. The SP-A1 SNP V50L was used to describe the SP-A1 haplotypes 6A
x
. CF patients with the 
haplotype 6A
3
 had a significantly lower Fev1 (%pred.) than patients with other haplotypes. According 
to this the V50L SNP which causes an aa exchange from valine to leucine at position 50 in the SP-A1 
protein could directly influence the lung disease pattern. An aa exchange could cause a 
conformational change and therefore influence the immunological capability of SP-A. This could affect 
the lung disease.  
Also the appearance of an ABPA infection was significantly associated with a SFTPA2 SNP N9T 
analyzed by χ
2
-test (p = 0.004). For SP-A2 N9T the wildtype allele was significantly associated with 
the group that had never ABPA. N9T is relevant for the haplotype 1A
0
 and 1A
3
. The 1A
0
 allele is 
associated with RDS (33), but there is nothing known about associations of the SNP itself. It is located 
in the coding area and causes an aa exchange from asparagine to threonine at position 9 in the 
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amino-terminal domain. This domain is important for the stimulation of inflammation and could 
therefore influence ABPA infection.  
The other characteristics, age at the first P. aer. infection, age at the first P. aer. mucoid infection, 
chronic or non-chronic P. aer. infection, age at the first chronic P. aer. infection, BMI and Fev1 (% 
pred.) estimated for age 20, had no significant correlations with any SNPs after Bonferroni correction.  
 
4.4.5.2) SP-A level and genetics in CF 
 
For SP-A there were significant genetical associations with the BAL and serum level. The SP-A BAL 
level was significantly associated with the SP-A1 SNP rs1136451 (p = 0.002) and the SP-A2 SNP 
rs17881665r (p = 0.002). Here the mutated allele was associated with lower SP-A levels like it was 
shown before with the CF part analyzed by gel chromatography. The SNPs regarding the SP-A level 
were discussed in 4.2.9. This significant correlation existed only by analyzing the SNP data with the 
χ
2
-test and grouping after BAL levels (group 1: 0-1,000 ng/ml; group 2: 1,000-10,000; group 3: 
>10,000) to compare the extremes. The correlation of the BAL level data by grouping regarding the 
genotype was not significant. The SP-A serum level was significantly associated with SP-A1 N9T (p = 
0.028). This SNP was also associated with ABPA infection (see above). Because of the location of the 
SNP in the coding region it is more likely that the SNP indirectly influences the SP-A level. Because 
the wildtype seems to protect against ABPA infection and is associated with lower serum levels the 
explanation could be that infection destroys the lung-blood barrier and therefore increases the SP-A 
level in serum.  
 
4.4.5.3) Fev1 (% pred.) estimated for age 20 correlates with SP-A level 
 
The SP-A levels in BAL and serum were measured by ELISA and correlated to the clinical data of the 
patients. In the CF study population there was a significant association between the SP-A level in BAL 
and the Fev1 (% pred.) estimated for age 20 (p = 0.009). The higher the SP-A levels were in BAL the 
bigger were the values of the Fev1 (% pred.) estimated for age 20. This is consistent with the finding 
that higher BAL levels lead to more complex oligomeric structures in BAL which are associated with a 
better lung disease outcome in CF patients. In serum there was no correlation with this characteristic 
(p = 0.33). There was also no correlation between the SP-A BAL or serum level and any other clinical 
characteristic such as BMI, age, gender, IgG or IgE in serum. 
 
4.4.5.4) SP-D genetics in CF 
 
After comparison of the lung disease groups, mild young, mild old and severe, for the CF population 
one SNP showed a significant allele distribution, SP-D M31T (p = 0.0005). 
Because the Fev1 (% pred.) estimated for age 20 had been shown to be an equivalent classification 
criteria for lung disease of CF patients (2) and the lung disease groups were significantly associated 
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with SP-D M31T this correlation was again analyzed in prism after grouping the patients regarding to 
their genotype. The same correlation could be shown that the mutated allele leads to a worse lung 
disease outcome (p = 0.0091).  
Analyzing the mean ΔFev1 (% pred.)/year regarding to the genotype of SFTPD M31T there was also a 
significant correlation (p = 0.019).  
As mentioned above the SP-D M31T influences the multimerization of the SP-D monomers which 
affects the immunological effect. Patients with a severe lung disease status had significantly more 
frequent the threonine allele. This supports the idea that the lack of higher multimers caused by the 
threonine at position 31 influences the lung disease because of the weaker pathogen defence. 
 
4.4.5.5) SP-D SNPs influencing the protein level in CF 
 
The SP-D serum level was significantly associated with the SNPs SP-D M31T (p = 0.04) and SP-D 
A180T (p = 0.013). These SNPs were also shown to be associated with the protein level by Leth-
Larsen et al., 2005 (34). They genotyped 143 individuals regarding these SNPs and measured the SP-
D level in serum. The p-value for the association of M31T with the serum level was 0.015, and the 
alleles of A180T were linked to the M31T alleles.  
In line with the study by Leth-Larsen also in this study the mutated alleles of both SNPs were 
associated with lower serum levels. 
 
4.4.5.6) Influence of lung disease, age and BMI on SP-D levels 
 
The SP-D level in serum of the CF study population was significantly associated with the lung disease 
(mild/severe, p = 0.0005) and the Fev1 (% pred.) estimated for age 20 (p = 0.0027). The higher the 
SP-D level was in serum the smaller was the value of the Fev1 (% pred.) estimated for age 20. In BAL 
there was no correlation (p = 0.9).  
The SP-D SNP M31T was associated with the serum levels, the lung disease group and lung disease 
pattern. This is consistent with the results from the ELISA measurements. Therefore the threonine 
allele at aa position 31 in the SP-D gene causes a low serum level and a worse lung disease outcome.  
Analyzing the SP-D levels in BAL and serum with respect to the age of the individuals there was a 
significant association between increasing SP-D serum level and increasing age (p = 0.001), but no 
correlation between the SP-D BAL level and age. Additionally by analyzing the BMI groups 
underweight, normal weight and overweight and the SP-D levels there was a significant difference 
between the serum levels of the underweight and the overweight group as well as between the normal 
weight group and the overweight group (both p < 0.01), but no significance regarding the BAL levels. 
While the underweight and normal weight groups had a similar SP-D level distribution in serum, the 
overweight group had significantly lower serum SP-D levels. 
There were two studies indicating a genetically and phenotypically association of SP-D with obesity 
(35,36). In these studies weight and BMI related significantly inversely to serum SP-D. Additionally a 
significant age-dependent increase in serum SP-D was prominent in lean persons (36). 
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In conclusion the SP-D level in serum is associated with the SFTPD SNP M31T, is a marker for the 
severity of lung disease and is also influenced by age and weight. 
 
4.5) Absence of SP-D in BAL 
After we identified subjects with no SP-D in their BAL common polymorphisms known to be associated 
with low serum SP-D levels were assessed in those subjects from whom informed consent could be 
obtained and DNA was available. The M31T polymorphism in exon 1, A180T in exon 4 and S290T in 
exon 7 were analyzed. DNA was available from 10 of the 12 children who had no SP-D detectable in 
their BAL by ELISA (n = 6) and Western blotting (n = 4). For comparison 8 children were selected with 
the same clinical characteristics, but detectable SP-D levels in serum. 
No significant genetic association could be found between the common polymorphisms known to be 
associated with low serum SP-D levels and the lack of SP-D in BAL or serum respectively. Because 
the SNPs are only associated with low serum levels and are not the only cause for it the small sample 
size could be the reason for the lack of an association in this study. 
 
 
 
4.6) TLR SNPs 
 
The SNP TLR4 A-2570G was significantly associated with the lung disease (mild/severe) in CF 
patients analyzed by χ
2
-test (p = 0.0003). No other correlation between any clinical characteristics 
could be found. TLR4 is a lipopolysaccharide receptor and initiates the innate immune response 
against gram-negative bacteria (37). Other polymorphisms have been shown to attenuate receptor 
signalling (38), but TLR4 A-2570G has not been described before. Additionally no linkage between 
this SNP and any other TLR4 SNP analyzed could be found. The TLR4 SNP is located in the 5’-UTR 
of the gene. It could influence the expression rate of TLR4 and therefore the immune response. A 
lower protein level could affect the lung disease. 
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5) Summary  
 
Surfactant associated protein-A (SP-A) is the most abundant pulmonary surfactant protein and 
belongs to the family of innate host defence proteins termed collectins. Besides pulmonary host 
defence, SP-A is also involved in the formation of pulmonary surfactant, as it is essential for the 
structure of tubular myelin. The human SP-A gene locus includes two functional genes, SFTPA1 and 
SFTPA2 which are expressed independently, and a pseudo gene. SP-A polymorphisms play a role in 
respiratory distress syndrome, allergic bronchopulmonary aspergillosis and idiopathic pulmonary 
fibrosis. The levels of SP-A are decreased in the lungs of patients with CF, respiratory distress 
syndrome and further chronic lung diseases.  
The aim of the study was to elucidate the role of SP-A in human lung disease. This study was 
designed to analyze the relation between genetics, structure and function of SP-A in a CF, chronic 
bronchitis and asthma and healthy control population ex vivo. 
Beginning with the analysis of SP-A oligomeric forms, there were no correlations between serum and 
BAL SP-A distribution forms. The forms showed only a significantly different distribution comparing 
serum samples from bronchitis patients and controls. In serum and BAL of CF patients the forms 
containing the first peak were correlated with a better lung function (Fev1 (% pred.)age20). Also higher 
relative SP-A amount in the first peak is associated with a milder lung disease and a better course of 
lung disease. Additionally, SP-A self-agglutination is dependent on the amount of particular SP-A 
oligomers present in a sample, i.e. the relative strength of SP-A molecular forms in a sample. All SP-A 
structures self-agglutinate in serum better than in BAL in samples of the patients groups while in 
control samples BAL and serum SP-A showed the same abilities. There was also a difference 
between the self-agglutination ability of BAL samples from CF, Bro and control derived SP-A, but none 
in serum. SP-A from control BAL agglutinated better than from bronchitis BAL and this better than 
from CF BAL. These results are also supported by the fact that a better agglutination ability of SP-A 
was significantly associated with lung function. Therefore the degree of the presence of active 
oligomeric forms within a BAL or serum sample seems to be important for a better lung function 
outcome.  
The SP-A oligomerization is associated with one SFTPA1 rs1136451 and one SFTPA2 SNP 
rs17881665 which are coupled, while the mutated allele seems to cause a lack of complex oligomers. 
The wildtype alleles of the SP-A2 SNPs rs1965708 and rs1975006 were associated with CF 
compared to the bronchitis and control group. There was a significant association between the mean ∆ 
Fev1 (%pred.) / year and V50L a SNP in the SFTPA1 gene (p = 0.0038) while the mutated allele was 
associated with a worse course of lung disease. The SP-A BAL level was significantly associated with 
the SP-A1 SNP rs1136451 (p = 0.002) and the SP-A2 SNP rs17881665r (p = 0.002). The SP-A serum 
level was significantly associated with SP-A1 N9T (p = 0.028).  
In addition in the CF study population there was a significant association between the SP-A level in 
BAL and the Fev1 (% pred.) estimated for age 20 (p = 0.009). The higher the SP-A levels were in BAL 
the bigger were the values of the Fev1 (% pred.) estimated for age 20. There was no correlation 
between the SP-A BAL or serum level and any other clinical characteristic such as BMI, age, gender, 
IgG or IgE in serum. 
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In conclusion, these results indicate a very important role for SP-A in human lung immunity. Future 
areas for clinical research include disease specific SP-A expression pattern and their functional 
consequences, the differential roles of SP-A1 and SP-A2 in human lung diseases, and therapeutic 
approaches to correct altered SP-A levels. 
 
For SP-D the SNP M31T influences the multimerization of the SP-D monomers which affects the 
immunological effect. M31T is like SFTPD A180T associated with the serum SP-D level. In line with 
the study by Leth-Larsen also in this study the mutated alleles of both SNPs were associated with 
lower serum levels. The SP-D level in serum is also influenced by age and weight. Nevertheless it is a 
good marker for the severity of lung disease. 
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Appendix 
A: SP-A1 and SP-A2 polymorphism data 
 
Table A.1: Polymorphism data from the Universitiy of California, Santa Cruz 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The table shows the reference number for each SNP used in studies to characterize the alleles of the 
SP-A genes, the alleles, the number of populations where it was observed in, and the allele 
frequencies. 
 
1
 http://genome.cse.ucsc.edu/ 
Polymorphism Reference SNP ID Alleles Number of populations studied Allele frequency 
N9T 
SP-A1 Not listed 
C/A 
- - 
SP-A2 rs1059046 2 0.032/0.968 
V19A 
SP-A1 rs1059047 
C/T 
2 0.047/0.953 
SP-A2 Not listed - - 
H39H 
SP-A1 Not listed 
C/T 
- - 
SP-A2 Not listed - - 
V50L 
SP-A1 Not listed 
G/C 
- - 
SP-A2 rs17883551 1 Not available 
P62P 
SP-A1 rs1136451 
G/A 
2 0.136/0.864 
SP-A2 rs2434114 0 Not available 
P91P 
SP-A1 Not listed 
G/C 
- - 
SP-A2 rs17886395 2 Not available 
T133T 
SP-A1 rs1059057 
G/A 
2 0.043/0.957 
SP-A2 Not listed - - 
S140S 
SP-A1 rs3997777 
C/T 
0 Not available 
SP-A2 rs1965707 0 Not available 
Y184Y 
SP-A1 rs4253526 
C/T 
2 0.032/0.968 
SP-A2 Not listed - - 
Q223K 
SP-A1 rs1965708 
A/C 
1 0.272/0.728 
SP-A2 rs17881479 2 Not available 
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B: SP-A BAL and serum structure distributions 
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Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
8, w, x, 2, 4, x, x, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Fuchs1 BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
11, m, 82.39%, 2, 9.7, x, 4, 861, x, 83
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
K401-1 BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
6, w, 86%, x, ...
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
BAL K419-3
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
12, w, x, x, x, 5, 0, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Jordan BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
29, w, 96%, x...
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
BAL K425-2
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
11, m, x, ...
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Zoricic BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
15, m, 95.2%, 1.2, x, x, x, 947, 1019, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Söyler BAL
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
14, w, 72%, 10, x, 10, 0, 14.2, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
BAL Mikalic
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
9, m, x, 1, x, 1, 0, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Freudenberg BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
7, w, 105%, 63, 9.3, 7, 0, 1950, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Ekic BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
6, w, 118%, 0.5, 7.9, 0, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Hoang BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
6, w, 82%, 7, 11, 59, 5, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
110
M509-1 BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
111 010 011
001
7, w, 88.89%, 2, 12.3, 90, 2, 772, x, 10
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
K424-2 BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
#
Bro-056
CF-390
CF-401
CF-449
CF-406
CF-419
CF-435
CF-441
CF-210
C-014
C-025
CF440
ro-007
CF-404
Bro-014 CF-450
C-024
C-009
C-010
Bro-065
Bro-036
Bro-012
111
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1, w, x, 4, 10.4, 14, 0, 396, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Harlander  BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
14, m, 72.86%, 3, 6.2, 54, 6, 1250, x, 10
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
E215-2 BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
15, w, x, x, x, 5, 1, 50, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Jost BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
4, m, x, x, 4.2, x, x, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Avdiu BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
9, m, 102.78%, 8.1, 6, x, 2, 4.06, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
H303-2 BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
4, w, x, 69.4, 15.8, x, x, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Yildiz BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
8, m, 121%, 0.4, 5, 31, 0.1, 673, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
H308-1 BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
8, m, x, 3, x, 1, 0, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Fuchs2 BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
7, w, 114.29%, 4.1, 11.4, 65.6, 1, 639, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
H309-2 BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
BAL HAN 11
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
11, w, 99.11%, 5, 8.5, x, 1, 13.09, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
K403-3 BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
BAL Han 9
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
15, m, 68%, x, x, 13.4, 0, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
BAL K417-2
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
BAL Han 10
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
17, w, 108%, 5.8, 13.8, 20, 1, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
BAL Lange
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
BAL Loibl
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
10, w, 91%, 3, 0.5, 43, 3, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
M511-1 BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
BAL Köhler
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
10, w, 74%, 41, x, 41, 2, 5, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Tusk BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
2, m, x, 3, x...
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Räuschl BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
17, w, 52%, x...
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Mertscheid BAL
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
100 110 101
B o-015
C-013
Bro-031 Bro-022
CF-322
CF-452
CF-175
CF-433
CF-420
CF-414
CF-413
CF-408
CF-401 Bro-059
Bro-041
Bro-013
C-035
C-033
C-034
C024
C-025
110
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B.2: Serum forms 
11, w, 68%, 9, 6, x, 1, 1220, x, 64
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
B102-1 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
1, w, x, 2, x, 72, 0, 275, 0.1, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Denk Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
1, m, x, 1.7, x, 23.6, 0.1, 163, 1.9, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Kamperidis Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
11, m, 82.39%, 2, 9.7, x, 4, 861, x, 83
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
K401-1 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
15, m, 72%, 4, 9.2, 67, 3, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
M504-2 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
13, w, 85%, 2, 9.1, 54, 5, 973, x, 10
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
E206-1 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
19, w, 102%, 6, 5200, 53, 1, 1012, x, 10
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
K414-2 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
7, w, 95.83, 14, 7900, 42, 5, 909, x, 100
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
K426-2 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
10, w, 132%, 6, 6.6, 47, 2, 1100, x, 10
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
E217-1 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
10, w, 74%, 41, x, 41, 2, 5, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Tusk Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
14, w, 72%, 10, x, 10, 0, 14.2, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Serum Mikalic
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
11, m, 164%, 1, 10.9, 49, 1, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
M506-1 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
9, m, x, 1, x, 1, 0, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Freudenberg Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
4, w, x, 69.4, 15.8, x, x, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Yildiz Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
16, m, 77%, 10, 7.1, 54, 0, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
M508-1 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
8, m, x, 3, x, 1, 0, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Fuchs2 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
4, m, x, x, 4.2, x, x, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Avdiu Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
21, m, 98%, 7, 7, x, 1, 1040, x, 10
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
B116-1 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
25, w
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
SH serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
8, w, x, 2, 4, x, x, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Fuchs1 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
17, w, 108%, 10, 7, x, 3, 1520, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
B118-1 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
23, w
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
NL serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
6, w, 118%, 0.5, 7.9, 0, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Hoang Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
14, m, 72.86%, 3, 6.2, 54, 6, 1250, x, 10
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
E215-2 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
24, w
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
MF serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
11, m, x, ...
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Zoricic Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
12, w, 103%, 2, 8, x, 2, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
H301-2 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
14, w, 109.04%, x, x, x, x, 404, 1047, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Wimmer Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
29, m
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
AH serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
9, w, 75.24%, 2, 6.2, 49, 1, x, x, 10
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
K407-3 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
   010        011 110
CF-373
CF-419
CF-430
CF-322
C-009
C-011
C-023
C-017
C-008
CF-354
Bro-014
CF-446
CF-442
CF-210
Bro-070
C-026
C-010
C-014
C-025
Bro-079
Bro-030
CF-393
CF-402
CF-447
CF-449
CF-383
CF-384
CF-401
CF-407
CF-423
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19, m, 57.41%, x, x, x, x, 69, 1405, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Landinger Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
37, m
10 15 20 25
0
50
100
MWm serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
12, m, 80%, x...
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Serum K415-2
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
36, m, 83.66%, x, x, x, x, 2087, 2048, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Heitzer Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
9, m, 71%, 4, 6, x, 1, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
K416-2 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
20, m, 84.82%, x, x, x, x, 2002, 1621, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Baur Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
15, m, 68%, x, x, 13.4, 0, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Serum K417-2
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
6, w, 86%, x, ...
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Serum K419-3
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
29, w, 96%, x...
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Serum K425-2
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
17, w, 108%, 5.8, 13.8, 20, 1, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Serum Lange
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
10, w, 91%, 3, 0.5, 43, 3, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
M511-2 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
7, w, 163%, 5, 4900, 36, 3, x, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
M512-2 Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
1, w, x, ...
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Brauchle Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
1, w, x, 4, 10.4, 14, 0, 396, x, x
10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Harlander Serum
Fraction
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
S
P
-A
 [
%
]
   010        011 110
CF-174
CF-115
CF-015
Bro-080 CF-431
CF-432
CF-433
CF-435
CF-441
CF-175
CF-452
CF-453
Bro-010
Bro-022
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